Document:

Exhibit 10.7

 

Execution Copy

 

EXCLUSIVE LICENSE AND ASSIGNMENT AGREEMENT

 

	Contents 	CONFIDENTIAL TREATMENT 
	 	REQUESTED
	Preamble 	THE PORTIONS OF THIS 
	Recitals 	AGREEMENT MARKED WITH 
	 	ASTERISKS WITHIN BRACKETS 
	1.      Definitions. 	(“[***]”) HAVE BEEN OMITTED 
	2.      Licenses and Assignments. 	PURSUANT TO A REQUEST FOR 
	3.      Joint Steering Committee and Alliance Managers. 	CONFIDENTIAL TREATMENT 
	4.      Commercialization. 	UNDER 17 C.F.R. SECTIONS 
	5.      Manufacture and Supply of Products. 	200.80(B)(4), 200.83 AND 230.406. A 
	6.      Development Activities by Licensee. 	COMPLETE COPY OF THIS 
	7.      Regulatory Matters. 	AGREEMENT HAS BEEN FILED 
	8.      Payment Obligations. 	SEPARATELY WITH THE UNITED 
	9.      Intellectual Property Matters. 	STATES SECURITIES AND 
	10.   Representations, Warranties, and Covenants. 	EXCHANGE COMMISSION.
	11.    Indemnification and Insurance. 	 
	12.    Limitation of Liability and Disclaimer of Warranty. 	 
	13.    Confidentiality. 	 
	14.    Term and Termination. 	 
	15.    Miscellaneous.	 

  

Exhibits and other Agreements (in the order in which they appear
in the Agreement):

 

Commercialization Plan (2)

Licensed CPEX Patent Rights (1)

Licensed Reprise Patent Rights (1)

Licensed Serenity Know-How (1)

Licensed Serenity Patent Rights (1)

Licensed Serenity Trademarks (1)

Licensed Serenity Copyrights (1)

Manufacturing and Supply Plan (2)

Pharmacovigilance Agreement (2)

Regulatory Rights Assignment and Assumption Agreement
(1)

Renaissance Agreements (3)

Renaissance Agreements Assignment and Assumption Agreement
(1)

Serenity Trademark Standards (2)

Third Party Supply Agreements (3)

Form of Press Release (1)

 

		(1)	attached to this Agreement upon its execution

		(2)	to be drafted following execution of this Agreement

		(3)	to be provided separately

 

Schedules (in the order in which they appear in the Agreement):

 

Exceptions to Licensor’s Representations and
Warranties

Exceptions to Licensee’s Representations and
Warranties

 

    	 	1	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

  

EXCLUSIVE LICENSE AND ASSIGNMENTS AGREEMENT

 

This Exclusive License and Assignments Agreement (this “Agreement”)
is made as of September 1, 2017, by and among SERENITY PHARMACEUTICALS, LLC, a limited liability company organized under the laws
of Delaware (“Licensor”), with offices at 105 Hawk Court, Milford, PA 18327, and AVADEL SPECIALTY PHARMACEUTICALS,
LLC, a limited liability company organized under the laws of Delaware (“Licensee”), with offices at16640 Chesterfield
Grove Road, Suite 200, Chesterfield, MO 63005. Licensor and Licensee are each sometimes referred to herein individually as a “Party”
and collectively as the “Parties”.

 

RECITALS

 

WHEREAS, Licensor has developed the Product (herein defined)
for treating certain medical conditions characterized by abnormalities or disorders in voiding and other urinary functions, and
the FDA (herein defined) has approved a New Drug Application (herein defined) for treating certain of these medical conditions
(herein defined as the “First Approved NDA);

 

WHEREAS, Licensee is engaged in the business of the development,
distribution, sale and marketing of pharmaceutical products;

 

WHEREAS, on the terms and conditions provided in this Agreement,
Licensor desires to grant to Licensee, and Licensee desires to be so granted, an exclusive license and sublicense to the Licensed
Rights (herein defined) and the Sublicensed Rights (herein defined), respectively, for the purpose of: (a) Commercializing
(herein defined) Products in the Field (herein defined) throughout the Territory (herein defined) and (b) Developing (herein defined)
and Commercializing the Product for the PNE Indication and Additional Indications (herein defined) in the Field and Territory;

 

WHEREAS, on the terms and conditions provided in this Agreement,
Licensor desires to assign and to delegate to Licensee, and Licensee desires to be so assigned and delegated, all of Licensor’s
right, title, and interest in and to, and the related regulatory obligations in respect of, the First Approved NDA and the related
IND (herein defined); and

 

WHEREAS, on the terms and conditions provided in this Agreement,
Licensor desires to assign and delegate to Licensee, and Licensee desires to be so assigned and delegated, all of Licensor’s
right, title, and interest in and to, and the related obligations under, the Renaissance Supply Agreements (herein defined),

 

NOW, THEREFORE, in consideration of the foregoing premises
and the mutual covenants contained herein, the Parties intending to be legally bound agree as follows:

 

		1.	DEFINITIONS.

 

When used in this Agreement each of the following terms whether
used in the singular or plural shall have the following meanings.

 

		1.1	“A/B Rated” means, (a) inside the United States, “therapeutically equivalent” as evaluated by the FDA,
applying the definition of “therapeutically equivalent” set forth in the preface to the then-current edition of the
FDA publication “Approved Drug Products With Therapeutic Equivalence Evaluations”, and (b) outside the United States,
such equivalent determination by the applicable Regulatory Authorities as is necessary to permit pharmacists or other individuals
authorized to dispense pharmaceuticals under Applicable Law to substitute one product for another product in the absence of specific
instruction from a physician or other authorized prescriber under Applicable Law.

 

    	 	2	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.2	“Acceptance” and its correlative “Accepted” means with respect to an NDA submitted to the FDA, receipt
by the sponsor thereof of written notice from the FDA that the FDA deems such NDA to be sufficiently complete for filing and filed
by the FDA pursuant to 21 C.F.R. 314.101 and any regulation successor thereto.

 

		1.3	“Additional Indications” means any other Indication for the Product in the Field in the Territory other than the
PNE Indication.

 

		1.4	“Adverse Drug Experience” has the meaning set forth in 21 CFR Sec. 314.80 and any regulation successor thereto.

 

		1.5	“Affiliate” means any Person who, directly or indirectly through one or more intermediates, controls or is controlled
by or is under common control with another Person, but only for so long as such relationship exists. For purposes of this definition,
the term “control” (including, with correlative meanings, the terms “controlled by” and “under common
control with”) as used with respect to a Person means the possession, directly or indirectly through one or more intermediates,
of the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of
voting securities, by contract or otherwise. Such power will be deemed to exist in the case of ownership, directly or through one
or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the
case of a corporation, or fifty percent (50%) or more of the equity interest, in the case of any other type of legal entity, or
status as a general partner in any partnership. The Parties acknowledge that, in the case of certain entities organized under the
laws of certain countries, the maximum percentage ownership permitted by Law for a foreign investor may be less than fifty percent
(50%), and in such case such lower percentage shall be substituted in the preceding sentence; provided, that such foreign investor
has the power to direct the management and policies of such entity.

 

		1.6	“Agreement” has the meaning set forth in the Preamble.

 

		1.7	“Alliance Manager” means, with respect to each of Licensor and Licensee, the individual designated by such Party
in accordance with Section 3.2(h).

 

		1.8	“Applicable Law” means, with respect to any action taken or omitted to be taken by a Party under this Agreement,
the Laws in any country and any jurisdiction therein that are applicable to such action or omission.

 

		1.9	“Bankruptcy Code” means the United States Bankruptcy Code, as amended and set forth in Title 11 of the United States
Code.

 

		1.10	“Branding Strategy” means the strategy, including messaging, for branding the Product for use in the Field in the
Territory, to be set forth in the Commercialization Plans for each combination of Product and Indication.

 

		1.11	“Business Day” means a day other than any Saturday, Sunday or other day on which banking institutions in New York,
New York are required by Applicable Law to remain closed.

 

		1.12	“Calendar Quarter” means each calendar quarter ending on the last day of each March, June, September and December
during the Term of this Agreement; provided, however, that (a) the first Calendar Quarter of the Term of this Agreement
will extend from the Effective Date to the end of the first complete Calendar Quarter thereafter; and (b) the last Calendar Quarter
of the term of this Agreement will end upon the expiration or termination of this Agreement.

 

		1.13	“Calendar Year” means each calendar year ending on December 31 of such year; provided, however, that (a)
the first Calendar Year of the Term of this Agreement will extend from the Effective Date to and including December 31, 2017; and
(b) the last Calendar Quarter of the term of this Agreement will end upon the expiration or termination of this Agreement.

 

		1.14	“CFR” means the United States Code of Federal Regulations.

 

    	 	3	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.15	“Change of Control” means with respect to Licensee:

 

		(a)	Licensee enters into a merger, consolidation, stock sale or sale or transfer of all or substantially all of its assets to which
this Agreement relates, or other similar transaction or series of transactions with a Third Party, unless, following such transaction
or transactions, (i) the individuals and entities who were the beneficial owners of the outstanding voting securities of Licensee
immediately prior to such transaction beneficially own, directly or indirectly, at least fifty percent (50%) of the combined voting
power of the then outstanding voting securities entitled to vote generally in the election of directors or similar governing persons
of the corporation or other entity resulting from such transaction (“Successor”) in substantially the same proportions
as their ownership immediately prior to such transaction of such outstanding voting securities, (ii) at least fifty percent (50%)
of the members of the Board of Directors or similar governing body of the Successor were members of the Board of Directors of Licensee
at the time of the execution of the initial agreement, or the action of the Board of Directors of Licensee, providing for such
transaction, (iii) Licensee retains title ownership after the transaction or transactions to properties and assets (x) representing
more than fifty percent (50%) of such Third Party’s consolidated total assets or (y) from which more than fifty percent (50%)
of such Third Party’s consolidated operating income for its most recent fiscal year was derived, and (iv) Licensee is the
surviving entity in such transaction or transactions; or

 

		(b)	any transaction or series of related transactions in which any Third Party or group of Third Parties acquires beneficial ownership
of securities of Licensee representing more than fifty percent (50%) of the combined voting power of the then outstanding securities
of Licensee.

 

Notwithstanding subsections (a) or (b), above, a stock
sale to underwriters of a public or private offering of Licensee’s capital stock shall not constitute a Change of Control.

 

		1.16	“Clinical Study” means (a) a Phase 1 Clinical Study, a Phase 2 Clinical Study, a Phase 3 Clinical Study, (b) variations
of such studies and/or trials (for example, a Phase 2/3 Clinical Study), as such terms are defined and understood by the FDA, and
(c) such other tests and studies in human patients that are required by Applicable Law, or otherwise recommended by applicable
Regulatory Authorities in the Territory, to obtain or maintain Regulatory Approvals, but excluding Post-Market Approval Studies
not required to be conducted under an IND.

 

		1.17	“CMC” means, as required by the context, the chemistry, manufacturing and controls processes applicable to the
manufacture of a product or the section of an IND or NDA that contains information on such processes.

 

		1.18	“Combination Product” means any product that comprises (a) the Compound and (b) at least one clinically active
therapeutic, or prophylactic ingredient or component (whether packaged together or in the same formulation) that is not the Compound.

 

		1.19	“Commercialize”, “Commercializing” or “Commercialization” means, with respect to any drug
product, any and all activities directed to using, launching, marketing, market researching, detailing, promoting, advertising,
educating, importing, exporting, distributing, selling, offering for sale, post-market approval pharmacovigilance and safety reporting,
legal, customer service, securing from both government agency payors and non-government third-party payors reimbursement of such
drug product after Regulatory Approval has been obtained (including, without limitation, obtaining pricing and reimbursement approvals),
regulatory compliance, planning with respect to each of the foregoing, and reporting. For clarity, “Commercialization”
shall not include any activities related to clinical research or Development of Products or to Manufacturing of Products.

 

    	 	4	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.20	“Commercialization Activities” means any of the activities described in the definition of “Commercialize”.

 

		1.21	“Commercialization Plan” means, from time to time and with respect to any period during the Term, Licensee’s
plan then in effect for Commercializing the Product during such period.

 

		1.22	“Commercially Reasonable Efforts” means, from to time to time with respect to the performance at such time of any
Development, Commercialization or other obligation of a Party under this Agreement that expressly requires efforts characterized
as such, the performance by such Party of such obligation by expending reasonable, diligent, good faith efforts to accomplish such
obligation as a similarly situated pharmaceutical company would use to accomplish a similar obligation under similar circumstances
through the exercise of reasonable business judgment, where the assessment of being similarly situated would be undertaken by reference
to company size and financial position, competitive factors in the relevant market relating to the proprietary position of the
relevant product in terms of market and profit potential, the safety and effectiveness profile of the relevant product, strategic
value, and applicable regulatory matters; provided, that, with respect to the Development and Commercialization of the Compound
or the Product, such efforts shall be substantially equivalent to those efforts and resources that a pharmaceutical company would
generally devote to its own internally discovered compounds or products of similar market and profit potential, safety and effectiveness
profile, strategic value, and regulatory matters at a similar stage in their development or life cycle, with respect to which it
does not owe license payments, milestone payments, royalties or similar financial obligations to licensors or other Persons, and
based on conditions then prevailing, with the goal of maximizing the revenue potential of such compounds or products. Commercially
Reasonable Efforts shall be determined on a country by country basis.

 

		1.23	“Compound” means “(a) the compound designated as Desmopressin (1-desamino-8-D-arginine vasopressin) and (b)
any and all functionally equivalent analogues thereof having antidiuretic activity disclosed in a patent or patent application
within the Patent Rights licensed and sublicensed hereunder.

 

		1.24	“Confidential Information” has the meaning set forth in Section 13.1.

 

		1.25	“Control” or “Controlled” means, with respect to any Know-How or Patent Right, the possession by a
Party, whether by ownership, license, sublicense or otherwise (other than pursuant to a license granted under this Agreement),
of the ability to grant the right to access or use, or to grant a license or a sublicense under, or to grant the right to disclose
or transfer, such Know-How or Patent Right, without violating the terms of any agreement or other arrangement with, or the rights
of, any Third Party. For clarity, the Patent Right or Know-How licensed to Licensee under this Agreement shall be deemed to be
Controlled by Licensee.

 

		1.26	“Cover”, “Covered”, or “Covering” means, (a) with respect to an issued patent, that, in
the absence of a license granted to a Person under a Valid Claim included in such patent, the practice by such Person of an invention
claimed in such Patent Right would infringe such Valid Claim, or (b) with respect to a patent application, that, in the absence
of a license granted to a Person under a Valid Claim included in such patent application, the practice by such Person of an invention
claimed in such patent application would infringe such Valid Claim if such patent application were to issue as a patent.

 

    	 	5	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.27	“CPEX” means CPEX Pharmaceuticals, Inc. (formerly Bentley Pharmaceuticals, Inc.), a corporation organized under
the laws of Delaware.

 

		1.28	“CPEX License Agreement” means that certain Development and License Agreement, dated February 4, 2008 and as amended
March 31, 2010, by and among Licensor and CPEX.

 

		1.29	“Detail” means a meeting (either in person or through live video conferencing) in respect of the Product (i) with
one or more physicians and other persons included in other medical professional categories (where, in the case of group presentations,
each such physician or other person participating in a group presentation shall be counted as a separate Detail), who are permitted
under the Applicable Law of the country in which they work to prescribe the Product and (ii) in which key attributes of the Product
are orally presented, but shall not include merely a reminder or a Sample or promotional material drop). When used as a verb, “Detail”
and “Detailing” shall have correlative meanings.

 

		1.30	“Develop” or “Development” means the undertaking of all activities relating to obtaining Regulatory
Approval for a product and all Manufacturing Activities reasonably required for development of CMC processes. For the sake of clarity,
such activities include preclinical testing, toxicology, formulation, Clinical Studies, and regulatory affairs required for Regulatory
Approval, and activities relating to the manufacture of Products that relate to regulatory matters are included in the definition
of Manufacturing.

 

		1.31	“Development Activities” means any of the activities described in the definition of “Develop”.

 

		1.32	“Development Budget” means, for any Development Activities to be undertaken with respect to the Product, the PNE
Indication and any Additional Indications, the detailed budget for all Development Costs for the Development Activities set forth
in any Development Plan in respect of such Development Activities.

 

		1.33	“Development Costs” means, in respect of the Development Activities described in any Development Plan, the following
costs: (i) Out-of-Pocket Costs attributable to such Development Activities and (ii) FTE Costs of Licensee’s internal personnel
that are attributable or reasonably allocable to such Development Activities. Such costs shall be determined in accordance with
GAAP.

 

		1.34	“Development Plan” means, in respect of the Product, the PNE Indication and each Additional Indication, from time
to time during the Term of this Agreement, any plan then in effect for the conduct of Development Activities in respect thereof,
and includes, without limitation, the Development Budget for such Development Activities.

 

		1.35	“Disclosing Party” means, with respect to any disclosure by a Party of any of its Confidential Information to the
other Party, the Party so disclosing such Confidential Information.

 

		1.36	“Disposition” means any disposition by Licensee of any of its assets, including any direct or indirect sale, lease,
exchange, transfer, contribution, license, spinoff, recapitalization, dividend, grant or other disposition, with or without value;
provided, however, that any sale of inventory by a Licensee Change of Control Party in the ordinary course of business, an offering
of debt or equity securities in a public financing, or any pledge of assets to secure acquisition debt financing on customary terms
which would not involve the issuance of equity that would otherwise result in a Change of Control, shall not be deemed a Disposition
hereunder.

 

		1.37	“Dispute” has the meaning set forth in Section 15.8(b).

 

    	 	6	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.38	“Dollars” or “$” means U.S. dollars.

 

		1.39	“Drug Master File” or “DMF” has the meaning set forth in 21 CFR Section 314.420 (and any regulation
successor thereto).

 

		1.40	[***].

 

		1.41	“Effective Date” shall mean the later of: (i) the date of this Agreement set forth in the Preamble or (ii) the
expiration of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

 

		1.42	“Enforceable IP Right(s)” shall mean any Patent Rights, Trademarks, Copyrights, or other intellectual property
rights within the Licensed Rights or the Sublicensed Rights that would be infringed by any Exploitation of any product in the Territory
in the absence of a valid and enforceable license, sublicense, or other right to engage in such Exploitation.

 

		1.43	“Exploit” and, with correlative meaning, “Exploitation”, means to Develop, Commercialize, Manufacture,
and otherwise exploit.

 

		1.44	“FDA” means the United States Food and Drug Administration and any agency successor thereto.

 

		1.45	“FDCA” means the United States Food, Drug and Cosmetic Act of 1938, as amended, and any law successor thereto.

 

		1.46	“Field” means the use of the Product for the Treatment in humans and animals of medical conditions characterized
by abnormalities or disorders in voiding and other urinary functions of a subject to control urination.

 

		1.47	“First Approved NDA” means U.S. NDA #201656, dated and received by the FDA on February 4, 2016 and as thereafter
amended, and approved by the FDA, as evidenced by that certain letter, signed March 3, 2017, from the FDA to Serenity.

 

		1.48	“First Approved Product” means the Product that is the subject of the First Approved NDA.

 

		1.49	“First Commercial Sale” means, with respect to the Product in each country in the Territory, the first sale in
such country by Licensee or any Third Party Distributor for consumption or use. Sales or transfers of reasonable quantities of
the Product for Clinical Study purposes or for compassionate or similar use, shall not be considered a first sale for consumption
or use.

 

		1.50	“First Position” means, with respect to the Detail of an applicable product, that the product is presented in such
Detail before any other product, such that the average time spent on all Details in any Calendar Quarter during the First Position
Period is approximately fifty (50%), excluding any Detail to a person or group of persons where for good reason Detailing of the
Product should either not be made or, if made, made substantially shorter than such average.

 

		1.51	“First Position Period” has the meaning set forth in Section 14.3(b).

 

		1.52	“Force Majeure” has the meaning set forth in Section 15.12.

 

		1.53	“FTE” means the hours of work devoted to or in support of Commercialization, Manufacture, or Development, as applicable,
of the Product, in accordance with the applicable Commercialization Plan, Manufacturing Plan, or Development Plan, that is carried
out by one or more employees, contract personnel or consultants of a Party, measured in accordance with such Party’s normal
time allocation practices from time to time. In no event shall an individual account for more than one FTE year in any Calendar
Year.

 

		1.54	“GAAP” means United States Generally Accepted Accounting Principles as applied in the United States.

 

    	 	7	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.55	“Generic Product” means, with respect to the Product, any product Commercialized by a Third Party in any country
in the Territory, that meets the following criteria: (i) such product contains a Low Dosage formulation of a compound that is an
active pharmaceutical ingredient in a product that is A/B Rated with respect to the Licensed Product (including, without limitation,
any salt, free acid or base, hydrate, isotopic, deuterated, solvate, polymorphic, crystalline, or non-crystalline form of such
Compound), and (ii) is A/B Rated with respect to the Product.

 

		1.56	“Generic TRxs-to-Total TRxs Percentage” means, with respect to any Calendar Quarter during the Term of this Agreement
in each country in the Territory, the quotient, expressed as a percentage, of (a) total TRxs for Generic Products during such Calendar
Quarter in such country DIVIDED BY (b) the sum of total TRxs for Generic Products during such Calendar Quarter in such country
PLUS total TRxs for Products during such Calendar Quarter in such country.

 

		1.57	“Governmental Authority” means any legislative, executive, judicial, regulatory, or administrative unit of any
governmental entity (multinational, foreign, federal, state, or local) or any department, commission, board, agency, bureau, ministry,
official, arbitrator (public), or other similar body exercising executive, legislative, regulatory, administrative, or judicial
authority or functions of or pertaining to government to perform any such functions.

 

		1.58	“IND” means, with respect to any investigational product, an Investigational New Drug Application filed with the
FDA under 21 CFR Part 312 (and any regulation successor thereto) or similar foreign application or submission in any country in
the Territory for permission to conduct human clinical investigations of such investigational product.

 

		1.59	“Indemnification Claim” has the meaning set forth in Section 11.2.

 

		1.60	“Indication” shall mean any human disease or condition, and any subcategories thereof, or sign or symptom of a
human disease or condition, and any subcategories thereof.

 

		1.61	“Inventions” means any and all inventions made, conceived, or discovered solely by employees, independent contractors,
or agents of either Party or their respective or jointly by employees, independent contractors, or agents of each of the Parties
or their respective Affiliates.

 

		1.62	“Joint Steering Committee” or “JSC” means the committee formed by designees of Licensor and Licensee
for the purpose of monitoring the Development, Commercialization, and Manufacture of the Product as contemplated by this Agreement
and governed in accordance with Article 3.

 

		1.63	“JSC Subcommittee” means any subcommittee established by the JSC in accordance with Article 3.

 

		1.64	“Know-How” means any nonpublic information, ideas, data, inventions, works of authorship, trade secrets technology,
or materials, including formulations, molecules, assays, reagents, compounds, compositions, human or animal tissues, samples or
specimens, and combinations or components thereof, whether or not proprietary or patentable, and whether stored or transmitted
in oral, documentary, electronic or any other form, including all Regulatory Documentation.

 

		1.65	“Launch” means, with respect to the Product or any Generic Product for an Indication in a country in the Territory,
the Product or such Generic Product first becoming available for commercial sale.

 

    	 	8	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.66	“Law” means any law, statute, rule, regulation, ordinance, regulatory guidance or other pronouncement having the
effect of law, of any federal, national, multinational, state, provincial, county, city or other political subdivision in each
country in the Territory, including, without limitation, (a) the FDCA in the United States and counterparts thereof in each other
country in the Territory, (b) good clinical practices and adverse event reporting requirements and all other rules, regulations
and requirements of the FDA and Regulatory Authorities that are counterparts of the FDA, as applicable, (c) the Foreign Corrupt
Practices Act of 1977, as amended, in the United States and any comparable laws in each other country in the Territory, and (d)
all export control laws in any country in the Territory.

 

		1.67	“LIBOR Rate” means, for any applicable interest period, the rate per annum equal to the average of the one month
US Dollar Rate Intercontinental Exchange London Interbank Offered Rate, as published by Thomson Reuters (or, if Thomson Reuters
does not publish quotations of such rate, another commercially available source providing quotations thereof as reasonably selected
by agreement of the Parties), with the average determined by adding such rate for each day on which such rate is published during
the applicable period, divided by the number of such days during such period. If such rate is not available at such time for any
reason, then the rate for that interest period will be determined by such alternate method as reasonably selected by agreement
of the Parties.

 

		1.68	“Licensed CPEX Patent Rights” means the Patent Rights set forth in Exhibit 1.68.

 

		1.69	“Licensed Reprise Know-How” means the Know-How licensed by Reprise to Serenity under the Reprise License Agreement.

 

		1.70	“Licensed Reprise Patent Rights” means the Patent Rights set forth in Exhibit 1.70.

 

		1.71	“Licensed Reprise Rights” means the Licensed Reprise Patent Rights and the Licensed Reprise Know-How.

 

		1.72	“Licensed Rights” means the rights under the licenses granted by Licensor to Licensee in Sections 2.1(a),(b), and
(c).

 

		1.73	“Licensed Serenity Copyrights” means the copyrights set forth in Exhibit 1.73.

 

		1.74	“Licensed Serenity Know-How” means the Know-How described in Exhibit 1.74.

 

		1.75	“Licensed Serenity Patent Rights” means the Patent Rights in the issued patents and patent applications set forth
in Exhibit 1.75.

 

		1.76	“Licensed Serenity Trademarks” means the trademarks set forth in Exhibit 1.76.

 

		1.77	“Licensee” has the meaning set forth in the Preamble.

 

		1.78	“Licensee Change of Control Party” means Licensee or any Affiliate of Licensee to the extent Licensee or such Affiliate
of Licensee, as applicable, is the subject of a Change of Control.

 

		1.79	“Licensee Insurance Policies” has the meaning set forth in Section 11.3.

 

		1.80	“Licensee Indemnitee(s)” means any of Licensee and its directors, officers, employees, agents, contractors and
agent of Licensee and its Affiliates (including without limitation Avadel Pharmaceuticals plc).

 

		1.81	“Licensee Inventions” means any and all Inventions with respect to the Product, Controlled by Licensee and not
made, conceived, or discovered by any employees, independent contractors, or agents of Licensor or any of its Affiliates, contractors,
or agents.

 

		1.82	“Licensee’s Sales and Marketing Force” means, from time to time, Licensee’s sales and marketing personnel
responsible for managing, coordinating and overseeing the Commercialization of the Product in the Field in the Territory.

 

		1.83	“Licensor” has the meaning set forth in the Preamble.

 

    	 	9	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.84	“Licensor Indemnitee(s)” means any of Licensor and its directors, officers, employees, agents, contractors and
agents of Licensor and its Affiliates (including, without limitation, Serenity).

 

		1.85	“Long Term Care” or “LTC” means the provision of health care in skilled nursing and other long-term
care and assisted living facilities.

 

		1.86	“Losses” means, with respect to any Claim for which one Party as an Indemnitee hereunder seeks indemnification
hereunder from the other Party as an Indemnitor hereunder, any and all liabilities, losses, costs, damages, fees or expenses (including
reasonable legal expenses and reasonable attorneys’ fees) of any kind payable to Third Parties (including attorneys for such
Indemnitees) incurred by the Indemnitees and arising out of such Claim.

 

		1.87	“Low Dosage” means, with respect to any product containing the Compound, that such product produces a peak blood
concentration (measured as a Cmax) equal to or less than [***] per milliliter of blood plasma or serum ([***]), where “Cmax”
means the maximum concentration of the Compound measured in blood plasma or serum following administration of the product
and prior to a subsequent administration of the product.”

 

		1.88	“LTC Activities” means, for each combination of Product, Indication, and country in the Territory, (a) meetings
(either in person or through live video conferencing), other than Details, with one or more physicians, administrators, and other
medical or other professional categories identified in the Annual Commercialization Plan for the purpose of marketing and promoting
such combination of Product and Indication to LTC organizations in such country and (b) activities connected with pricing,
rebate and other contract-related negotiations, contracting, and processing and implementation of agreements with LTC organizations.

 

		1.89	“Manufacture”, “Manufacturing”, or “Manufacturing Activities” means, as applicable, all
activities associated with the production, manufacture, supply, processing, filling, packaging, labeling, shipping, and storage
of bulk and finished forms of bulk and finished forms of Products and/or any components thereof, including, without limitation,
process and formulation development, process validation, stability testing, manufacturing scale-up, manufacture for preclinical
and clinical studies and Commercialization, analytical development, product characterization, quality assurance and quality control
development, testing and release, and any technical support activities that are necessary for Regulatory Approval and Commercialization
of Products.

 

		1.90	“Manufacturing and Supply Plan” means the plan attached as Exhibit 5.5 and relating to the manufacture by or for
Licensee of quantities of the Product and subsequent supply thereof for Commercialization and Development Activities by Licensee,
as such plan may be modified from time to time for the Territory.

 

		1.91	“Marketing Authorization Application” or “MAA” means, with respect to any product and each country
in the Territory, an application to the applicable Regulatory Authority for approval to commercially market and sell the product
in such country. For the sake of clarity, this term (and its abbreviation) includes NDAs and sNDAs in the United States.

 

		1.92	“New Drug Application” or “NDA” means, with respect to any product, the application referred to as
such by FDA and that must be approved by FDA before such product can be commercially marketed and sold in the United States, and
such term includes, without limitation, and, unless the context otherwise states to the contrary, any supplemental NDAs (“sNDAs”),
each such application having the form and containing the substance specified by the FDA for such applications and supplemental
applications.

 

    	 	10	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.93	“Net Sales” means, with respect to a given period of time, gross sales of the Product in such period to unrelated
Third Parties in bona fide arm’s length transactions, (excluding sales or dispositions for use in Clinical Studies or other
scientific testing or reasonable quantities of samples, in each case for which Licensee and any such Third Party Distributors receive
no revenue), less the following deductions which are actually incurred, allowed, paid, accrued or specifically allocated to such
gross sales amounts of the Product and not separately invoiced:

 

		(a)	credits or allowances actually granted for damaged Product, returns or rejections of Product, price adjustments, and billing
errors;

 

		(b)	governmental and other rebates (or equivalents thereof) granted to: managed health care organizations; pharmacy benefit managers
(or equivalents thereof); federal, state/provincial, local and other governments, their agencies and purchasers and payors, including,
without limitation, any state or federal Medicare, Medicaid or similar program); or trade customers;

 

		(c)	normal and customary trade, cash and quantity discounts, allowances and credits actually allowed and taken specifically with
respect to sales of other dispositions of the Product;

 

		(d)	distribution services agreement fees allowed or paid to Third Party distributors;

 

		(e)	transportation costs, including without limitation insurance, for outbound freight related to delivery of the Product to the
extent included in the gross amount invoiced;

 

		(f)	excise and sales taxes, tariffs, duties, value added taxes, and other taxes applied to the sale of the Product imposed upon
and paid directly with respect to such sales or (reduced by any refunds of such taxes deducted in the calculation of Net Sales
for prior periods and, for the avoidance of doubt, no deduction shall be permitted for income, withholding, corporate or similar
taxes); and

 

		(g)	any other items that reduce gross sales amounts as required by GAAP.

 

Transfers and sales of the Product between or among a
Party and its Affiliates or Third Party Distributors shall be excluded from the computation of Net Sales, but the subsequent final
sales of the Product to Third Parties by such Affiliates or Third Parties shall be included in the computation of Net Sales.

 

There shall be no double counting in determining the
foregoing deductions from gross amounts invoiced to calculate Net Sales. The deductions set forth above in this definition of Net
Sales shall be determined in accordance with GAAP, as consistently applied by Licensee and such Third Party Distributors across
all of their products. The amounts set forth in clauses (a) through (g) above shall only be deducted from gross invoiced sales
where gross invoiced sales before deductions are non-discounted gross sales amounts.

 

In the event Licensee or such Third Party Distributors
sell the Product together with other products to Third Parties in a particular country in the Territory and the price attributable
to the Product is less than the average price of “arm’s length” sales of the Product alone in the particular
country for the reporting period in which such sales occur (such sales to be excluded from the calculation of the average price
of “arm’s length“ sales of the Product alone), Net Sales for any such sales shall be the average price of “arm’s
length” sales by Licensee or Third Party Distributors, as applicable, of the Product alone and in the country during the
reporting period in which such sales occur. If the average price of “arm’s length” sale of the Product cannot
be determined in any given country, the Net Sales will be determined by the value of the Product sold to similar customers in countries
with similar pricing and reimbursement structures and for similar quantities. Any dispute as to the determination of fair market
value that cannot be resolved through discussion between the Parties shall be determined in accordance with Section 3.2(i). Notwithstanding
the foregoing, in the event the Product is sold as a Combination Product, for purposes of determining the royalties payable by
Licensee to Licensor hereunder, Net Sales shall be calculated by the Net Sales for such Combination Product in a manner to be negotiated
and agreed upon by Licensor and Licensee, reasonably and in good faith, prior to any sale of such Combination Product, which shall
be based upon the respective fair market values of the active pharmaceutical ingredients in such Combination Product; provided
that in no event shall the royalty rate payable by Licensee to Licensor for such Combination Product be greater than the royalty
rate of the Product containing the Compound as the sole active ingredient.

 

    	 	11	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.94	“Noctiva Launch” shall mean the date the Noctiva Product has been supplied, to wholesalers, retail chains and pharmacy
benefit managers and is widely available for commercial sale to patients.

 

		1.95	“Noctiva Product” shall mean .83mcg or 1.66mcg desmopressin acetate nasal spray product.

 

		1.96	“Nocturia Indication” means an Indication characterized by urination in a human aged 18 years or older wherein,
during a defined period of such human’s normal period of sleep at night, two or more non-incontinent urinary void(s) of any
volume during such period of sleep, each such void following an initial period of sleep and, thereafter, followed by sleep or an
attempt to sleep.

 

		1.97	“Out-of-Pocket Costs” means the direct expenses paid or payable by Licensee to any Third Parties in respect of
any Development Activities or Commercialization Activities, as applicable, performed for such Party (or its Affiliates) by such
Third Party.

 

		1.98	“Party” means Licensor or Licensee; “Parties” means Licensor and Licensee.

 

		1.99	“Patent Rights” means, with respect to each country in the Territory (except as otherwise stated to be with respect
to any country in or outside the Territory), (a) patent applications (including provisional applications) pending in such country,
(b) any patents issuing in such country from such patent applications (including certificates of invention), (c) all patents and
patent applications issued or pending, as applicable, in such country based on, corresponding to or claiming the priority date(s)
of any of the foregoing, (d) rights in such country derived from any of (a), (b) or (c), including any substitutions, extensions
(including supplemental protection certificates), registrations, confirmations, reissues, divisionals, continuations, continuations
in part, reexaminations, renewals, revalidations, revivals, patents of addition, and (e) all patents and patent applications issued
or pending, as applicable, in such country claiming overlapping priority therefrom.

 

		1.100	“Person” means any individual, corporation, limited or general partnership, limited liability company, joint venture,
trust, unincorporated association, governmental body, authority, bureau or agency, or any other entity or body.

 

		1.101	“Pharmacovigilance Agreement” means the pharmacovigilance agreement to be entered into by Parties, Third Party
Distributors, and any Third Parties which such Third Parties are licensed or sublicensed to Commercialize the Product in countries
outside the Territory.

 

		1.102	“Phase 1 Clinical Study”, with respect to any investigational drug product, means a human clinical study that provides
for the introduction into humans of such investigational drug product and that is intended to initially evaluate the safety, tolerance
or pharmacological effects of such investigational drug product in human subjects, or that is otherwise described in 21 CFR Sec
312.21 (a) or its foreign counterpart.

 

    	 	12	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.103	“Phase 2 Clinical Study” means a human clinical study that is intended to initially evaluate the dosing and effectiveness
of the Product, and to further evaluate the safety of the Product, or that is otherwise described in 21 CFR Sec. 312.21(b) or its
foreign counterpart.

 

		1.104	“Phase 3 Clinical Study” means a human clinical study that is prospectively designed to demonstrate statistically
whether the Product is safe and effective to control, mitigate, prevent, treat or cure a particular Indication in a manner sufficient
to obtain Regulatory Approval to market the Product, or that is otherwise described in 21 CFR Sec. 312.21(c) or its foreign counterpart.

 

		1.105	“PNE Indication” means the Primary Nocturnal Enuresis Indication and is characterized by the occurrence of one
or more incontinent urinary voids occurring during sleep in a person under the age of eighteen (18) years.

 

		1.106	“Post-Market Approval Study” means a human clinical study in respect of the Product for a specified Indication
that is conducted under the Applicable Law of any country in the Territory after Regulatory Approval of the Product for such Indication
has been obtained from the applicable Regulatory Authority in that country, and includes trials conducted (a) voluntarily for the
purpose of enhancing marketing or scientific knowledge of such Indication or (b) at the request or requirement of the applicable
Regulatory Authority.

 

		1.107	“Product” means any product for a specific Indication within the Field that contains the Compound in any form,
presentation, formulation and dosage form, and (a) is at any time during the Term of this Agreement Covered by a Licensed Serenity
Patent Right, Licensed CPEX Patent Right, or Licensed Reprise Patent Right. For purposes of this Agreement, Net Sales of any such
Product so Covered by any such Patent Right at any time during the Term of this Agreement will continue to be treated, from and
after the time that the Product is no longer Covered by any Valid Claim of any such Patent Right, as a Product for purposes of
calculating any payments to be made to Licensor under Article 8. For the sake of clarity, the term “Product” includes
the First Approved Product.

 

		1.108	“Product Regulatory Approvals and Documentation” means all Regulatory Approvals and Regulatory Documentation in
respect of the Product and each country in the Territory (including, without limitation, the First Approved NDA and any INDs in
respect of the Product open as of the Effective Date).

 

		1.109	“Promotional Materials” means any printed or other materials bearing the name (trade name or generic name) used
to promote the Product in any country in the Territory, including brochures, journal ads, selling aids, posters, reprints, video
or audio tapes, press releases, Internet pages and websites, radio or television advertisements and textbooks.

 

		1.110	“Publication” means any publication in a scientific journal, any abstract to be presented to any scientific audience,
any presentation at any scientific conference, any other scientific presentation and any other oral, written or electronic disclosure
directed to a scientific audience which pertains to the Product or the use of the Product.

 

		1.111	“Receiving Party” means, with respect to the receipt by a Party of any Confidential Information from the other
Party, the Party so receiving such Confidential Information.

 

		1.112	“Regulatory Approval” means, with respect to a drug product and a specified country in the Territory, the act of
the applicable Regulatory Authority in such country necessary for the marketing and commercial sale of such drug product in such
country (including pricing and/or reimbursement approval in such country in which such pricing and/or reimbursement approval is
required by Applicable Laws), including, without limitation, the approval of an NDA for the Product by the FDA and other regulatory
agencies in the Territory.

 

    	 	13	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.113	“Regulatory Authority” means, in any country in the Territory, any applicable government regulatory authority involved
in the granting of Regulatory Approval for the Product in such country or regulatory jurisdiction, including the FDA in the United
States and counterparts thereof in other country in the Territory.

 

		1.114	“Regulatory Documentation” means, with respect to the Product, all INDs, NDAs (including, without limitation, sNDAs),
MAAs or other regulatory applications submitted to any Regulatory Authority, preclinical and clinical data and information, regulatory
materials, drug dossiers, master files (including, without limitation, Drug Master Files), and any other reports, records, regulatory
correspondence and other materials relating to Development or Regulatory Approval of the Product, including, without limitation,
those materials necessary to Develop, Manufacture, Commercialize and otherwise Exploit the Product, including, without limitation,
any information that relates to pharmacology, toxicology, chemistry, manufacturing and controls data, batch records, safety and
efficacy, and any safety database.

 

		1.115	“Regulatory Exclusivity” means, with respect to a country, any exclusive marketing rights or data exclusivity rights
conferred by any applicable Regulatory Authority with respect to the Product in such country, other than a Patent Right.

 

		1.116	“Regulatory Rights Assignment and Assumption Agreement” means that certain agreement of even date herewith entered
into by Licensor and Licensee, relating to the assignment by Licensor to Licensee of the Product Regulatory Approvals and Documentation
relating to the Commercialization and Development of Products in each country in the Territory, including, without limitation,
U.S. IND 076667 and U.S. NDA 201656 (also referred to herein as the First Approved NDA), and the assumption by Licensee of all
of the obligations under Applicable Law as the sponsor thereunder.

 

		1.117	“Remedial Action” means any recall, market withdrawal, safety alert, corrective action or other regulatory action
taken with respect to the Product by virtue of Applicable Laws.

 

		1.118	“Renaissance” means Renaissance Lakewood, LLC (formerly DPT Lakewood, LLC), a limited liability company organized
under the laws of the State of Delaware.

 

		1.119	“Renaissance Agreements” means (a) that certain Manufacturing Agreement, dated July 14, 2014, between Serenity
and Renaissance, relating to the manufacture by Renaissance of Product and supply thereof to Serenity or any third party designated
by Serenity and (b) that certain Quality Agreement, dated January 16, 2015, between Serenity and Renaissance, relating to compliance
with current Good Manufacturing Practices guidances and directives applicable to the manufacture by Renaissance of Products.

 

		1.120	“Renaissance Agreements Assignment and Assumption Agreement” means that certain agreement of even date herewith
entered into by Licensor and Licensee, relating to the assignment by Licensor to Licensee and the assumption by Licensee of the
Renaissance Agreements.

 

		1.121	“Reprise” means Reprise Biopharmaceutics, LLC, a limited liability company organized under the laws of the State
of New York.

 

		1.122	“Reprise License Agreement” means that certain license agreement, effective as of May 28, 2017, by and between
Reprise and Serenity, relating to the grant by Reprise to Serenity of an exclusive license under the patent rights and know-how
specified therein.

 

		1.123	“Right of Reference or Use” has the meaning set forth in 21 CFR Sec. 314.3(b) with respect to the United States,
and any provisions equivalent thereto in the Applicable Laws of any other country in the Territory.

 

    	 	14	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		1.124	“Royalty Term” means, with respect to the Product and each country in the Territory, the period of time commencing
on the date of First Commercial Sale by Licensee or its Sublicensees of the Product in such country and ending upon the termination
of this Agreement in accordance with Article 14.

 

		1.125	“Serenity” has the meaning set forth in the Preamble.

 

		1.126	“Serenity Trademark Standards” means the set of policies, specifications, directions, and standards for use of
the Licensed Serenity Trademarks to be prepared in accordance with Section 4.4 and to be attached hereto as Exhibit 1.124.

 

		1.127	“Sublicensed Rights” has the meaning set forth in Section 2.2(b).

 

		1.128	“Term” means the period commencing on Effective Date and ending upon the termination of this Agreement in accordance
with Article 14.

 

		1.129	“Territory” means the United States, Canada, and each of their respective territories and possessions.

 

		1.130	“Third Party” means any Person other than the Parties and their Affiliates.

 

		1.131	“Third Party Distributor” means any Third Party engaged and authorized by Licensee Party to distribute, import,
market, promote and sell the Product in any country in the Territory.

 

		1.132	“Third Party Infringement Claim” has the meaning set forth in Section 9.4(a).

 

		1.133	“Third Party License(s)” has the meaning set forth in Section 8.3(b)(ii)(A).

 

		1.134	“Third Party Supply Agreements” means the agreements originally executed by and between Serenity and the Third
Parties named therein, relating to the manufacture and supply of certain components of the First Approved Product (including, without
limitation, the applicable drug substance, ingredients for formulating the applicable drug product, and intranasal delivery device)
and the manufacture and supply of the First Approved Product in finished form, including, the Renaissance Agreements and the other
agreements set forth in Exhibit 1.134.

 

		1.135	“Toll Period” has the meaning set forth in Section 14.2(b).

 

		1.136	“TRx” shall mean total prescriptions of a product for a specified period.

 

		1.137	“Treatment” (or, when required by the context, “Treat” or “Treats”) means, with respect
to an Indication, the diagnosis, prevention, palliation, amelioration, control, mitigation, treatment, cure, or prognosis of such
Indication.

 

		1.138	“Unexpected Adverse Drug Experience” has the meaning set forth in 21 CFR Section 314.80 and any regulation successor
thereto.

 

		1.139	“Valid Claim” means, with respect to a particular country in the Territory, a claim within an issued patent or
patent application included in the Licensed Serenity Patent Rights, Licensed Reprise Patent Rights, or Licensed CPEX Patent Rights
that has not expired, lapsed, or been abandoned, and that has not been held unenforceable, invalid, or been cancelled by a court
or administrative agency of competent jurisdiction in an order or decision from which no appeal has been or can be taken, including
without limitation through opposition, re-examination, reissue, or disclaimer.

 

    	 	15	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		2.	LICENSES AND ASSIGNMENTS.

 

		2.1	Licenses of Patent Rights, Know-How, Trademark, and Copyrights. 

 

		(a)	Subject to the terms and conditions of this Agreement, Licensor hereby grants Licensee under Licensor’s right, title,
and/or interest in or to the Licensed Serenity Patent Rights and the Licensed Serenity Know-How, a transferable (subject to
Section 15.2), sublicenseable (subject to Section 2.4), royalty-, fee- and milestone payment-bearing, exclusive (subject to Section
2.5, even as to Licensor) license to make, have made, use and have used, offer to sell, sell and have sold, import and have imported,
and to otherwise Commercialize the Product in the Field throughout the Territory.

 

		(b)	Subject to the terms and conditions of this Agreement, Licensor hereby grants Licensee under Licensor’s right, title,
and/or interest in or to the Licensed Serenity Trademarks, a transferable (subject to Section 15.2), sublicenseable (subject
to Section 2.4), royalty-, fee- and milestone payment-bearing, exclusive (even as to Licensor) license to use the Licensed Serenity
Trademarks to Commercialize the Product in the Field throughout the Territory.

 

		(c)	Subject to the terms and conditions of this Agreement, Licensor hereby grants Licensee under Licensor’s right, title,
and/or interest in or to the Licensed Serenity Copyrights, a transferable (subject to Section 15.2), sublicenseable (subject
to Section 2.4), royalty-, fee- and milestone payment-bearing, exclusive (even as to Licensor) license to use, copy, publish, and
distribute the content that is the subject of the Licensed Serenity Copyrights for the purpose of Commercializing the Product in
the Field throughout the Territory.

 

		(d)	The license in, to, and under the Licensed Patents granted in Sections 2.1(a), (b) and (c) includes, without limitation,

 

		(i)	the right to sue for past and future infringement, violation, or misappropriation of any of such Licensed and any invention
claimed therein and all applications for industrial property protection hereafter filed for any such invention, including, without
limitation, all applications for patents, utility models, and designs which may be filed for any such invention in any country
or countries in the Territory,

 

		(ii)	the right to file such applications in such countries in the Territory,

 

		(iii)	the right to claim for such applications the priority rights derived from the corresponding patent application under the patent
laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement
or the domestic laws of the country in which any such application is filed, as may be applicable; and

 

		(iv)	all forms of industrial property protection, including, without limitation, patents, utility models, inventors’ certificates
and designs which may be granted for any such invention in any country or countries in the Territory and all extensions, renewals
and reissues thereof.

 

		2.2	Grant of Sublicenses to Licensee. Subject to the terms and conditions of this Agreement, the CPEX License Agreement,
and the Reprise License Agreement, Licensor hereby grants Licensee under Licensor’s rights in the Licensed CPEX Patent Rights
and the Licensed Reprise Rights (collectively, the “Sublicensed Rights”) a transferable (subject to Section 15.2),
sublicenseable (subject to the terms of Section 2.4, and each of the CPEX License Agreement and the Reprise License Agreement,
as applicable), royalty-, fee-, and milestone payment-bearing, exclusive (even as to Licensor) sublicense to make, have made, use
and have used, offer to sell, sell and have sold, import and have imported, and to otherwise Commercialize the Product in the Field
throughout the Territory.

 

    	 	16	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		2.3	Assignments.

 

		(a)	Assignment of Supply Agreement.  Simultaneously with the execution and delivery of this Agreement, the Parties
will execute and deliver to each other the Renaissance Supply Agreement Assignment and Assumption Agreement.

 

		(b)	Assignment of Regulatory Rights. Simultaneously with the execution and delivery of this Agreement, the Parties
will execute and deliver to each other the Regulatory Rights Assignment and Assumption Agreement.

 

		2.4	Sublicensing by Licensee.

 

		(a)	Subject to the terms and conditions of this Agreement, Licensee shall have the right to grant to Third Parties sublicenses
under the license to the Licensed Rights granted to Licensee in Sections 2.1(a), (b) and (c) and the sublicense to the Sublicensed
Rights granted to Licensee in Section 2.2; provided that Licensee hereby covenants that it will not grant any such sublicense unless
(i) in the case of any such sublicense of the Licensed Rights or the Sublicensed Rights, Licensor has consented thereto, which
such consent shall not be unreasonably withheld, conditioned or delayed, (ii) in the case of any such sublicense of the Sublicensed
Rights, such sublicense complies with the terms and conditions set forth in the CPEX License Agreement or Reprise License Agreement,
as applicable; and provided, further, that except for sublicenses granted in respect of Development and Commercialization of the
Product in Canada, Licensee will not grant any such sublicenses during the first two (2) years immediately following the Effective
Date.

 

		(b)	Licensee will be solely responsible for the performance of any sublicensee under each such sublicense agreement granted in
accordance with this Section 2.4.

 

		(c)	Each such sublicense granted by Licensee in accordance with this Section 2.4 will be set forth in a sublicense agreement that
includes provisions that obligate the sublicensee thereunder to abide by and be subject to all of the terms and conditions of (i)
this Agreement as are applicable to Licensee as licensee hereunder and (ii) the CPEX License Agreement and the Reprise License
Agreement as are applicable to Licensee as a sublicensee thereunder.

 

		(d)	Licensee will provide Licensor with a copy of each such executed sublicense agreement within ten (10) days after the execution
and delivery thereof.

 

		(e)	The existence and any and all of the contents of any such executed sublicense agreement will be deemed to be Confidential Information
of each Party under this Agreement (except to the existence of any obligations to disclose such sublicense agreement to the licensors
under CPEX License Agreement or the Reprise License Agreement, as applicable).

 

		(f)	Each such sublicense granted by Licensee will terminate immediately upon the termination of this Agreement, unless:

 

		(i)	such sublicensee is not in material breach of its obligations thereunder,

 

		(ii)	if this Agreement was terminated for Licensee’s material breach of the terms and conditions hereof, such sublicensee
cures such material breach by Licensee within thirty (30) days after such termination; and

 

		(iii)	such sublicensee agrees in writing to be bound directly to (A) Licensor as licensee under the Licensed Rights and sublicensee
under the Sublicensed Rights in accordance with the terms and conditions of this Agreement and (B) CPEX and Reprise in accordance
with terms and conditions of the CPEX License Agreement and the Reprise License Agreement, respectively.

 

    	 	17	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		2.5	Licenses Granted by Licensee to Serenity.

 

		(a)	License for Development and Commercialization Activities. Subject to the terms and conditions of this Agreement
Licensee hereby grants to Serenity and its Affiliates, under Licensee’s rights in any and all intellectual property (including,
without limitation, Know-How and any Patent Rights, trademarks, and copyrights) with respect to the Product that Licensee or any
of its Affiliates owns or otherwise controls by license or otherwise,

 

		(i)	an exclusive (even as to Licensee), sublicenseable (subject to Section 2.5(b)), transferable (subject to Section 15.2), sublicense
to Develop, Commercialize, and Manufacture outside the Territory Products for any Indications, which such sublicense (A) in the
case of any such intellectual property not originally licensed, sublicensed, or assigned by Licensor to Licensee in accordance
with this Agreement shall bear royalties, fees, and/or milestone payments to be mutually agreed upon by the Parties and (B) in
the case of any such intellectual property originally licensed, sublicensed, or assigned by Licensor to Licensee in accordance
with this Agreement shall not bear any royalties, fees, or milestone payments;

 

		(ii)	in the event that Licensor engages, in accordance with Section 2.6, Section 6.2, Article 14, or otherwise under the terms
and conditions of this Agreement, in any Development, Commercialization, or Manufacture of Products in the Territory for any Indications,
an exclusive (even as to Licensee), sublicenseable (subject to Section 2.5(b)), transferable (subject to Section 15.2), sublicense
to so Develop, Commercialize in the Territory, and Manufacture such Products for such Indications, which such sublicense (A) in
the case of any such intellectual property not originally licensed, sublicensed, or assigned by Licensor to Licensee in accordance
with this Agreement shall bear royalties, fees, and/or milestone payments to be mutually agreed upon by the Parties and (B) in
the case of any such intellectual property originally licensed, sublicensed, or assigned by Licensor to Licensee in accordance
with this Agreement shall not bear any royalties, fees, or milestone payments; and

 

		(iii)	in the event that Licensor engages in any Development of Products in the Territory for any Indications in connection with any
Development Activities contemplated by Article 6, a non-exclusive sublicense to Develop such Products for such Indications, which
such sublicense shall not bear any royalties, fees, or milestone payments.

 

		(b)	Sublicensing by Licensor. 

 

		(i)	Subject to the terms and conditions of this Agreement, Licensor shall have the right to grant to Third Parties sublicenses
under the license granted to Licensor under Section 2.5(a); provided that Licensor hereby covenants that it will not grant
any such sublicense unless Licensee has provided its consent, which consent shall not be unreasonably withheld or delayed and such
sublicense complies with the terms and conditions set forth in this Agreement.

 

		(ii)	Licensor shall be solely responsible for the performance of any sublicensee under each such sublicense agreement granted in
accordance with this Section 2.5(b).

 

		(iii)	Each sublicense agreement granted by Licensor in accordance with this Section 2.5(b) will be set forth in a sublicense agreement
that includes provisions that obligate the sublicensee thereunder to abide by and be subject to all of the terms and conditions
of this Agreement as are applicable to the intellectual property so licensed by Licensee to Licensor under Section 2.5(a).

 

    	 	18	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(iv)	Licensor will provide Licensee with a copy of each such executed sublicense agreement within ten (10) days after the execution
and delivery thereof.

 

		(v)	The existence and any and all of the contents of any such executed sublicense agreement will be deemed to be Confidential Information
of each Party under this Agreement.

 

		(vi)	Each such sublicense granted by Licensor in accordance with this Section 2.5(b) shall terminate immediately upon the termination
of this Agreement, unless:

 

		(A)	such sublicensee is not in material breach of its obligations thereunder,

 

		(B)	if this Agreement was terminated for Licensor’s material breach of the terms and conditions hereof, such sublicensee
cures such material breach by Licensor within thirty (30) days after such termination; and

 

		(C)	sublicensee agrees in writing to be bound directly to Licensee as licensee under the intellectual property sublicensed under
such sublicense.

 

		(c)	Right of Reference or Use. 

 

		(i)	Licensee hereby grants to Licensor a Right of Reference or Use in all Regulatory Approvals and Regulatory Documentation (for
purposes of this Section 2.5(c), “Licensee Regulatory Approvals and Regulatory Documentation”) relating to the Compound
and any Products in respect of which Licensee is the sponsor for purposes of:

 

		(A)	Licensor’s Development, Commercialization, or Manufacture of Products outside the Territory and

 

		(B)	Licensor’s Development, Commercialization, or Manufacture of Products for any Indications inside the Territory in the
event that Licensor engages in any such Development, Commercialization, or Manufacture of Products in the Territory for such Indications
in accordance with Section 2.6, Section 6.3, and/or Article 14, or otherwise under the terms and conditions of this Agreement.

 

		(ii)	The Parties agree that prior to any exercise by Licensor of the Right of Reference or Use granted by Licensee to Licensor under
Section 2.5(c)(i), the Parties will mutually agree upon the amount and timing of one or more payments by Licensor to Licensee as
consideration to Licensee for the grant of such Right of Reference or Use, which such payments shall be fair and reasonable in
respect of the expenditures that Licensee incurs to obtain such Regulatory Approvals and Regulatory Documents and only payable
in the event that such Regulatory Approvals and/or Regulatory Documents are referenced or used by Licensor to support a Regulatory
Approval of the Product that is granted by the applicable Regulatory Authority.

 

		(iii)	The Parties agree that for purposes of Section 2.5(c)(ii),

 

		(A)	[***]; and

 

    	 	19	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(B)	to the extent Licensor licenses or sublicenses the Commercialization of any Products pursuant to any arrangement that becomes
effective following the first anniversary of the Effective Date and in respect of which the applicable Regulatory Approval has
been supported at least in part by any Regulatory Approvals or Regulatory Documents of Licensee that are referenced or used as
contemplated by this Section 2.5(c), payments of such consideration in respect of any Calendar Quarter will not exceed more
than [***] percent ([***]%) of the consideration received by Licensor from any sublicensee of Licensor in respect of such Commercialization.

 

		2.6	Right of First Negotiation. Licensee covenants and agrees that if at any time during the Royalty Term with respect to
any country in the Territory, Licensee decides to seek to negotiate an agreement with any Third Party relating to the Commercialization
of Generic Products in such country by such Third Party, Licensee will not enter into any such negotiations with any such Third
Party before providing Licensor prior written notice thereof, whereupon Licensor will, upon written notice to Licensee within thirty
(30) days after the receipt of such notice from Licensee, have the right to enter into good faith, exclusive negotiations with
Licensee with respect to Licensor obtaining the right to so Commercialize in such country Generic Products, and further provided
that as a condition to Licensee agreeing to grant Licensor any rights to so Commercialize any Generic Products for any Indications
in any country in the Territory, Licensor must demonstrate that Licensor possesses or otherwise has access to the resources required
to so Commercialize any such Generic Products and Licensor agrees not to otherwise Commercialize any Generic Products in the Territory.
Notwithstanding anything to the contrary set forth herein, Licensee has the right to Develop and Commercialize Generic Products
in any country in the Territory and the TRxs in respect of such Commercialization of Generic Products by Licensee will be included
in TRxs of Generic Products for purposes of the definition of Royalty Term, provided that if Licensee Launches any such Generic
Product prior to the Launch of a Generic Product in any country in the Territory prior to the Launch in such country of a Generic
Product by a Third Party, then Licensee must obtain the written consent of Licensor prior to such Launch.

 

With respect to Products, Licensor from time to time may
notify and demonstrate to Licensee that Licensor possesses or has access to the resources required for performing Commercialization
Activities in respect of such Products in the Territory. Licensee agrees that upon demonstration that Licensor possesses or has
access to such resources, Licensee will in good faith consider Licensor to perform such Commercialization Activities prior to negotiating
an agreement with a Third Party related to such Commercialization Activities.

 

		2.7	No Implied Rights or Licenses. No Party grants to the other Parties any rights or licenses in or to any intellectual
property right or regulatory right whether by implication, estoppel, or otherwise, except to the extent expressly provided in this
Agreement. Nothing in this Agreement shall in any manner limit the activities of Licensor or its Affiliates with respect to the
Product outside the Territory.

 

		3.	JOINT STEERING COMMITTEE AND ALLIANCE MANAGERS.

 

		3.1	Generally. 

 

		(a)	Joint Steering Committee. Licensor and Licensee shall form the Joint Steering Committee. The JSC will have only
such powers as are specifically delegated to it in this Agreement, and such powers shall be subject to the terms and conditions
set forth in this Agreement.

 

		(b)	JSC Subcommittees. The JSC is hereby authorized to appoint one or more JSC Subcommittees to which the JSC may
assign responsibility for specific matters (including, without limitation, matters arising with respect to Development, Commercialization,
and Manufacturing. Each JSC Subcommittee will have only such powers as are specifically delegated to it by the JSC, and the delegation
of any such powers to any JSC Subcommittee shall be subject to the terms and conditions set forth in this Agreement.

 

    	 	20	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(c)	Limitation of Power of JSC and JSC Subcommittees. Without limiting the generality of Sections 3(a) and 3(b),
neither the JSC nor any JSC Subcommittee shall have any power to amend this Agreement or bind or incur liability on behalf of either
Party without such Party’s express prior written authorization.

 

		(d)	Compliance with JSC and JSC Subcommittee Decisions. Each Party will comply with the decisions of the JSC and
any JSC Subcommittee to the extent such decisions arise from the JSC or such JSC Subcommittee, as applicable, carrying out its
powers and responsibilities as set forth in this Agreement and not otherwise inconsistent with the terms and conditions of this
Agreement. Notwithstanding the foregoing, and is expressly set forth herein, Licensee shall have the sole and absolute right and
discretion to decide matters related to the Commercialization, Manufacturing, or Development of the Product.

 

		3.2	Membership and Governance of JSC and JSC Subcommittees.

 

		(a)	Membership.

 

		(i)	The JSC will be comprised of six (6) members who, except as otherwise provided in clause (iii) of this Section 3.2(a), are
employees of the Parties (each a “JSC Member”), with three (3) JSC Members designated by Licensor and three (3) JSC
Members designated by Licensee.

 

		(ii)	Each JSC Subcommittee will be comprised of the total number of members (each a “JSC Subcommittee Member”) as is
designated by the JSC in forming such JSC Subcommittee, with the number of JSC Subcommittee Members appointed to such JSC Subcommittee
from each Party to be designated by the JSC in forming such JSC Subcommittee. In determining the number of JSC Subcommittee Members
to serve on any JSC Subcommittee formed by the JSC, the JSC will provide that the number of such JSC Subcommittee Members to be
designated by each Party will be reasonable with respect to the experience and expertise of the human resources of each such Party
in respect of the matters for which such JSC Subcommittee is responsible.

 

		(iii)	Each of Licensor and Licensee, upon prior written notice to the other Party, may (i) replace each person such Party has designated
as a JSC Member or a JSC Subcommittee Member for any reason at any time, upon prior written notice to the other Party, (ii) designate
a substitute for each person such Party has designated as a JSC Member or JSC Subcommittee Member, and (iii) appoint non-employees
of such Party as JSC Members and JSC Subcommittee Members only upon the prior consent and approval of the other Party.

 

		(b)	Decision-Making. While the JSC and each JSC Subcommittee will seek to decide matters under their respective consideration
by consensus of all of its members, Licensee reserves the right to decide each such matter in its sole and absolute discretion.

 

		(c)	Meetings. The JSC and each JSC Subcommittee will meet as agreed upon by the JSC Members or the applicable JSC
Subcommittee Members, respectively, in person or by teleconference or video-teleconference; provided that the first meeting of
the JSC Committee or such JSC Subcommittee, as applicable, will be within ninety (90) days after the Effective Date.

 

    	 	21	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(d)	Observers. Except for matters in respect of which the JSC or any JSC Subcommittee needs to meet in executive
session, the meetings of the JSC and any JSC Subcommittee may be attended by non-Member observers at the invitation of an executive
officer of either Party (the “Inviting Party”), provided that (i) the Inviting Party provides reasonable prior notice
of such invitation to the other Party, (ii) the other Party has consented to such invitation in advance of the applicable meeting,
which such consent shall not be unreasonably withheld, delayed or conditioned and (iii) any such observer has agreed in writing
to obligations to safeguard the confidentiality and restrictions on use of Confidential Information that are no less restrictive
than the obligations in Section 13.2.

 

		(e)	Chairperson.

 

		(i)	Of JSC. At the first meeting of the JSC following the Effective Date and at the first meeting of the JSC in each calendar
year beginning after the Effective Date, the JSC Members will select a chairperson to serve until such person’s successor
has been designated in accordance herewith. The chairperson of the JSC shall rotate annually between JSC Members designated by
Licensor and those designated by Licensee. The first chairperson of the JSC shall be selected from the JSC Members designated by
the Licensee.

 

		(ii)	Of Each JSC Subcommittee. Each JSC Subcommittee shall have a chairperson appointed in accordance with the directions
of the JSC in establishing such JSC Subcommittee.

 

		(f)	Secretary. 

 

		(i)	Of JSC. The chairperson of the JSC shall designate a secretary of the JSC who will be responsible for calling meetings,
preparing and circulating an agenda in advance of each meeting, and preparing and circulating minutes within thirty (30) days after
each meeting of such committee setting forth, among other things, a description, in reasonable detail, of the discussions at the
meeting and a list of any actions, decisions or determinations approved by the JSC. Such minutes shall be effective only after
being approved by both Parties. Definitive minutes of all committee meetings shall be finalized no later than sixty (60) days after
the meeting to which the minutes pertain.

 

		(ii)	Of Each JSC Subcommittee.  Each JSC Subcommittee shall have a secretary appointed in accordance with the directions
of the JSC in establishing such JSC Subcommittee.

 

		(g)	Term of JSC and JSC Subcommittees.

 

		(i)	The JSC shall continue to exist for the Term of this Agreement or upon its termination upon mutual agreement of the Parties.

 

		(ii)	Each JSC Subcommittee shall continue to exist for the term to be set forth by the JSC in establishing such JSC Subcommittee,
but in no event for a period extending beyond the Term of this Agreement

 

		(h)	Alliance Managers. 

 

		(i)	Each of Licensor and Licensee shall appoint an Alliance Manager, who shall be an individual authorized to act as such Party’s
point of contact for communications between and among the Parties relating to the Commercialization, Manufacturing and Supply,
and any Development Activities contemplated by this Agreement. Each Party may change its designated Alliance Manager from time
to time upon written notice to the other Party. The Alliance Manager of a Party may designate a substitute to temporarily perform
the functions of that Alliance Manager by written notice to the other Party.

 

    	 	22	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(ii)	Each Alliance Manager shall be charged with creating and maintaining a collaborative work environment between and among the
Parties and within the JSC and each JSC Subcommittee.

 

		(iii)	Each Alliance Manager will also: (i) be the point of first referral in all matters of conflict resolution; (ii) identify and
bring disputes to the attention of the JSC or the relevant JSC Subcommittee, as applicable, in a timely manner; (iii) plan and
coordinate cooperative efforts and internal and external communications; and (iv) take responsibility for ensuring that governance
activities, such as the conduct of required JSC and JSC Subcommittee meetings and production of meeting minutes occur as set forth
in this Agreement, and that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed

 

		(i)	Dispute Resolution.

 

		(i)	In the event that any dispute arises with respect to matters falling within the scope of the role and the powers and responsibilities
of the JSC or any JSC Subcommittee as set forth in or contemplated by this Article 3 or elsewhere in this Agreement, then either
Licensor or Licensee or any of the Members of such Committee may notify the Alliance Managers of such disputed matter.

 

		(ii)	The Alliance Managers shall discuss in good faith any such disputed matter referred to them in accordance with Section 3.2(i)(i).
If the Alliance Managers are unable to resolve any such matter, either Licensor or Licensee may refer the matter to the Chief Executive
Officer or President of Licensor and the Chief Executive Officer, President, or an Executive Vice President of Licensee, which
such two individuals shall meet at an agreed location or by telephone to resolve the matter within twenty (20) days after the meeting
at which such matter arose.

 

		(iii)	If such two officers of the Parties are unable to resolve the disputed matter so referred to them in accordance with Section
3.2(i)(ii) within an additional thirty (30) day period, then the following procedures shall apply:

 

		(A)	in the case of matters with respect to which Licensee is authorized hereunder to decide in its sole and absolute discretion,
including, without limitation, any Commercialization or Manufacturing and Supply matter, Licensee shall have final decision-making
rights with respect thereto and shall promptly provide written notice to Licensor of its final position regarding such matter and
Licensor will comply with the position taken by Licensee on such matter unless compliance with such position would result in the
incurrence of a direct material financial expenditure or imposition of some other non-financial burdensome obligation upon Licensor
that would be greater than would have been the case absent compliance with such position, which in such case shall be referred
for dispute resolution under Section 15.8 and

 

		(B)	in the case of matters with respect to which Licensee is not authorized hereunder to decide such matters in its sole and absolute
discretion, such matters shall be referred for dispute resolution under Section 15.8.

 

		3.3	Committee Oversight of Commercialization Activities.

 

		(a)	Role. The JSC and any JSC Subcommittee established for the purpose of oversight of Commercialization Activities,
will monitor, assess, and make recommendations to Licensee in respect of the Commercialization of the Product contemplated in Article
4 of this Agreement.

 

    	 	23	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(b)	Powers and Responsibilities. With respect to Product Commercialization Activities, the powers and responsibilities
of the JSC and any JSC Subcommittee established for the purpose of oversight of such Commercialization Activities are limited to
the matters set forth in this Section 3.3 and Article 4. Neither the JSC nor any JSC Subcommittee shall have the power to amend,
modify, or waive compliance with this Agreement with respect to Commercialization Activities required to be undertaken by Licensee
under this Agreement, including, without limitation, the Commercialization Plans for the Product and any Indications. Notwithstanding
the foregoing, Licensee reserves the right to decide each such Commercialization matter in its sole and absolute discretion, including
amending or modifying any Commercialization Plan.

 

		(c)	Annual Review of Commercialization Plan. On an annual basis, beginning in the first full Calendar Year
following the Effective Date, no later than sixty (60) days before the end of such Calendar Year, the JSC or any JSC Subcommittee
responsible for oversight of Commercialization Activities will review, analyze, and comment on the Annual Commercialization Plan
then in effect and any revisions thereto proposed by Licensee or Licensor, which such review, analysis, and comment will include,
without limitation:

 

		(i)	an assessment of whether the Commercialization Activities contemplated by the Annual Commercialization Plan for the then current
Calendar Year have been successfully undertaken and have achieved or are achieving the strategic objectives set forth in the Commercialization
Plan;

 

		(ii)	an assessment of whether the strategic objectives set forth in the Annual Commercialization Plan, together with any revisions
then proposed by Licensee or Licensor, continue to reflect the best interests of the Parties;

 

		(iii)	the submission to Licensee of any recommended revisions to the Annual Commercialization Plan then in effect and any revisions
then proposed by Licensee or Licensor, in order to reflect the aforementioned assessments.

 

		(d)	Regulatory Exclusivity. The JSC and any JSC Subcommittee responsible for oversight of Commercialization Activities
shall monitor the process of applying for and securing Regulatory Exclusivity that may be available under the applicable Law of
countries in the Territory, including, without limitation, any data or market exclusivity periods such as those periods listed
in the FDA’s Orange Book. Each of Licensor and Licensee shall use Commercially Reasonable Efforts to cooperate with each
other and to take such reasonable actions to obtain such Regulatory Exclusivity in each country in the Territory.

 

		3.4	Oversight of Manufacturing and Supply Activities.

 

		(a)	Role. The JSC and any JSC Subcommittee responsible for oversight of Manufacturing and Supply Activities will
monitor, assess, and make recommendations to Licensee in respect of the manufacture and supply of the Product as contemplated in
Article 5 for purposes of Commercializing the Product for any Indications that are the subject of Regulatory Approvals and any
Development Activities in respect of the Product for the PNE Indication, any Additional Indications and the Nocturia Indication
throughout the Territory.

 

    	 	24	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(b)	Powers and Responsibilities. With respect to Product Manufacturing Activities, the powers and responsibilities
of the JSC and any JSC Subcommittee responsible for oversight of such Manufacturing Activities are limited to the matters set forth
in this Section 3.4 and Article 5. Neither the JSC nor any JSC Subcommittee shall have the power to amend, modify or waive compliance
with this Agreement with respect to Manufacturing Activities required to be undertaken by Licensee under this Agreement, including,
without limitation, the Manufacturing and Supply Plan for the Product. Notwithstanding the foregoing, Licensee reserves the right
to decide each such manufacturing and supply matter in its sole and absolute discretion, including amending or modifying any Manufacturing
and Supply Plan.

 

		(c)	Annual Review of Manufacturing and Supply Plan. On an annual basis, beginning in the first full Calendar Year
following the Effective Date, no later than sixty (60) days before the end of such Calendar Year, the JSC or any JSC Subcommittee
responsible for oversight of Manufacturing Activities will review, analyze, and comment on the Manufacturing and Supply Plan then
in effect, and any revisions thereto proposed by Licensee or Licensor, which such review, analysis, and comment will include, without
limitation:

 

		(i)	an assessment of whether the Manufacturing Activities contemplated by the Manufacturing and Supply Plan for the then current
Calendar Year have been successfully undertaken and have achieved or are achieving the strategic objectives set forth in the Manufacturing
and Supply Plan; and

 

		(ii)	an assessment of whether the strategic objectives set forth in the Manufacturing and Supply Plan, together with any revisions
then proposed by Licensee or Licensor, continue to reflect the best interests of the Parties.

 

		3.5	Oversight of Development Activities. 

 

		(a)	Role. The JSC and any JSC Subcommittee responsible for oversight of any Development Activities contemplated in
Article 6 of this Agreement will monitor such Development Activities. In this role the JSC or such JSC Subcommittee, as applicable,
will (i) assist Licensee in overseeing any Development of, Clinical Studies for, and preparation and submission of Regulatory Documentation
for obtaining Regulatory Approval of the Product contemplated by any Development Plan, including, without limitation, review of
any relevant Regulatory Documents and Regulatory Documentation and (ii) provide a forum for sharing advice, progress, and results
and documents, including, without limitation, relevant Clinical Study designs, protocols, study reports, and any other material
information with respect to any such Development Activities.

 

		(b)	Powers and Responsibilities. With respect to any Product Development Activities, the powers and responsibilities
of the JSC and any JSC Subcommittee responsible for oversight of such Development Activities are limited to the matters set forth
in this Section 3.5 and Article 6. Neither the JSC nor any JSC Subcommittee shall have the power to amend, modify or waive compliance
with this Agreement with respect to Development Activities, including, without limitation, any Development Plan in effect from
time to time. Notwithstanding the foregoing, Licensee reserves the right to decide each such Development matter in its sole and
absolute discretion, including amending or modifying any Development Plan.

 

		(c)	Annual Review of Development Plan. If Licensee determines to engage in any Product Development Activities in
accordance with Article 6, on an annual basis, beginning in the first full Calendar Year following the Effective Date, no later
than sixty (60) days before the end of such Calendar Year, the JSC and any JSC Committee responsible for oversight of Development
Activities that Licensee may so determine to undertake in accordance with Article 6 will review, analyze, and comment on the Development
Plan then in effect, and any revisions thereto proposed by Licensee or Licensor, which such review, analysis, and comment will
include, without limitation:

 

    	 	25	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(A)	an assessment of whether the Development Activities contemplated by the Development Plan for the then current Calendar Year
have been successfully undertaken and have achieved or are achieving the strategic objectives set forth in the Development Plan;

 

		(B)	an assessment of whether the strategic objectives set forth in the Development Plan, together with any revisions then proposed
by Licensee or Licensor, continue to reflect the best interests of the Parties;

 

		(C)	the submission to Licensee of any recommended revisions to the Development Plan then in effect and any revisions then proposed
by Licensee or Licensor, in order to reflect the aforementioned assessments.

 

		4.	COMMERCIALIZATION.

 

		4.1	Preparation and Scope of Commercialization Plan.

 

		(a)	Preparation. Licensee agrees to prepare and provide to Licensor within one hundred twenty (120) days immediately
following the Effective Date the initial Commercialization Plan.

 

		(b)	Scope. The Commercialization Plan for the Product in respect of the Nocturia Indication, PNE Indication and any
Additional Indication will consist of a Pre-Launch Commercialization Plan, an Annual Commercialization Plan, and, in respect of
the initial three-year period following the Effective Date, the three-year Commercialization Plan described below.

 

		4.2	Timing of Product Launches. The initial Commercialization Plan will set forth the timing of the Launch of the Product
in the United States for the Nocturia Indication. To the extent, Licensee or any sublicensee intends in accordance with Article
6 to engage in any Development Activities in order to (a) Commercialize the Product for the Nocturia Indication in Canada, the
Commercialization Plan then in effect will be amended to include such Commercialization at such time and (b) Commercialize any
Product for the PNE Indication and any Additional Indication in either country in the Territory, the Commercialization Plan then
in effect will be amended to include such Commercialization at such time.

 

		4.3	Diligent Commercialization of the Product in the Territory. 

 

		(a)	Licensee covenants that at all times during the Term of this Agreement it will use Commercially Reasonable Efforts to Commercialize
the Product in each country in the Territory, including, without limitation, the making and implementation of decisions and allocation
of Licensee’s resources for the purpose of achieving the objectives set forth in the Commercialization Plan, which such objectives
will include, without limitation, the placement of the Product in First Position in all Detailing of the Product with the Sales
Representatives for the Product for the First Position Period achieving the timing and geographic extent of Detailing of the Product
set forth in the Commercialization Plan, and the continued optimization of such Detailing to maximize Net Sales of the Product.
Failure by Licensee to use Commercially Reasonable Efforts to Commercialize the Product will be deemed to be a material breach
of this Agreement for purposes of Section 14.3.

 

    	 	26	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(b)	The term “First Position Period” means the four (4) year period commencing upon the Launch of the Product in the
United States; provided, however, that if Licensee has not been the subject of a Change of Control prior to the end of such
four-year period, the First Position Period shall be extended to the earlier of (x) the fifth (5th) anniversary of the
commencement thereof and (y) any such Change of Control; and further, provided, however, that if any such Change of
Control occurs prior to the fourth (4th) anniversary of the commencement of the First Position Period, then the party
surviving such Change of Control will be obligated to continue Detailing of the Product in First Position until such fourth (4th)
anniversary and Licensee will use Commercially Reasonable Efforts to obtain the agreement of the party surviving such Change of
Control to continue Detailing of the Product in First Position until the fifth (5th) anniversary of the commencement
of the First Position Period, and if such Change of Control occurs after the fourth (4th) anniversary of such commencement
of the First Position Period but before the fifth (5th) such anniversary, then Licensee will use Commercially Reasonable
Efforts to obtain the agreement of the party surviving such Change of Control to continue Detailing of the Product in First Position
until such fifth (5th) anniversary.

 

		4.4	Commercialization Plan and Budgets, Generally.

 

		(a)	In General. Subject to the terms of this Agreement, the preparation of the Commercial Plan and any and all updates,
revisions, amendments, and the like thereof will be the responsibility of Licensee, and Licensee will bear the expense of the preparation
of the initial Commercial Plan and any and all updates, revisions, amendments and the like thereof. The Commercialization Plan
for the Product for each Indication for which Regulatory Approval is obtained in each country in the Territory will include the
following:

 

		(i)	prior to the Launch of a Product, a detailed Pre-Launch Commercialization Plan covering the period from the date such pre-Launch
Commercialization Plan as approved by the JSC or the JSC Subcommittee responsible for oversight of Commercialization and adopted
by Licensee (generally, upon commencement of the first Phase 3 Clinical Studies in respect of such combination through the end
of the second (2nd) full Calendar Year following Launch of the Product for such Indication in such country (the “Pre-Launch
Commercialization Plan”), provided that the Pre-Launch Commercialization Plan for the Product for the Nocturia Indication
for the United States is set forth in the Commercialization Plan in Exhibit 4.4 to be attached hereto following its preparation
and adoption in accordance with the provisions of this Agreement);

 

		(ii)	an annual Commercialization plan and budget for such Product (the “Annual Commercialization Plan”) for each full
Calendar Year following the end of the period of time covered in the Pre-Launch Commercialization Plan for such Product, each of
which such annual Commercialization Plans shall be reviewed and analyzed by the JSC (or the JSC Subcommittee responsible for oversight
of Commercialization) in accordance with Section 3.3(c)(ii);

 

		(iii)	a three-year Commercialization plan and budget (the “Long-Term Commercialization Plan”) that sets forth the Branding
Strategy for the Product for the initial three year period, the anticipated Commercialization programs and funding requirements
for the Commercialization of the Product for such combination during such three-year period, and anticipated gross sales and Net
Sales of the Product during each quarter in such three-year period, and which such Long-Term Commercialization Plan will be used
to guide the formulation of the applicable Pre-Launch Commercialization Plan and the Annual Commercialization Plan for such Product.

 

    	 	27	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(b)	Content of Commercialization Plan, More Specifically. The Commercialization Plan will specify in detail the content
of the Commercialization Activities contemplated hereby.

 

		(c)	Preparation of Serenity Trademark Standards. As part of the preparation of the initial Commercialization Plan,
Licensee will prepare a proposed set of Serenity Trademark Standards for review and approval by the JSC (or the JSC Subcommittee
responsible for Commercialization matters) in accordance with Section 3.3(b).

 

		4.5	Annual Commercialization and Pre-Launch Commercialization Plans.

 

		(a)	Interim Updating Annual Commercialization Plan. Each Annual Commercialization Plan shall be updated by Licensee
as frequently as needed during a Calendar Year to take into account developments in the Commercialization of the Product for the
applicable Indication and country.

 

		(b)	Pricing and Reimbursement Approvals.

 

		(i)	Where pricing and reimbursement approvals are required for Commercialization of the Product in any country in the Territory,
Licensee, will be responsible for obtaining such approvals in a timely manner, and shall consider in good faith any suggestions
and comments from or on behalf of Licensor with respect thereto.

 

		(ii)	As part of its responsibility for oversight of Commercialization Activities, the JSC and any JSC Subcommittee responsible for
oversight of Commercialization Activities shall review and comment on matters relating to pricing and reimbursement approvals in
respect of the Product. Such review shall include review of any materials, presentations, documents, agendas, and other relevant
information to be presented or followed in meetings and communications with Regulatory Authorities and third party payors to the
extent the timing of such meetings and communications reasonably allows for such review and the outcome of any such meetings.

 

		(iii)	Following any meetings or material communications with Regulatory Authorities and third party payors relating to pricing and
reimbursement approvals, Licensee will provide to the members of the JSC or any JSC Subcommittee responsible for oversight of Commercialization
Activities, copies of any materials, presentations, documents, agendas, and other relevant information to be presented or followed
at such meetings, to the extent not previously provided to the members of the JSC or such JSC Subcommittee pursuant to clause (ii)
of this Section 4.5(b), and a summary of the outcome of such meetings.

 

		4.6	Sales Training.

 

As specified in the Commercialization Plan and in accordance
with dates specified therein, Licensee, at its expense, will develop a sales training plan and sales training materials for the
Product for the Nocturia Indication in the United States and, if Licensee determines to Develop, directly or indirectly through
a sublicensee, the Product for the Nocturia Indication in Canada, a sales training plan and sales training materials therefor.
The JSC or the JSC Subcommittee responsible for oversight of Commercialization Activities, as applicable, will review such training
materials and make recommendations for any revisions and updates thereto as the JSC or such JSC Subcommittee, as applicable, may
deem appropriate. Thereafter, Licensee, at its expense, will train its Sales Representatives in accordance with such sales training
plan and sales training materials in sufficient time to ensure that the Sales Representatives are fully trained prior to the date
specified in the Commercialization Plan for the Launch of the Product for the Nocturia Indication in the United States and, if
applicable, Canada.

 

    	 	28	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		4.7	Advertising and Promotional Materials and Promotional Policies.

 

		(a)	Tools, Materials, and Samples.

 

		(i)	Licensee, at its expense, and in accordance with the Commercialization Plan, will develop all advertising and promotional tools
and materials relating to the Commercialization of the Product in the Territory.

 

		(ii)	The JSC or the JSC Subcommittee responsible for oversight of Commercialization Activities shall monitor Licensee’s use
of such tools and materials.

 

		(b)	Use of Promotional Materials by Sales Representatives. Licensee agrees that:

 

		(i)	it will instruct its Sales Representatives to use, and will use Commercially Reasonable Efforts to train and monitor its Sales
Representatives to ensure that such Sales Representatives use, only promotional materials, the Product Samples, and literature
approved for use under this Section 4.6 for the promotion of the Product in the Territory;

 

		(ii)	any promotional material, promotional literature, and the Product Samples supplied to it shall not be misbranded, changed,
altered or adulterated by it or any of its agents in any way prior to their distribution or use by such Party or its Sales Representatives;
and

 

		(iii)	it will instruct its Sales Representatives to do, and will use Commercially Reasonable Efforts to train its Sales Representatives
to do, and will establish appropriate internal systems, policies and procedures for the monitoring of its Sales Representatives
with the goal of ensuring that such personnel do, the following:

 

		(A)	limit claims of efficacy and safety for the Product to those that are (1) consistent with approved promotional claims
in, and not add, delete or modify claims of efficacy and safety in the promotion of the Product in any respect from those claims
of efficacy and safety that are contained in, the then effective Pre-Launch Commercialization Plan and Annual Commercialization
Plans and Budgets, (2) consistent with Applicable Law, and (C) consistent with the Product labeling approved by the FDA and other
Regulatory Authorities;

 

		(B)	(1) refrain from making any changes in promotional materials and literature provided in accordance with this Section 4.6, and
(2) use promotional materials, literature, and Samples within the Territory only in a manner that is consistent with (I) the then
effective Pre-Launch Commercialization Plan and Annual Commercialization Plans and Budgets, (II) applicable Law and (III) the Product
labeling approved by the FDA or other applicable Regulatory Authorities; (3) promote the Product in compliance with applicable
legal and professional standards that are generally accepted by the pharmaceutical industry in the applicable market, such as the
FDA Guidance for Industry-Supported Scientific and Educational Activities; the Pharmaceutical Research and Manufacturers of America
Code on Interactions with Healthcare Professionals; the Office of Inspector General Compliance Program Guidance for Pharmaceutical
Manufacturers; the Accreditation Council for Continuing Medical Education Standards for Commercial Support of Continuing Medical
Education; the American Medical Association Gifts to Physicians From Industry Guidelines; the Pharmaceutical Marketing Research
Group Guidelines on market research activities; the Prescription Drug Marketing Act of 1987, as amended, and the rules, regulations
and guidelines promulgated thereunder; federal, state and local agencies and all “fraud and abuse”, and consumer protection
and false claims statutes and regulations, including the Medicare and State Health Programs Anti- Kickback Law (42 USC Sec 1320a-7b(b))
and the “Safe Harbor Regulations” which are found at 42 CFR Sec 1001_952 et seq.; the U.S. Foreign Corrupt Practices
Act (and foreign equivalents); the U.S. Physician Payments Sunshine Act of 2010; and, to the extent not inconsistent with the foregoing,
such Party’s policies communicated in writing to its Sales Representatives in accordance with this Article 4; and (4) not
to, directly or indirectly, pay, promise to pay, or authorize the payment of any money, or give, promise to give, or authorize
the giving of anything of value to any official or employee of any government, or of any agency or instrumentality of any government,
or to any political party, or official thereof, or to any candidate for political office (including any party, official, or candidate)
for the purpose of promoting the sale or improper use of the Product.

 

    	 	29	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(c)	Detailing. 

 

		(i)	Licensee will use Commercially Reasonable Efforts to Detail the Product in accordance with the Commercialization Plan.

 

		(ii)	All written, electronic and visual communications provided by Licensee to its Sales Representatives Detailing the Product regarding
Product strategy, positioning, Regulatory Approval, or selling messages for use by such personnel in Detailing the Product will
be subject to being monitored by the JSC or the JSC Subcommittee responsible for oversight of Commercialization.

 

		(d)	Medical Education Activities. Funding for Medical Education Activities for the Product in the Territory will
be set forth in the applicable Annual Commercialization Plan.

 

		(e)	Direct-to-Consumer Advertising. In each country in the Territory, Licensee will observe any and all Applicable
Law relating to direct-to-consumer advertising for the Product in such country.

 

		(f)	Obligations in Respect of Product Samples.

 

		(i)	Licensee will: (i) maintain an investigation, corrective and preventive action program for the handling of Product Samples
in accordance with its internal policies and procedures; (ii) maintain monitoring and auditing programs capable of detecting losses,
potential diversion and falsification of records related to Product Samples; (iii) implement processes for the inventory, distribution
reconciliation and storage of Product Samples; (iv) review with the JSC its practices with respect to its contacts and communications
with Regulatory Authorities with respect to matters relating to the Product Samples; and (v) administer the Product Samples program
described in any applicable Annual Commercialization Plan in accordance with such standard operating procedures for product sampling
that comply with “best practices” in the pharmaceutical industry.

 

		(ii)	Licensee will be responsible for compliance with Applicable Law with respect to its Product Samples program.

 

    	 	30	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		4.8	Sales and Distribution. Licensee will be responsible for warehousing and distributing in the Territory the Product and
will perform related distribution activities. Licensee will also be solely responsible for handling all returns, recalls (in accordance
with Section 4.11), order processing, invoicing and collection, distribution and inventory and receivables.

 

		4.9	Sales Representatives.

 

The following provisions shall apply to each Party’s
Sales Representatives in the Territory:

 

		(a)	Licensee will use Commercially Reasonable Efforts to ensure that it has the appropriate number of Sales Representatives and
managers to Commercialize the Product.

 

		(b)	Except as otherwise provided in this Article 4, Licensee’s Sales Representatives will be full-time employees of Licensee
or its Affiliates or an individual acting as an independent contractor as permitted below.

 

		(c)	Licensee may engage individuals as independent contractors to provide the Details to be provided by it in a country in the
Territory and may use such independent contractors as Sales Representatives for the Product in a country in the Territory. Licensee
will inform the JSC or any JSC Subcommittee responsible for oversight of Commercialization Activities of the extent to which Licensee
engages such independent contractors for purposes of Detailing.

 

		(d)	Licensee will be responsible for the compliance by its independent contractors engaged pursuant to this section with applicable
terms and conditions of this Agreement and shall be jointly and severally liable with any independent contractors who serve as
Licensee’s Sales Representatives for any breach of this Agreement or failure by independent contractors to perform such delegated
duties (as well as for any breach by such independent contractors of its agreement with Licensee), and shall use Commercially Reasonable
Efforts to cause such independent contractor to perform his, her or its services as a Sales Representative in compliance with the
provisions of this Agreement. All compensation, reimbursement of costs and other payments to be made to any of such independent
contractors shall be solely a matter between Licensee and such independent contractor.

 

		(e)	Licensee may from time to time use part-time employee Sales Representatives to sell the Product on behalf of Licensee in a
country to the extent that such use is consistent with Licensee’s practice in such country with respect to the majority of
its other pharmaceutical products.

 

		(f)	Licensee will use Commercially Reasonable Efforts to provide full training (both general and Product-specific training) to
its Sales Representatives, to deploy such number of Sales Representatives as may be necessary to fulfill its duties to Commercialize
the Product and, consistent with its normal business practices, to minimize turnover of its Sales Representatives Detailing the
Product and to cause its Sales Representatives to adhere to the sales call plan included in the Annual Commercialization Plan.
Licensee will establish reasonable qualifications and experience levels (measured in years of experience selling or promoting ethical
pharmaceutical products to health care professionals with actual prescribing authority) for Sales Representatives, and Licensee
will use Commercially Reasonable Efforts to provide Sales Representatives that meet such qualifications and experience levels.
Unless the JSC establishes a different time, within forty-five (45) days after the end of each Year, Licensee will provide Licensor
and the JSC with a report with respect to the number of its Sales Representatives assigned to the promotion of the Product and
the length of time each such Sales Representative has been assigned to the promotion of the Product to the extent not previously
provided to the JSC.

 

    	 	31	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(g)	In the event that information comes to Licensor’s attention that provides it a reasonable basis to believe that Licensee’s
Sales Representatives may have (i) violated any Applicable Law, or (ii) failed to provide satisfactory service or to comply with
this Agreement, Licensor will have the right to request that Licensee immediately assess the performance of such individual, and
to exercise any other rights or remedies available to Licensor under this Agreement, at law or in equity. Licensee will promptly
use Commercially Reasonable Efforts to evaluate and resolve such issue in accordance with its policies or as it may otherwise deem
appropriate, will (to the extent permitted by Applicable Law) keep Licensor informed of the progress of, and information learned
during, its evaluation, and within fifteen (15) Business Days after Licensor first brought such information to Licensee’s
attention will provide Licensor, to the extent possible in compliance with Applicable Law, with a reasonably detailed written report
summarizing any steps taken toward resolution of the matter.

 

		(h)	Licensee will comply with all Applicable Laws, rules and regulations applicable to the hiring, employment, and discharge of
its Sales Representatives and its employees involved in marketing and promoting the Product. Licensee represents to Licensor that
Licensee is an equal opportunity employer and does not discriminate against any person because of race, color, creed, age, sex,
or national origin.

 

		(i)	Licensee will be responsible for any failure of its Sales Representatives or employees to comply with the terms of this Agreement.

 

		(j)	Licensee will be solely responsible and liable for all probationary and termination actions taken by it with respect to its
Sales Representatives, as well as for the formulation, content, and for the dissemination (including content) of all employment
policies and rules (including written probationary and termination policies) applicable to its Sales Representatives.

 

		(k)	Licensee shall in its sole discretion have the right to determine the configuration of its sales force(s) including, the geographical
assignments of its Sales Representatives.

 

		4.10 	Incentive Plans for Sales Representatives. Licensee, in its sole discretion, will establish and implement a target bonus
or sales incentive program whereunder Licensee’s Sales Representatives are compensated for their efforts with respect to
the Product in a manner consistent with such Party’s other programs for similar products (and taking into consideration the
commercial life cycle of the Product). All such programs shall be in compliance with all Applicable Law.

 

		4.11 	Product Claims. Licensee will not, and will cause each of its Sublicensees, contractors, and other agents not to, make
any medical or promotional claim for the Product beyond the scope of the relevant Regulatory Approvals then in effect for the Product;
provided, that Licensee may, subject to Section 13.7, distribute any information concerning the Product or its use, including scientific
articles, reference publications and healthcare economic information, in accordance with Applicable Law.

 

		4.12 	Recalls and Withdrawals.

 

		(a)	Following consultation between Licensee and Licensor (or its designee), Licensee shall have final decision-making authority
with respect to any recall or withdrawal of the Product from any market.

 

		(b)	The costs of any such recall or withdrawal will be borne by Licensee.

 

    	 	32	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(c)	In the event of any recall or withdrawal, Licensee shall implement any necessary action, with assistance from Licensor as reasonably
requested by Licensee.

 

		5.	MANUFACTURE AND SUPPLY OF PRODUCTS. 

 

		5.1	Manufacture and Supply of the Product, Generally. Licensee will be responsible for the manufacture and supply of the
Product for Commercialization and any Development.

 

		5.2	Scope of Manufacturing and Supply Plan. In accordance with Article 5, the Manufacturing and Supply Plan for the Product
in respect of the Nocturia Indication, the PNE Indication and any Additional Indication will address manufacturing and supply requirements
for both the Commercialization Activities and any Development Activities contemplated by this Agreement.

 

		5.3	Existing Inventory. Upon request of the Licensee, Licensor agrees to sell to Licensee at Licensor’s cost, any
and all inventory of Product, both in bulk drug and finished product form, existing as of the Effective Date. Licensee will make
payment for any such inventory of Product requested by Licensee in two equal installments each at the time Licensee makes it first
and second royalty payments to Licensee, respectively, in accordance with Article 8.

 

		5.4	Manufacturing for Licensor. Licensee agrees that following any written request from Licensor during or after the Term
of this Agreement, Licensee will within sixty (60) days after the date of such request, will use Commercially Reasonable Efforts
to enter into an agreement with Licensor (which shall be transferable and sublicensable by Licensor to the same extent as contemplated
in Section 2.5 in respect of sublicenses granted under this Agreement by Licensee to Licensor) containing fair and reasonable terms
and conditions to be negotiated by Licensor and Licensee pursuant to which Licensee will designate under each of the Third Party
Supply Agreements (and any successor agreements thereto and additional agreements entered into by Licensee relating to the manufacture
and supply of Products and any components thereof) Licensor (and any transferee, sublicensee, or subcontractor of Licensor) as
a party for which the applicable Third Party under such Third Party Supply Agreement (and any such successor agreements and any
such additional agreements) will manufacture and supply Products thereunder on terms and conditions no less favorable to Licensor
as those applicable to Licensee under such Third Party Supply Agreement (and any such successor agreements and any such additional
agreements), subject to the agreement of such Third Party. Licensor acknowledges and agrees that any use of such Product so manufactured
and supplied will only be used by Licensor for purposes not in conflict with Licensee’s rights under this Agreement. With
respect to any such additional agreements entered into by Licensee relating to the manufacture and supply of Products and any components
thereof, Licensee will use Commercially Reasonable Efforts to cause to be included in such additional agreements provisions that
so allow Licensee to so designate Licensor (and any transferee, sublicensee, or subcontractor of Licensor) to so obtain Products
and any components thereof in accordance with this Section 5.3.

 

		5.5	Manufacturing and Supply Plan. The Manufacturing and Supply Plan for the First Approved Product will be set forth in
Exhibit 5.5 to be attached to this Agreement. The JSC or any JSC Subcommittee responsible for reviewing, assessing, and revising
this Plan in accordance with Section 3.4(c), including, without limitation, such revision as are necessary to address Development
and Commercialization of Products for the Nocturia Indication in Canada, the PNE Indication and any Additional Indications in the
United States and/or Canada.

 

    	 	33	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		6.	DEVELOPMENT ACTIVITIES BY LICENSEE.

 

		6.1	Determination by Licensee to Engage in Development Activities. 

 

		(a)	Within one hundred eighty (180) days immediately following the Effective Date, Licensee will provide written notice to Licensor
of Licensee’s decision to undertake Development of the Product for the Nocturia Indication in Canada and the PNE Indication
in the United States and/or Canada. For any such Indication and country in respect of which Licensee timely provides such notice
of its decision to undertake Development of the Product, Licensor and Licensee hereby agree to engage in good faith negotiations
in respect of the consideration to be received by Licensor from Licensee from the Commercialization of the Product for the Indication
and the country for which Regulatory Approval is obtained as a result of such Development, including, without limitation, consideration
in the form of licensing fees, development and commercialization milestone payments, and royalties. Upon mutual agreement of the
Parties, such time period which Licensee must provide its written notice of its decision pursuant to this Section 6.1 may be extended.

 

		(b)	As part of the process by which Licensee determines whether to engage in Development of the Product for the Nocturia Indication
in Canada and the PNE Indication and any Additional Indications in the United States and/or Canada, the Parties will engage in
good faith discussions as to Development Activities that Licensor can undertake to support and collaborate with Licensee with respect
to Licensee’s undertaking of such Development.

 

		6.2	Development Plan. In respect of any Development of the Product specified in Section 6.1 that Licensee decides to undertake
in accordance with Section 6.1, Licensee shall include with the notice specified in Section 6.1 a copy of the initial Development
Plan in respect of such Development, which such Development Plan will describe the Development Activities necessary or advisable
to obtain Regulatory Approvals of the Product for the Nocturia Indication in Canada and/or the PNE Indication and in the United
States and/or Canada, as the case may be.

 

		6.3	Licensor’s Rights to Develop and Commercialize. For the PNE Indication in either country in the Territory and
the Nocturia Indication in Canada in respect of which Licensee does not decide in accordance with Section 6.1 to undertake Development,
Licensor has the right, as contemplated by Section 2.5(c), to engage in such Development and the Commercialization of the Product
for such Indication and country for which Regulatory Approval is obtained as a result of such Development. To the extent that Licensor
engages in any such Development Activities and Commercialization Activities under this Section 6.3, Licensor will keep Licensee
informed thereof. To the extent that Licensee believes in good faith that such Commercialization Activities by Licensor would compete
with the Commercialization of the Product by Licensee contemplated by this Agreement, the Parties will discuss such matter in good
faith and seek to agree upon such measures as are reasonable to minimize any adverse impact of such Commercialization Activities
by Licensor on such Commercialization of the Product in the Territory by Licensee.

 

		7.	REGULATORY MATTERS.

 

		7.1	Ownership of Product Regulatory Approvals and Documentation. Licensee shall own all Product Regulatory Approvals and
Documentation in respect of each country in the Territory.

 

		7.2	Conduct and Management of Regulatory Activities. Licensee will use its Commercially Reasonable Efforts:

 

(a) to maintain the First Approved NDA in the United States;

 

(b) to obtain Regulatory Approval for the Product for
the Nocturia Indication in each other country in the Territory in accordance with the Development Plan;

 

and

 

(c) to obtain Regulatory Approval for the Product for
the PNE Indication in each country in the Territory in accordance with the Development Plan.

 

    	 	34	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

Any breach by Licensee of its obligations under Section
7.2(a) shall be deemed to be a material breach of this Agreement for purposes of Article 14.

 

		7.3	Transfer to Licensee of Product Regulatory Approvals and Documentation. Following the transfer to Licensee of ownership
of the Product Regulatory Approvals and Documentation in each such country in the Territory pursuant to Section 2.3(b),

 

		(a)	Licensee or its designee shall be the owner of any and all Product Regulatory Approvals and Documentation in each such country
in the Territory, subject to the Right of Reference or Use hereby granted by Licensee to Licensor in Section 2.5(c) for purposes
of Development and Commercialization of Products outside the Territory;

 

		(b)	Except for the Development and Commercialization of Products by Licensor in the Territory pursuant to Section 6.3, Licensee
shall have the responsibility, at its expense, for all regulatory activities (including, without limitation, Development Activities
undertaken to support obtaining or maintaining Regulatory Approvals) and interactions relating to the Product in each country in
the Territory, including without limitation preparing, obtaining, and maintaining Regulatory Approvals in each country in the Territory
and all substantive interactions with such Regulatory Authorities relating thereto; and

 

		(c)	Licensee shall determine, in its sole discretion, the content of all such submissions and of all correspondence with Regulatory
Authorities relating to the Product in the Territory.

 

		(d)	To the extent Licensor has not undertaken any Product Development Activities in the Territory under Section 2.5(c), Section
2.6, Section 6.1 and/or Article 14, Licensor hereby grants to Licensee a Right of Reference or Use in all Regulatory Approvals
and Regulatory Documentation in respect of the Compound and any Products in respect of which Licensor is the sponsor for purposes
of Licensee’s Development and Commercialization of Products in the Field and in the Territory. In consideration of such grant,
Licensee will make one or more payments to Licensor determined in accordance with the same provisions set forth in clauses (ii)
and (iii) in Section 2.5(c) in respect of Licensee’s grant of the Right of Reference or Use set forth in clause (i) of Section
2.5(c).

 

		7.4	Regulatory Documentation for Generic Products.

 

		(a)	Each Party shall deliver written notice to the other Party of any notice it receives as to the submission, filing, or approval
of an application, including, without limitation, an Abbreviated New Drug Application in the United States or the equivalent thereof
in any other country in the Territory, in respect of a Generic Product within three (3) days after receipt or such notice thereof.

 

		(b)	Licensee shall have the sole right to respond to each such application, provided that Licensee shall consult with Licensor
regarding any such application and the response thereto.

 

		7.5	Audits. Licensor will have the continuing right during the Term of this Agreement, upon reasonable prior written notice
to Licensee, to inspect, audit, and investigate any facilities, equipment, record-keeping procedures, and records utilized by Licensee
and its subcontractors in connection with the Manufacture and Commercialization of the Product and any Development (including,
without limitation, the conduct of Clinical Studies) of the Product.

 

    	 	35	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		7.6	Regulatory Authority Communications Received by a Party. 

 

		(a)	Each Party shall immediately notify the other Party of any information it receives regarding any threatened or pending action,
inspection, or communication by or from any Person, including, without limitation, any Regulatory Authority in any country in the
Territory, that may affect the safety or efficacy claims of the Product, have a material adverse effect on the Commercialization
of the Product, or that otherwise suggests the Product may be in violation of Applicable Laws in such country.

 

		(b)	Upon receipt of such information described in Section 7.7(a), the Parties shall consult with each other in an effort to arrive
at a mutually acceptable procedure for Licensee to take at Licensee’s expense.

 

		(c)	Each Party shall keep the other Party informed, in a timely manner consistent with the reporting requirements of Regulatory
Authorities, of notification of any action by any Regulatory Authority, or notification or other information that the Party receives
(directly or indirectly) from any such Regulatory Authority, and provide to such other Party copies of all documents, if any, it
received from such Regulatory Authority.

 

		(d)	Each Party will provide the other Party in a timely manner with a copy of all correspondence received from a Regulatory Authority
specifically regarding the matters referred to in this Section 7.7.

 

		7.7	Adverse Event Reporting and Safety Data Exchange. 

 

		(a)	Licensee shall be responsible, at Licensee’s expense, in each country in the Territory for the monitoring of all clinical
experiences, post-marketing experiences, and filing of all required reports with respect to the Product.

 

		(b)	Licensor shall transfer to Licensee the patient database, including without limitation the databases, in their entirety, containing
pharmacokinetic, pharmacodynamic, efficacy, and safety information, developed in connection with the conduct of Clinical Studies
for the Product under U.S. IND 076667, and all information relating thereto, in the format requested by Licensee. Licensor shall
have the right to retain a copy of any and all such information transferred to Licensee.

 

		(c)	Each Party shall (i) notify the other Party immediately, but in no event later than three (3) Business Days, after becoming
aware of any information concerning any complaint involving the possible failure of Product to meet any requirement of Applicable
Laws, and any Unexpected Adverse Drug Experience or other serious or unexpected side effect, injury, toxicity, or sensitivity reaction
or any unexpected incidents associated with the distribution or use of the Product and (ii) with respect to adverse events, comply
with the provisions of this Section 7.7, and the applicable agreements described herein. Specific details regarding the exchange
and management of information relating to adverse events related to the use of the Product shall be delineated and product labeling
personnel of each Party shall work in good faith together during such time to negotiate an agreement that:

 

		(i)	identifies which safety information shall be exchanged, which shall include without limitation all adverse events for any Indication
or condition;

 

		(ii)	identifies when such information shall be exchanged (which SAE information shall be provided within two (2) Business Days after
notification of such SAE);

 

		(iii)	provides that Licensee shall (i) have regulatory reporting responsibilities, (ii) manage the global safety database, (iii)
be obligated to obtain follow-up information on incomplete safety reports, (iv) review the literature for safety report information,
and (v) prepare required periodic safety updates;

 

    	 	36	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(iv)	sets forth the roles and responsibilities of the Parties related to review and approval of safety information for inclusion
in the Product labeling; provided that Licensee shall have the final decision-making authority with respect to any disputes regarding
such activities with respect to Product in accordance with the terms and conditions hereof;

 

		(v)	identifies any other details required to appropriately manage safety information for the Product; and

 

		(vi)	as soon as reasonably practicable following the Effective Date, but in no event later than sixty (60) days thereafter Licensor
and Licensee will agree upon the terms and conditions of the Pharmacovigilance Agreement and will thereupon execute and deliver
to the other Party a copy of such Agreement.

 

		7.8	Remedial Actions. 

 

		(a)	Each Party will notify the other Party immediately, and promptly confirm such notice in writing, if it obtains information
indicating that the Product in the Field may be subject to a Remedial Action.

 

		(b)	The Parties will assist each other in gathering and evaluating such information as is required to determine the necessity of
conducting a Remedial Action with respect to the Product in the Field in the Territory; provided, however, that Licensee
shall have sole responsibility for collecting information from its customers in the Territory, including, without limitation, customer
complaints, in accordance with the terms and conditions hereof.

 

		(c)	Each Party will maintain adequate records to permit the Parties to trace the manufacture of the Product in the Field and the
distribution and use of the Product in the Field. In the event Licensee determines that any Remedial Action with respect to the
Product in the Field in the Territory should be commenced or Remedial Action is required by any Governmental Authority having jurisdiction
over the matter, Licensee will control and coordinate all efforts necessary to conduct such Remedial Action, provided that Licensee
shall consult with Licensor or its designee regarding any such Remedial Action.

 

		(d)	The cost and expense of a Remedial Action (including the Parties’ reasonable costs and expenses in conducting such Remedial
Action, but excluding claims described in Article 10) shall be allocated as follows:

 

		(i)	If such Remedial Action is due to Licensee’s gross negligence or willful misconduct, material breach of this Agreement,
or material violation of or substantial noncompliance with any Law, but only to the extent such Remedial Action is due thereto,
such costs and expenses shall be borne and paid by Licensee;

 

		(ii)	if and to the extent that such Remedial Action is due to Licensor’s gross negligence or willful misconduct, Licensor’s
material breach of this Agreement, or Licensor’s material breach of or substantial noncompliance with any Law, but only to
the extent such Remedial Action is due thereto, such costs and expenses shall be borne and paid by Licensor; and

 

    	 	37	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(iii)	if and to the extent that such Remedial Action is due to reasons other than as set forth in Sections 7.8(d)(i) and (ii), then:
(A) Licensor shall bear and pay the costs and expenses incurred by the Parties in connection with a Remedial Action with respect
to any lots of the Product subject to such Remedial Action that were manufactured by or for Licensor, as Licensor’s predecessor
in interest; and (B) except for the Development and Commercialization of Product in the Territory by Licensor pursuant to
Section 6.3, Licensee shall bear and pay the costs and expenses incurred by the Parties in connection with a Remedial Action with
respect to any lots of the Product subject to such Remedial Action that were manufactured by or for Licensee and its contractors;
provided, however, that nothing in this Section 7.8(d)(iii) is intended to limit or supersede any obligation that Renaissance
may have in respect of any such lots of the Product subject to such Remedial Action.

 

		8.	PAYMENT OBLIGATIONS.

 

		8.1	Initial Fee. In consideration of the license and sublicense granted by Licensor to Licensee in accordance with Sections
2.1 and 2.2, respectively, and the assignments by Licensor to Licensee in accordance with Section 2.3, Licensee shall pay to Licensor
a one-time, nonrefundable, non-creditable initial fee of Fifty Million Dollars ($50,000,000) on the Effective Date.

 

		8.2	Milestone Payments. 

 

		(a)	Launch Milestone Payment. Licensee shall notify Licensor promptly of the date of the Noctiva Launch, but in no
event later than twenty (20) days thereafter. In further consideration of the license and sublicense granted by Licensor to Licensee
in accordance with Sections 2.1 and 2.2, respectively, and the assignments by Licensor to Licensee in accordance with Section 2.3,
Licensee shall pay to Licensor a one-time, nonrefundable, non-creditable payment of Twenty Million Dollars ($20,000,000) in respect
of such Noctiva Launch on the earlier to occur of: (i) the thirtieth (30th) day immediately following the date of the
Noctiva Launch and (ii) June 30, 2018. Such payment shall not require Licensor to provide any invoice in respect thereof.

 

		(b)	Tier One Commercialization Milestone Payments. Licensee shall notify Licensor promptly, but in no event later
than thirty (30) days, after the first achievement of the relevant sales milestone for the Product as set forth in the table below
in this Section 8.2(b). In further consideration of the license and sublicense granted by Licensor to Licensee in accordance with
Sections 2.1 and 2.2, respectively, and the assignments by Licensor to Licensee in accordance with Section 2.3, Licensee shall
make the following one-time, nonrefundable, non-creditable milestone payments to Licensor within thirty (30) days after receipt
of an invoice from Licensor therefor.

 

    	 	38	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

 

	 	 	Milestone Event	 	 	Payment
 (millions of

                                                                                Dollars)
	 
	(i)	 	Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications in the aggregate reach $50 million on a cumulative basis beginning with the first dollar of Royalty-Bearing Net Sales	 	$	[***]	 
	(ii)	 	Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications in the aggregate reach $[***] on a cumulative basis beginning with the first dollar of Royalty-Bearing Net Sales	 	$	[***]	 
	(iii)	 	Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications in the aggregate reach $[***] on a cumulative basis beginning with the first dollar of Royalty-Bearing Net Sales	 	$	[***]	 
	(iv)	 	Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications in the aggregate reach $200 million on a cumulative basis beginning with the first dollar of Royalty-Bearing Net Sales	 	$	[***]	 

 

		(c)	Tier Two Commercialization Milestone Payments. Licensee shall notify Licensor promptly, but in no event later
than thirty (30) days, after the first achievement of the relevant sales milestone for the Product as set forth in the table below
in this Section 8.2(c). In further consideration of the license and sublicense granted by Licensor to Licensee in accordance with
Sections 2.1 and 2.2, respectively, [and the assignments by Licensor to Licensee in accordance with Section 2.3,] Licensee shall
make the following one-time, nonrefundable, non-creditable milestone payments to Licensor within thirty (30) days after receipt
of an invoice from Licensor therefor; provided, however, in the event that the last of the milestone payments described in the
table below becomes payable, the due date for Licensee to make payment to Licensor of such milestone payment will be the first
anniversary of the payment of the $[***] milestone payment in the penultimate row of the table below.

 

    	 	39	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

	 	 	Milestone Event	 	 	Payment
 (millions of
 Dollars)	 
	(i)	 	Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications reach $300 million in any consecutive 12-month period beginning after achievement of milestone (iv) described in Section 8.2(b)	 	$	[***]	 
	(ii)	 	Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications reach $[***] in any consecutive 12-month period beginning after achievement of milestone (iv) described in Section 8.2(b)	 	$	[***]	 
	(iii)	 	Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications reach $ [***] in any consecutive 12-month period beginning after achievement of milestone (iv) described in Section 8.2(b)	 	$	[***]	 
	(iv)	 	Upon the first time Royalty-Bearing Net Sales by Licensee and its Sublicensees of the Product for all Indications reach $ 1.5 billion in any consecutive 12-month period beginning after achievement of milestone (iv) described in Section 8.2(b)	 	$	[***]	 

 

		(d)	Change of Control Payment. If a Change of Control occurs, simultaneously with the consummation of such Change
of Control, Licensee shall pay to Licensor the amount of [***] Dollars ($[***]) less the sum of the following allocable portions
of any of the milestone payments described in Section 8.2(b) that are paid to Licensor prior to such Change of Control:

 

		(i)	[***] Dollars ($[***]) of the [***] Dollars ($[***]) set forth in item (i) of the table in Section 8.2(b);

 

		(ii)	[***] Dollars ($[***]) of the [***] Dollars ($[***]) set forth in item (ii) of the table in Section 8.2(b);

 

		(iii)	[***] Dollars ($[***]) of the [***] Dollars ($[***]) set forth in item (iii) of the table in Section 8.2(b); and

 

		(iv)	[***] Dollars ($[***]) of the [***] Dollars ($[***]) set forth in item (iv) of the table in Section 8.2(b).

 

For the sake of clarity, in respect of any occurrence
of a Change of Control (x) in no event shall any payment by Licensee to Licensor under this Section 8.3(c) in respect of such
Change of Control exceed $[***], (y) each Tier One Milestone Payment that is not paid to Licensor prior to such Change of Control,
less the allocable portion of the amount of such Tier One Milestone Payment paid to Licensor pursuant to this Section 8.3(c),
shall survive such Change of Control, and (z) the Tier Two Milestone payment obligations shall survive such Change of Control.

 

    	 	40	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		8.3	Royalties; Non-Royalty Commercialization Consideration. 

 

		(a)	Royalties. In further consideration of the license and sublicense granted by Licensor to Licensee in accordance
with Sections 2.1 and 2.2, respectively, Licensee shall pay Licensor royalties on Net Sales of the Product by Licensee and any
of its Sublicensees and Third Party Distributors in accordance with the rates set forth in the tables set forth below in this Section
8.3(a)(i).

 

	Royalty-Bearing Net Sales in each Calendar Year (millions of Dollars)	 	Royalty Rate	 
	That portion of Annual Net Sales greater than $0 and less than or equal to $ 500 million	 	 	28	%
	That portion of Annual Net Sales greater than $ 500 million and less than or equal to
 $ 1 billion	 	 	30	%
	That portion of Annual Net Sales greater than $ 1 billion	 	 	33	%

 

		(b)	Third Party Royalties.

 

		(i)	CPEX and Reprise. Licensor will be responsible for payment of any amounts payable to CPEX and Reprise under the terms
of the CPEX License Agreement and the Reprise License Agreement, respectively.

 

		(ii)	Other Third Parties.

 

		(A)	In the event that after the Effective Date Licensee reasonably determines that it is necessary or advisable for Licensee to
obtain a license under any Patent Rights from any Third Party in order for Licensee (each a “Third Party License”;
collectively, “Third Party Licenses”), its Sublicensees, and any Third Party Distributors to Commercialize the Product
in the Field in any country in the Territory as contemplated by this Agreement, the Parties shall discuss the best course of action
to resolve such potential license requirement, provided that such discussions shall not limit or delay Licensee’s right to
obtain any such Third Party Licenses.

 

		(B)	With respect to any such Third Party Licenses that Licensor reasonably agrees are necessary for Licensee to be able to Commercialize
the Product in the Field in any country in the Territory, Licensee shall have the right to set off an amount equal to [***] percent
([***]%) of the aggregate of any and all payments required to be paid by Licensee to the licensors under such Third Party Licenses
in respect of any Calendar Quarter against payments otherwise payable to Licensor under Section 8.3(a) in respect of such Calendar
Quarter; provided, however, that in no event shall the aggregate set off in any Calendar Quarter resulting from such payments
in respect of such Third Party Licenses exceed an amount equal to [***] percent ([***]%) of the royalty payments otherwise payable
to Licensor under Section 8.3(a) in respect of such Calendar Quarter.

 

    	 	41	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(c)	Royalty Term. Licensee’s obligation under Sections 8.3(a) to pay Licensor royalties on Net Sales of the
Product in each country in Territory will apply to any and all sales or other dispositions of such the Product in such country
made during the Term of this Agreement.

 

		(d)	Generic Product. If, during the Royalty Term, one or more Third Parties is selling in any country in the Territory
any product that is a Generic Product in relation to the Product being sold in such country by Licensee or any of its Sublicensees
or Third Party Distributors, Licensee’s royalty obligations under Section 8.3(a) for sales in such country of the Product
shall be reduced as follows:

 

	If the Generic TRxs-to-Total TRxs

Percentage in such country during such

Calendar Quarter is: 	 	Licensee’s royalty

obligations under Section

8.3(a) shall be reduced by the

Percentage Indicated Below
	[***]% or greater	 	[***]%
	[***]%; but less than [***]%	 	[***]%
	[***]%; but less than [***]%	 	[***]%

 

		8.4	Reports and Payments. During the Term of this Agreement following the First Commercial Sale of the Product by Licensee,
its Sublicensees, or its Third Party Distributors, within five (5) Business Days after the filing by Licensee of each Form 10-K
or Form 10-Q, Licensee shall pay to Licensor the royalty payments payable by Licensee for the Calendar Quarter preceding the Calendar
Quarter in which such Form 10-K or 10-Q, as applicable, is filed, and shall provide a report showing, on a country-by-country basis:

 

		(a)	the net quantity of the Product sold, total gross sales, an itemized list of the deductions applied to total gross sales, and
Net Sales of the Product sold in the Calendar Quarter in respect of which such report has been prepared;

 

		(b)	the calculation in Dollars of royalty payments due hereunder with respect to such Net Sales, including any deductions for any
offsets in accordance with Section 8.3(b)(ii);

 

		(c)	withholding taxes on Net Sales, if any, required by Applicable Laws to be deducted with respect to such royalties; and

 

		(d)	the rate of exchange used by Licensee in determining the amount of Dollars payable hereunder.

 

If no royalty or other payment is due for any period
hereunder, Licensee shall so report.

 

Currency of Payment. All payments to be made
under this Agreement shall be made in Dollars by electronic funds transfer to such bank accounts as Licensor may designate from
time to time. When Licensee or any of its Sublicensee of Third Party Distributors sells the Product for monies other than Dollars,
Licensee will convert any non-Dollar currencies into Dollars with the exchange rate for the purchase of Dollars with such domestic
currency as quoted by The Wall Street Journal, New York edition, at an average rate for the Calendar Quarter for which the payment
is made.

 

    	 	42	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		8.5	Accounting. 

 

		(a)	Licensee shall determine Net Sales with respect to the Product sold using its standard accounting procedures, consistent with
GAAP, as if the Product was a solely owned product of Licensee, except as specifically provided in this Agreement. In the case
of amounts to be determined by Third Parties (for example, Net Sales by Sublicensees), such amounts shall be determined in accordance
with generally accepted accounting principles in effect in the country in which such Third Party is engaged. Licensor and Licensee
also recognize that such procedures may change from time to time and that any such changes may affect the definition of Net Sales.
Licensor and Licensee agree that, where such changes are economically material to Licensor, adjustments shall be made to compensate
Licensor in order to preserve the same economics as are reflected under this Agreement under Licensee’s accounting procedures
in effect prior to such change. Where the change is or would be material to Licensor, Licensee shall provide an explanation of
the proposed change and an accounting of the effect of the change on the relevant revenue, cost, or expense category.

 

		(b)	In the event of the payment or receipt of noncash consideration in connection with the performance of activities under this
Agreement Licensee shall advise Licensor of such transaction, including without limitation Licensee’s assessment of the fair
market value of such noncash consideration and the basis therefor. Such transaction shall be accounted for on a cash equivalent
basis, as mutually agreed by Licensor and Licensee in good faith.

 

		(c)	Withholding Tax. Notwithstanding anything to the contrary herein, in the event that withholding taxes apply with respect
to any amounts due from Licensee hereunder, Licensee shall be entitled to withhold from any payment due to Licensor under this
Agreement any taxes that Licensee is required to pay and such withholding shall decrease by an equivalent amount the payment due
to Licensor. Licensee shall provide Licensor with notification of any anticipated withholding requirements with as much advance
notice as practicable and shall cooperate in good faith with Licensor to legally minimize such withholding taxes. Licensee will
timely pay to the proper governmental authority the amount of any taxes withheld and will provide Licensor with an official tax
certificate or other evidence of tax obligation, together with proof of payment from the relevant governmental authority sufficient
to enable Licensor to claim such payment of taxes.

 

		8.6	Books and Records; Audit Request. 

 

		(a)	During the term of this Agreement and for three (3) years thereafter, Licensee shall keep and maintain, and shall cause each
of its Affiliates, and Sublicensees, if any, to keep and maintain, at their respective regular places of business complete and
accurate books, records, and accounts in accordance with GAAP, or other accounting standards mandated by the U.S. Securities and
Exchange Commission if applicable to Licensee, in sufficient detail to reflect all amounts required to be paid under this Agreement,
as well as any other books, records or accounts required to be maintained in connection with the Product under any Applicable Laws,
necessary to permit the audits contemplated under Section 8.8(b). Prior to destroying any books, records or accounts which are
material to the Parties’ rights and obligations under this Agreement, Licensee must seek prior written consent from Licensor,
which consent may not be unreasonably withheld.

 

    	 	43	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(b)	During the term of this Agreement and for three (3) years thereafter, Licensor shall have access to and the right to examine
such relevant records and accounts that Licensee is required to maintain pursuant to Section 8.8(a) at Licensee’s premises
for the sole purpose of verifying the accuracy of any report or payment made under this Agreement in the three (3) preceding years;
provided, however, that any such examination: (i) shall not occur more than once during each Calendar Year (except that
if as a result of any audit pursuant to this Section 8.8(b), an error in favor of Licensee exceeding five percent (5%) of any payments
previously reported as owed by Licensee to Licensor is discovered, the frequency of audits under this Section 8.10(b) shall not
be so limited); (ii) shall be during normal business hours upon reasonable prior written notice which shall in no event be less
than thirty (30) days; and (iii) shall not unreasonably interfere with Licensee’s operations and activities. If Licensor
desires to audit such records, it shall engage an independent, certified public accountant reasonably acceptable to Licensee, to
examine such records under conditions of confidentiality with respect thereto at least as stringent as those specified in Article
13. The expense of any such audit shall be borne by Licensor; provided, however, that, if an error of more than five percent
(5%) in favor of Licensor is discovered as a result of such audit, then such expenses shall be paid by Licensee. If such accountant
concludes that additional payment amounts were owed to Licensor during any period, Licensee shall pay such payment amount (including
without limitation interest thereon from the date such amounts were payable) within thirty (30) days after the date Licensor delivers
to Licensee such accountant’s written report so concluding, unless Licensee notifies Licensor of any dispute regarding the
audit. If such accountant concludes that Licensee has overpaid any amounts to Licensor during any period, in Licensor’s discretion,
Licensee may credit such amounts against future payments due Licensor or Licensor may pay such amounts (including without limitation
interest thereon from the date such amounts were payable), unless Licensor notifies Licensee of any dispute regarding the audit.
Any Information received by Licensor pursuant to this Section 8.10 shall be deemed to be Confidential Information of Licensee for
purposes of Article 13.

 

		8.7	Blocked Currency. If by Applicable Laws or fiscal policy of a particular country, conversion into Dollars or transfer
of funds of a convertible currency to the United States is restricted or forbidden, royalties accrued in such country shall be
paid to Licensor in the country in local currency by deposit in a local bank designated by Licensor for such deposit, unless Licensor
and Licensee otherwise agree.

 

		8.8	Interest. If Licensor does not receive payment of any sum due to it on or before the due date, simple interest shall
thereafter accrue on the sum due to Licensor from the due date until the date of payment at a rate equal to three month Dollar
LIBOR Rate, as reported in the online edition of The Wall Street Journal as of Noon (New York Time) on such due date, or the maximum
rate allowable by Applicable Laws, whichever is less.

 

		8.9	Transaction Expenses. Licensee shall upon execution and delivery of this Agreement pay the documented reasonable fees
and expenses of Licensor’s advisors and counsel incurred by Licensor in structuring, negotiating, memorializing, and otherwise
undertaking the transaction contemplated by this Agreement. Notwithstanding the foregoing, Licensee’s obligation under this
Section 8.11 shall be limited to an amount not to exceed $2,000,000.

 

		9.	INTELLECTUAL PROPERTY MATTERS.

 

		9.1	Existing Intellectual Property.

 

		(a)	Other than as provided in this Agreement, neither Party grants any right, title, or interest in any Patent Right, information,
or other intellectual property right Controlled by such Party to the other Party.

 

    	 	44	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(b)	Except as otherwise provided herein, Licensor shall be responsible for the preparation, filing, prosecution (including, without
limitation, any interferences, inter partes proceedings, reissue proceedings, cancellations, oppositions, and reexaminations),
and maintenance of any and all Licensed Serenity Patent Rights. Licensor shall consult with Licensee, and consider Licensee’s
comments, in good faith with respect to the preparation, filing, prosecution, and maintenance of any Licensed CPEX Patent Rights
or Licensed Reprise Patent Rights to the extent that Licensor has the right, under any agreement with any applicable licensor,
to file, prosecute, and maintain such Licensed Patent Rights.

 

		(c)	Licensee agrees and acknowledges that Licensor intends to continue to use, in Licensor’s discretion, patent counsel currently
retained by Licensor to prosecute and maintain the Licensed Serenity Patent Rights. Licensee shall execute, acknowledge and deliver
any instruments, and to do all such other acts, as may be necessary or appropriate in order to enable such patent counsel to continue
to prosecute and maintain such Licensed Serenity Patent Rights. The Parties shall reasonably consult with each other, and shall
consider any comments from each other in good faith, with respect to the preparation, filing, prosecution, and maintenance of such
Licensed Serenity Patent Rights and patent strategy for the Licensed Serenity Patent Rights. Licensee shall reimburse Licensor
for all costs and expenses incurred by Licensor after the Effective Date in the preparation, filing, prosecution, and maintenance
of any Licensed Serenity Patent Rights in the Territory, up to an amount not to exceed [***] Dollars ($[***]), which is the estimated
cost set forth on Schedule 9.1(c). Licensor shall provide to Licensee copies of any papers relating to the filing,
prosecution or maintenance of the Licensed Serenity Patent Rights promptly upon their being filed or received. Licensee shall not
knowingly take any action during prosecution and maintenance of the Licensed Serenity Patent Rights.

 

		(d)	Licensor shall not knowingly permit any of the Licensed Serenity Patent Rights to be abandoned in any country in the Territory
without Licensor first giving Licensee an opportunity to assume full responsibility for the continued prosecution and maintenance
thereof. In the event that Licensee decides not to continue the prosecution or maintenance of a Licensed Serenity Patent Rights
in any country in the Territory, Licensor will provide Licensee with notice of this decision at least thirty (30) days prior to
any pending lapse or abandonment thereof. In the event that Licensee elects to assume responsibility for such prosecution and maintenance
within thirty (30) days of Licensor’s notice, Section 9.1(c) shall thereafter apply to such Licensed Serenity Patent Rights
except that the role of Licensee and Licensor shall be reversed thereunder (except further that Licensee will continue to be responsible
for all costs and expenses thereafter incurred in the preparation, filing, prosecution, and maintenance of any Licensed Serenity
Patent Rights). Any such Serenity Patent Right that is subject to such election by Licensee shall otherwise continue to be subject
to all of the terms and conditions of the Agreement in the same way as the other Licensed Serenity Patent Rights.

 

		9.2	Inventions by Licensee. 

 

		(a)	Disclosure. Licensee shall promptly disclose to Licensor the invention of any Licensee Inventions.

 

		(b)	Ownership. As between the Parties, all Licensee Inventions will be owned and Controlled by Licensee.

 

    	 	45	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(c)	Patent Filings.

 

		(i)	Licensee, at its expense, will have sole discretion and responsibility to prepare, file, prosecute, and maintain any patent
applications and patents claiming Licensee Inventions. The Parties’ respective patent counsel shall meet no fewer than once
per Calendar Year to discuss strategies for the preparation, filing, prosecution, and maintenance of any such patent applications
and patents claiming Licensee Inventions. Licensee shall consider in good faith any comments provided by Licensor with respect
to the foregoing. In the event of any dispute between Parties with respect to such strategies, either Party may notify the Alliance
Managers for purposes of resolving such dispute; provided, however, that Licensee shall have the final decision-making authority
with respect to any such dispute.

 

		(ii)	Licensee shall not knowingly permit any Patent Rights with claims to any Licensee Inventions to be abandoned in any country
without Licensee first giving Licensor an opportunity to assume full responsibility for the continued prosecution and maintenance
thereof. In the event that Licensee decides not to continue the prosecution or maintenance of any Patent Right claiming a Licensee
Invention in any country, Licensee will provide Licensor with notice of this decision at least thirty (30) days prior to any pending
lapse or abandonment thereof. In the event that Licensor elects to assume responsibility for such prosecution and maintenance within
thirty (30) days of Licensor’s notice, Section 9.1(c) shall thereafter apply to such Patent Right claiming such Licensee
Invention except that the role of Licensee and Licensor shall be reversed thereunder.

 

		9.3	Infringement, Violation, or Misappropriation by Third Parties. 

 

		(a)	Notice. Each Party shall promptly notify the other Party in writing of any alleged or threatened infringement,
violation, or misappropriation by any Third Party of the Licensed Rights or the Sublicensed Rights of which it becomes aware, and
following such notification, the Parties shall confer as to any response thereto. The notice shall set forth the facts of such
infringement, violation, or misappropriation in reasonable detail.

 

		(b)	Response to Infringement, Violation, or Misappropriation by Third Parties.

 

		(i)	If a Third Party is infringing, violating, or misappropriating, or either Party reasonably believes a Third Party may be infringing,
violating, or misappropriating any Enforceable IP Right in any country in the Territory, Licensee shall have the first right, but
not the obligation, to institute, prosecute, and control any action or proceeding with respect to such infringement, violation,
or misappropriation by counsel of its own selection, at its expense. Licensor shall have the right to participate in such action
and be represented, if it so desires, by counsel of its own selection and at its own expense. To the extent required by Applicable
Laws, Licensor agrees to be joined as a party plaintiff (with Licensor having the right to be represented, if it so desires, by
counsel of its own selection and at its own expense) if necessary for Licensee to bring and prosecute such action or proceeding,
and to give Licensee reasonable assistance and authority to bring and prosecute such action or proceeding. If Licensee fails to
bring an action or proceeding within ninety (90) days after receiving or giving written notice pursuant to Section 9.3(a), then
Licensor shall have the right, but not the obligation, to bring and control any such action by counsel of its own selection, at
its expense (with Licensee having the right to participate in such action and be represented, if it so desires, by counsel of its
own selection and at its own expense). To the extent required by Applicable Laws, Licensee agrees to be joined as a party plaintiff
(with Licensee having the right to be represented, if it so desires, by counsel of its own selection and expense therein) if necessary
for Licensor to bring and prosecute such action or proceeding, and to give Licensor reasonable assistance and authority to bring
and prosecute such action or proceeding. No settlement of any such action or consent judgment or other voluntary final disposition
which restricts the scope, or adversely affects the enforceability, of an Enforceable IP Right may be entered into by either Party
without the prior written consent of the other Party, which consent shall not be unreasonably withheld, delayed or conditioned.

 

    	 	46	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(ii)	Each Party shall share in any recoveries obtained in connection with any action or proceeding described in Section 9.3(b)(i)
as follows:

 

		(A)	each Party’s costs and expenses incurred in connection with bringing and prosecuting any such action or proceeding, including
without limitation attorneys’ fees, first shall be reimbursed from such recoveries, and if such recovery is insufficient
to cover all such costs and expenses of both Parties, it shall be shared in proportion to the total of such costs and expenses
incurred by each Party, and

 

		(B)	if Licensee controlled such action or proceeding Licensee shall receive one hundred percent (100%) of such remaining recoveries,
provided that such recoveries shall be deemed Net Sales for purposes of Section 8.3(a)(i); and if Licensor controlled such action
or proceeding, each Party shall receive fifty percent (50%) of such remaining recoveries, provided that Licensee’s portion
shall not be deemed as Net Sales for purposes of Section 8.3(a)(i) in such case.

 

		(c)	Withdrawal. If either Party brings an action or proceeding under Section 9.3(b)(i) and subsequently ceases to
pursue or withdraws from such action or proceeding, it shall promptly notify the other Party and the other Party may substitute
itself for the withdrawing Party under the terms of Section 9.3(b)(i).

 

		(d)	Oppositions by Parties. If either Party desires to bring an opposition, action for declaratory judgment, nullity
action, interference, reexamination, inter partes proceeding, or other attack upon the validity, title, or enforceability of any
intellectual property right Controlled by a Third Party that Covers the Product in the Field in any country in the Territory, such
Party shall so notify the other Party and the Parties shall promptly confer to determine whether to bring such action or the manner
in which to settle such action. Each Party shall be entitled to separate representation in any such action by counsel of its own
choice and at its own expense, and shall cooperate fully with the other Party. The costs of any such action shall be borne by the
Party bringing the action, and such Party shall retain any recoveries obtained in connection therewith.

 

		9.4	Infringement of Third Party Rights. 

 

		(a)	Notice. If the Exploitation of the Product pursuant to this Agreement results in a claim, action, suit, or proceeding
that such activity infringes or misappropriates the intellectual property rights of a Third Party (“Third Party Infringement
Claim”), the Party first receiving notice thereof shall promptly notify in writing the other Party thereof. The notice
shall set forth the facts of the Third Party Infringement Claim in reasonable detail.

 

		(b)	Litigation. 

 

		(i)	Licensee shall have the sole right, but not the obligation, to defend, at its expense, against any Third Party Infringement
Claim. Licensee shall have full control over the defense and settlement of such Third Party Infringement Claim, provided that Licensee
shall not settle any Third Party Infringement Claim that is subject to indemnification pursuant to Section 11.1 without the prior
written consent of Licensor, which consent shall not be unreasonably withheld, delayed, or conditioned. Licensor shall cooperate
with Licensee, at Licensee’s expense and reasonable request, in such defense and shall have the right to be represented by
counsel of its own choice, at Licensor’s expense. Licensee will pay any losses incurred in defense or settlement of, or imposed
pursuant to settlement of or judgment on, such Third Party Infringement Claim.

 

    	 	47	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(ii)	If Licensee decides not to commence a defense against any Third Party Infringement Claim pursuant to Section 9.4(b)(i), then
Licensee will promptly notify Licensor of such decision in a timely manner so as to allow Licensor, who shall have the right, but
not the obligation, to commence such a defense by counsel of its own selection, at its expense (with Licensee having the right
to participate in such defense and be represented, if it so desires, by counsel of its own selection and at its own expense). Licensor
shall thereupon have full control over the defense and settlement of such Third Party Infringement Claim, provided that Licensor
shall not settle any Third Party Infringement Claim without the prior written consent of Licensee, which consent shall not be unreasonably
withheld, delayed, or conditioned. Licensee shall cooperate with Licensor, at Licensor’s expense and reasonable request,
in such defense and shall have the right to be represented by counsel of its own choice, at Licensee’s expense. Licensor
will pay any losses incurred in defense or settlement of, or imposed pursuant to settlement of or judgment on, such Third Party
Infringement Claim, subject to Section 11.1.

 

		(iii)	Notwithstanding any provisions set forth herein to the contrary, Licensor shall be responsible for continuing to manage, at
Licensor’s expense, that certain litigation with Ferring Pharmaceuticals that is described in Schedule 10.2. Notwithstanding
the foregoing, any settlement of any such action or consent judgment or other voluntary final disposition with respect to the litigation
with Ferring Pharmaceuticals described in Schedule 10.2, which restricts the scope, or adversely affects the enforceability, of
an Enforceable IP Right may not be entered into by Licensor without the prior written consent of the Licensee, which consent shall
not be unreasonably withheld, delayed or conditioned.

 

		(c)	Oppositions by Third Parties. If any patent, trademark, copyright, or other intellectual property right within
the Licensed Rights or the Sublicensed Rights becomes after the Effective Date the subject of any proceeding commenced by a Third
Party in connection with an opposition, reexamination request, action for declaratory judgment, nullity action, interference, inter
partes proceeding, or other attack upon the validity, title, or enforceability thereof, then Licensee shall control such defense
at its sole cost. Licensee shall permit Licensor to participate in the proceeding to the extent permissible under Applicable Laws,
and to be represented by its own counsel in such proceeding, at Licensor’s expense. If Licensee elects not to defend against
such action with respect to any such intellectual property right with the Licensed Rights or the Sublicensed Rights within ninety
(90) days after first receiving notice or otherwise becoming aware of such action or proceeding, then Licensor shall have the right
to assume defense of such Third Party action at its own expense. Any awards or amounts received in bringing any such action shall
be first allocated to reimburse the Parties’ expenses in such action, and any remaining amounts shall be retained by the
Party defending against such proceeding.

 

    	 	48	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		9.5	Use of Licensed Serenity Trademark. 

 

		(a)	Licensee agrees and acknowledges that (i) as between the Parties, Licensor is and shall remain the owner of the Licensed Serenity
Trademarks, and (ii) all of the goodwill associated with the Licensed Serenity Trademarks, in all countries of the world, and all
uses thereof by Licensee, its Affiliates, sublicensees, and Third Party Distributors shall inure to the benefit of Licensor.

 

		(b)	Licensee will cooperate with Licensor for the purpose of protecting, preserving, registering, and enhancing the Licensed Serenity
Trademarks and Licensor ‘s interest therein and in furtherance of such obligations, Licensee will promptly execute and deliver
to Licensor all documents and instruments that Licensor, acting reasonably, determines are necessary or prudent from time to time.
If and to the extent that Licensee, its Affiliates, sublicensees, or Third Party Distributors obtain any rights (other than the
licenses granted herein) to the Licensed Serenity Trademarks in any country in the world, at the request of Licensor, Licensee
shall immediately and automatically assign, and ensure that its Affiliates, sublicensees, and Third Party Distributors immediately
and automatically assign, to Licensor all right, title and interest in and to the Licensed Serenity Trademarks, and all goodwill
with respect thereto.

 

		(c)	Licensee will use the Licensed Serenity Trademarks (i) only in compliance with all Applicable Law and the express terms of
this Agreement and the Serenity Trademark Standards, and (ii) not as part of any composite trademark in close proximity or
in combination with any other trademark.

 

		(d)	Licensee agrees to conform, and to cause any of its Affiliates, sublicensees and Third Party Distributors to conform, the manner
of their respective use of the Licensed Serenity Trademarks with the policies, specifications, directions, and standards for use
thereof set forth in the Serenity Trademark Standards, and to maintain the quality standards of Licensor set forth in the Serenity
Trademark Standards with respect to the Products sold. Except to the extent that any use of the Licensed Serenity Trademarks by
Licensee and any of its Affiliates, sublicensees, and Third Party Distributors is not in accordance with the Serenity Trademarks
Standards, Licensee shall not be required to submit to Licensor any materials bearing any Licensed Serenity Trademark for review
and approval prior to the use thereof.

 

		(e)	To the extent Licensee desires to use any Licensed Serenity Trademark in a manner not expressly permitted under the Serenity
Trademark Standards, Licensee will submit to Licensor for Licensor’s review all packaging, advertising, brochures, and other
material (including, without limitation, mockups or models thereof), that evidence such use. Within fifteen (15) calendar days
after Licensor receives any such material, Licensor will provide Licensee with (i) approval of Licensee’s proposed use of
the Licensed Serenity or (ii) comments as to any revisions Licensor reasonably believes are necessary or advisable to achieve
compliance with the Licensed Trademark Standards. In each case where Licensor provides any such comments, Licensor and Licensee
will promptly discuss and resolve whether any such revisions are necessary or advisable and, if determined to be so necessary or
advisable, Licensee will make such revisions. From and after such approval of Licensor of such use, the Serenity Trademark Standards
shall be amended or revised to reflect such approved use.

 

		(f)	All rights in and to any new version, translation, or arrangement of the Licensed Serenity Trademarks, or other change in the
Licensed Serenity Trademarks created by Licensee, with Licensor’s prior written consent or otherwise, will be and will remain
the exclusive property of Licensor, and the provisions of this Agreement will apply to the same.  

 

    	 	49	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		10.	REPRESENTATIONS, WARRANTIES, AND COVENANTS.

 

		10.1	Mutual Representations and Warranties. Licensor and Licensee (each, a “Representing Party”) each
hereby represents and warrants to each other, as of the Effective Date and except as otherwise set forth in Schedule 10.2 (in the
case of Licensor) and Schedule 10.3 (the case of Licensee), that:

 

		(a)	such Representing Party is a corporation or limited liability company, as applicable, duly organized and subsisting under the
laws of its jurisdiction of organization;

 

		(b)	such Representing Party has the power, authority, and legal right, and is free, to enter into this Agreement on behalf of itself
and its Affiliates and to perform its respective obligations hereunder and to cause its Affiliates to perform their respective
obligations hereunder;

 

		(c)	such Representing Party has the power, authority, and legal right to own and operate its property and assets and to carry on
its business as it is now being conducted and as it is contemplated to be conducted by this Agreement;

 

		(d)	this Agreement constitutes a legal, valid, and binding obligation of such Representing Party and is enforceable against it
in accordance with its terms, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting
the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles
of equity, whether enforceability is considered a proceeding at law or equity;

 

		(e)	the execution and delivery of this Agreement and the performance of such Representing Party’s and its Affiliates’
obligations hereunder (i) have been duly authorized and approved by all necessary action by such Representing Party, and all necessary
consents, approvals, and authorizations of all Regulatory Authorities and other Third Parties required to be obtained by such Representing
Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been
obtained; (ii) do not conflict with or violate any requirement of Applicable Laws or any provision of the articles of incorporation,
bylaws, limited partnership agreement, or any similar instrument of such Representing Party, as applicable, in any material way;
and (iii) do not, and will not, conflict with or otherwise interfere with in such a manner as to result in a violation, breach,
or default under or require any consent that has not been obtained under any contract between such Representing Party and any Third
Party;

 

		(f)	there are no, and shall be no, liens, conveyances, mortgages, assignments, encumbrances, or other agreements that would prevent
or impair such Representing Party’s or any of its Affiliates’ full and complete exercise of the terms and conditions
of the Agreement;

 

		(g)	such Representing Party and its Affiliates shall at all times comply with all Applicable Laws relating or pertaining to their
obligations under the Agreement;

 

		(h)	with respect to the services provided hereunder to the other Party, its Affiliates, and their respective employees, officers,
contractors and agents who perform such services have the experience, capability, and resources to efficiently and skillfully perform
the services, and shall perform, where applicable, all such services in a professional and workmanlike manner and in accordance
with the generally accepted then-current standards, forms, procedures, and techniques established from time to time by the industry;

 

    	 	50	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(i)	all of such Representing Party’s employees, officers, contractors, and consultants have executed agreements requiring
assignment to such Representing Party of all inventions created by such persons in the course of their employment by such Representing
Party and obligating each such employee, officer, contractor, and consultant to maintain and safeguard the confidentiality of (i)
any information that is confidential to such Representing Party or (ii) any information that is confidential to any other Person
and that such Representing Party is obligated to maintain and safeguard as confidential; and

 

		(j)	neither such Representing Party, nor any of its employees, officers, subcontractors, or consultants who have rendered or will
render services relating to the Product: (i) has ever been debarred or is subject or debarment or convicted of a crime for which
an entity or person could be debarred under 21 U.S.C. Section 335a or (ii) has ever been under indictment for a crime for which
a person or entity could be debarred under said Section 335a.

 

		10.2	Additional Representations, Warranties, and Covenants of Licensor. Licensor hereby represents, warrants, and covenants
to Licensee, as of the Effective Date and except as otherwise set forth in Schedule 10.2, that:

 

		(a)	Licensor is entitled to grant the rights and licenses purported to be granted to Licensee under this Agreement, and to assign
the rights purported to be assigned to Licensee under this Agreement, and is not currently bound by any agreement with any Third
Party, or by any outstanding order, judgment, or decree of any court or administrative agency, that restricts it from granting
to Licensee the rights, licenses and sublicenses purported to be so granted in this Agreement;

 

		(b)	Licensor is the sole and exclusive owner of all right, title, and interest, in, to, and under the Licensed Rights and has the
right under the Licensed CPEX Patent Rights and the Licensed Reprise Patent Rights to grant the sublicenses thereunder in accordance
with Section 2.2;

 

		(c)	the Licensed Rights are free and clear of any liens, charges, encumbrances, or judgments, and Licensor has sufficient rights
to grant the licenses and rights purported to be granted herein, free and clear of any security interests, claims, encumbrances,
or charges of any kind;

 

		(d)	Licensor has not granted, and will not grant during the term of this Agreement, any right, option, license, or interest in
or to any of the Licensed Rights that is in conflict with the rights assigned or granted to Licensee under this Agreement;

 

		(e)	there is no legal, administrative, arbitration, or other proceeding, suit, claim, or action of any nature, judgment, decree,
decision, injunction, writ, or order pending, or to Licensor’s knowledge threatened by, against or involving Licensor, regarding
the Licensed Rights, whether at law or in equity, before or by any Third Party, and Licensor has not received any written communications
alleging that it has violated, through the manufacture, Development, import, or other exploitation of the Product, any intellectual
property rights of any Third Party;

 

		(f)	to Licensor’s knowledge:

 

		(i)	the patents in the issued Licensed Serenity Patent Rights, the Licensed CPEX Patent Rights, and the Licensed Reprise Patent
Rights are valid and enforceable; and

 

		(ii)	no Third Party has asserted that any of the Licensed Rights or the Sublicensed Rights is invalid or unenforceable;

 

		(g)	all applications, registrations, maintenance and renewal fees due in respect of any of the Licensed Serenity Patent Rights
and, to Licensor’s knowledge, the Licensed Reprise Patent Rights and the Licensed CPEX Patent Rights, have been paid and
all documents and certificates required to be filed with the relevant agencies for the purpose of maintaining such Licensed Serenity
Patent Rights, and to Licensor’s knowledge, the Licensed Reprise Patent Rights and Licensed CPEX Patent Rights have been
filed;

 

    	 	51	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(h)	none of the Licensed Serenity Patent Rights, the Licensed Serenity Know-How and, to Licensor’s knowledge, none of the
Licensed CPEX Patent Rights and the Licensed Reprise Patent Rights were developed with funding from any Governmental Authority
such that any Governmental Authority has any march in rights or other rights to use the Licensed Serenity Patent Rights, the License
Serenity Know-How, the Licensed Reprise Patent Rights, or the Licensed CPEX Patent Rights;

 

		(i)	to Licensor’s knowledge, no Third Party has infringed or misappropriated any of the Licensed Rights or the Sublicensed
Rights;

 

		(j)	all inventors of any inventions included within the Licensed Serenity Patent Rights and, to the knowledge of Licensor, the
Licensed CPEX Patent Rights and the Licensed Reprise Patent Rights have assigned their entire right, title, and interest in and
to such inventions and the corresponding patents and patent applications to Licensor, Reprise, or CPEX, as applicable, and have
been listed as inventors in the Licensed Serenity Patent Rights, the Licensed CPEX Patent Rights, and the Licensed Reprise Patent
Rights, as applicable;

 

		(k)	no agreements that Licensor or its Affiliates may have with any Third Party provide such Third Party with any rights of first
offer, rights of first refusal, or any other rights to make, have made, use, conduct Clinical Studies for, sell, offer for sale,
have sold, import, export, or otherwise Exploit the Product in the Field in the Territory or the right to use the Licensed Rights
or the Sublicensed Rights in connection with the Exploitation of the Product in the Field in the Territory; and Licensor has received
no notice from a Third Party of any suit, action, proceeding, or arbitration pending or threatened against it that the proposed
terms and conditions of this Agreement, and the Parties’ performance in accordance therewith, do or shall conflict or interfere
with in a manner resulting in a breach or default under, or other violation of, any agreements that Licensor or its Affiliates
may have with any Third Party;

 

		(l)	to Licensor’s knowledge, (i) each of the CPEX License Agreement and the Reprise License Agreement is valid and enforceable
in accordance with its terms, is in full force and effect, and there are no approvals or consents required to make it effective,
(ii) Licensor has supplied Licensee with a true and correct copy of the CPEX License Agreement and the Reprise License Agreement
, together with all amendments, waivers, or other changes thereto, (iii) Licensor has performed all material obligations required
to be performed by it in connection with the CPEX License Agreement and the Reprise License Agreement, (iv) Licensor shall not
materially breach and is not in material breach of the CPEX License Agreement or the Reprise License Agreement, (v) Licensor is
not in receipt of any claim of default, cure notice, or show cause notice under the CPEX License Agreement or the Reprise License
Agreement, and (vi) there is no current material breach or anticipated material breach by any other party to the CPEX License Agreement
or the Reprise License Agreement;

 

		(m)	(i) Licensor is the named sponsor of the First Approved NDA for the Product; and (ii) with respect to all Regulatory Documentation
to obtain Regulatory Approvals for the Product in the Field: (A) the data, information and/or all other documents in Licensor’s
or its Affiliates submissions were, are and shall be free from fraud or material falsity, and neither Licensor nor its Affiliates
has made any material misrepresentation or omission in connection with such data; (B) the Regulatory Approvals have not been and
will not be obtained either through bribery or the payment of illegal gratuities by Licensor; (C) the data, information and/or
all other documents in Licensor’s or its Affiliates’ submissions are, were and shall be accurate and reliable for purposes
of supporting approval of the submissions; and (D) the Regulatory Approvals shall be obtained without illegal or unethical behavior
of any kind by Licensor or its Affiliates; provided that Licensor shall not be deemed to be in breach of this Section 10.2(m) if
the violation of this Section 10.2(m) results from the action or omission of Licensee of Licensee’s Affiliates, Sublicensees,
or contractors (other than Licensor);

 

    	 	52	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(n)	Licensor believes in good faith, based on the information set forth in Schedule 10.2(n), that FDA will consider amending or
supplementing the First Approved NDA (or the related IND) in the manner described in Schedule 10.2(n); provided, however,
that Licensor cannot assure that FDA will approve such amendment or supplement.

 

		(o)	except as expressly permitted hereunder, Licensor agrees not to, and agrees to cause its Affiliates and Sublicensees not to
(i) assign, transfer, convey or otherwise encumber any right, title or interest in or to the Licensed Rights, the Sublicensed
Rights, or any Regulatory Approvals and Documentation in respect of the Product, (ii) grant in any manner any license or other
right, title or interest in or to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation
in respect of the Product, or (iii) agree to or otherwise become bound by any covenant not to sue for any infringement, misuse
or other action or inaction with respect to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and
Documentation in respect of the Product; and

 

		(p)	other than the CPEX License Agreement, the Reprise License Agreement, the Renaissance Supply Agreements, and the other Third
Party Supply Agreements, Licensor and/or its Affiliates have not entered into any agreements with any Third Party, pursuant to
which any Third Party has granted to Licensor, or Licensor has granted to any Third Party, any rights to licenses to, in or under
any of the Licensed Rights or the Sublicensed Rights or other intellectual property rights that relate to the Product, or relating
to the manufacture of the Product.

 

		10.3	Additional Representations, Warranties, and Covenants of Licensee. Licensee hereby represents, warrants, and covenants
to Licensor, as of the Effective Date and except as otherwise stated in Schedule 10.3, that:

 

		(a)	if, during the term of this Agreement Licensee has reason to believe that it or any of its employees, officers, subcontractors,
or consultants rendering services relating to the Product: (i) is or will be debarred or convicted of a crime under 21 U.S.C. Section
335a, or (ii) is or will be under indictment under said Section 335a, then Licensee shall immediately notify Licensor in writing;

 

		(b)	as of the Effective Date, there is no legal, administrative, arbitration, or other proceeding, suit, claim, or action of any
nature, judgment, decree, decision, injunction, writ, or order pending or, to the knowledge of Licensee’s senior management,
threatened by, against Licensee regarding this Agreement, whether at law or in equity, before or by any Third Party; and Licensee
shall provide notice of any of the foregoing to the extent it affects Licensee’s performance of its obligations under this
Agreement;

 

		(c)	except for information provided by Licensor, its Affiliates or Sublicensees: (i) the data and information in Licensee’s
submissions and modifications of Regulatory Documentation relating to the Product shall be free from fraud or material falsity;
(ii) Regulatory Approvals for the Product hereafter obtained will not be obtained either through bribery or the payment of illegal
gratuities by Licensee; (iii) the data and information in Licensee’s submissions and modifications of any Regulatory Documentation
shall be accurate and reliable; and (iv) any such the Regulatory Approvals will be obtained without illegal or unethical behavior
of any kind by Licensee; provided that Licensee shall not be deemed to be in breach of this Section 10.3(c) if the violation of
this Section 10.3(c) results from the action or omission of Licensor or its Affiliates, Sublicensees (other than Licensee), or
contractors; and

 

    	 	53	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(d)	except as expressly permitted hereunder, Licensee agrees not to, and agrees to cause its Affiliates and Sublicensees not to
(i) assign, transfer, convey or otherwise encumber any right, title or interest in or to the Licensed Rights, the Sublicensed
Rights, or any Regulatory Approvals and Documentation in respect of the Product, (ii) grant in any manner any license or other
right, title or interest in or to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation
in respect of the Product, (iii) agree to or otherwise become bound by any covenant not to sue for any infringement, misuse or
other action or inaction with respect to any of the Licensed Rights, the Sublicensed Rights, or the Regulatory Approvals and Documentation
in respect of the Product, or (iv) bring any action or proceeding or otherwise assert any claim under any Applicable Law in the
event any licensee (or sublicensee or any entity or person acting on its behalf) initiates any proceeding or otherwise assert any
claim in any court, administrative agency, or other forum with jurisdiction over such proceeding or claim, that any of the Licensed
Rights or Sublicensed Rights are invalid, unenforceable, or not infringed, violated, or misappropriated. In the event that Licensee
or any Affiliate or Sublicensee of Licensee initiates any proceeding or otherwise asserts any claim in violation of clause (iv)
of this Section 10.3, and the result thereof is a final decision, ruling, holding, award, or other disposition to the effect that
any of the Licensed Rights or Sublicensed Rights are valid, enforceable, or infringed, violated, or misappropriated, then each
of the royalty rates set forth in the table in Section 8.3(a) will each be increased by [***] and the party initiating such proceeding
or otherwise asserting such claim shall pay the attorneys’ fees and expenses incurred by Licensor in defending against such
proceeding or claim.

 

		10.4	Inaccuracies. Without limiting either Party’s rights and remedies at law, in equity or under this Agreement, if,
at any point in time (not just at the times when the warranties are deemed granted), either Party becomes aware of any inaccuracies
in the foregoing warranties and representations, such Party shall promptly notify the other Party of such inaccuracies, with a
detailed written explanation.

 

		11.	INDEMNIFICATION AND INSURANCE.

 

		11.1	Indemnification by Licensee.  Licensee shall defend, indemnify and hold harmless any Licensor Indemnitee from and against
any and all Losses arising out of a claim by a Third Party arising out of, resulting from or relating to: (a) the gross negligence
or willful misconduct of Licensee and/or its Sublicensees and its or their respective directors, officers, employees, and agents,
in connection with Licensee’s performance of its obligations or exercise of its rights under this Agreement; (b) any material
breach by Licensee of any obligation, representation, warranty, or covenant set forth in this Agreement; (c) any Development Activities
and Commercialization Activities in respect of the Product, undertaken by Licensee or any of its Affiliates, Sublicensees, agents,
and contractors (other than Licensor); (d) the failure to comply with Applicable Laws by Licensee, or any of its Affiliates, Sublicensees,
agents, or contractors (other than Licensor); and (e) any allegation that personal injury or death, or any damage to any property,
was caused or allegedly caused by a manufacturing defect in the Product manufactured by Licensee or for Licensee by Third Parties.

 

    	 	54	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		11.2	Indemnification by Licensor. Licensor shall defend, indemnify and hold harmless any Licensee Indemnitee from and against
any and all Losses arising out of a claim by a Third Party arising out of, resulting from or relating to: (a) the gross negligence
or willful misconduct of Licensor and/or its Sublicensees and its or their respective directors, officers, employees, and agents,
in connection with Licensor’s performance of its obligations or exercise of its rights under this Agreement; (b) any material
breach by Licensor of any obligation, representation, warranty, or covenant set forth in this Agreement; (c) any Development Activities
and Commercialization Activities in respect of the Product, undertaken by Licensor or any of its Affiliates, Sublicensees, agents,
and contractors (other than Licensee); and (d) the failure to comply with Applicable Laws by Licensor, or any of its Affiliates,
Sublicensees, agents, or contractors (other than Licensor).

 

		11.3	Process for Indemnification. A claim to which indemnification applies under Section 11.1 shall be referred to herein
as an “Indemnification Claim”. If a Licensor Indemnitee or Licensee Indemnitee (each being an “Indemnitee”
for purposes of this Section 11.3) intends to claim indemnification under Section 11.1, such Indemnitee must notify Licensee or
Licensor, as the case may be (each in such capacity of providing indemnification hereunder, the “Indemnitor”), in writing
promptly upon becoming aware of any claim that may be an Indemnification Claim (it being understood and agreed, however, that the
failure by an Indemnitee to give such notice shall not relieve the Indemnitor of its indemnification obligation under this Agreement
except and only to the extent that the Indemnitor is actually prejudiced as a result of such failure to give notice). The Indemnitor
shall have the right to assume and control the defense of the Indemnification Claim at its own expense with counsel selected by
the Indemnitor and reasonably acceptable to the Indemnitee; provided, however, that the Indemnitee shall have the right to retain
its own counsel, with the fees and expenses to be paid by the Indemnitor, if representation of such Indemnitee by the counsel retained
by the Indemnitor would be inappropriate due to actual or potential differing interests between the Indemnitor and the Indemnitee
and any other party represented by such counsel in such proceedings. If the Indemnitor does not assume the defense of the Indemnification
Claim as described in this Section 11.2, the Indemnitee may defend the Indemnification Claim but shall have no obligation to do
so. An Indemnitee shall not settle or compromise any Indemnification Claim without the prior written consent of the Indemnitor,
and the Indemnitor shall not settle or compromise any Indemnification Claim in any manner that would have an adverse effect on
the Indemnitee’s interests, without the prior written consent of the Indemnitee, which consent, in each case, shall not be
unreasonably withheld, delayed, or conditioned. Each Indemnitee shall reasonably cooperate with the Indemnitor at the Licensor’s
expense and shall make available to the Licensee or Licensor all pertinent information under the control of the Indemnitee, which
information shall be subject to Article 13.

 

		11.4	Insurance.

 

		(a)	At all times during the term of this Agreement and for five (5) years thereafter, Licensee shall at its sole cost: (i) maintain
Commercial General Liability, including without limitation product liability insurance (including without limitation bodily injury
and property damage coverage) including coverages of: (A) products and completed operations; (B) premises – operations; and
(C) broad form contractual liability at limits not less than $5,000,000 per occurrence/$10,000,000 aggregate (collectively, the
“Licensee Insurance Policies”); (ii) include Licensor as “Additional Insured” under the Licensee
Insurance Policies; and (iii) provide Certificates of Insurance verifying insurance limits agreed upon as well as a thirty
(30) day notice of cancellation, non-renewal or material change. Licensee will obtain such Licensee Insurance Policies from insurers
having A.M. Best’s Ratings of–A - VII or equivalent. Any and all deductibles in such Licensee Insurance Policies shall
be assumed by Licensee. The policy limits stated above do not limit the obligation of Licensee under this Agreement.

 

    	 	55	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(b)	At all times during the term of this Agreement and for five (5) years thereafter, Licensor, to the extent that it is engaged
in any Development Activities hereunder, shall at its sole cost: (i) maintain Commercial General Liability, including without limitation
product liability insurance (including without limitation bodily injury and property damage coverage) including coverages of: (A)
products and completed operations; (B) premises – operations; and (C) broad form contractual liability at limits not less
than $1,000,000 per occurrence/$ 2,000,000 aggregate (collectively, the “Licensor Insurance Policies”); (ii) include
Licensee as “Additional Insured” under the Licensor Insurance Policies; and (iii) provide Certificates of Insurance
verifying insurance limits agreed upon as well as a thirty (30) day notice of cancellation, non-renewal or material change. Licensor
will obtain such Licensor Insurance Policies from insurers having A.M. Best’s Ratings of–A - VII or equivalent. Any
and all deductibles in such Licensor Insurance Policies shall be assumed by Licensor. The policy limits stated above do not limit
the obligation of Licensor under this Agreement,

 

		12.	LIMITATION OF LIABILITY AND DISCLAIMER OF WARRANTY.

 

		12.1	LIMITATION OF LIABILITY. EXCEPT FOR BREACH BY EITHER PARTY OF ARTICLE 13, AND WITHOUT LIMITING THE PARTIES’ OBLIGATIONS
UNDER ARTICLE 11, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR TO ANY THIRD PARTY FOR ANY INDIRECT, INCIDENTAL,
SPECIAL, PUNITIVE, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES RESULTING FROM LOSS OF USE, LOSS OF
PROFITS, INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING FROM OR RELATING TO THIS AGREEMENT, WHETHER THE BASIS
OF THE LIABILITY IS BREACH OF CONTRACT, TORT, STATUTES, OR ANY OTHER LEGAL THEORY, AND WHETHER SUCH FIRST PARTY HAS BEEN ADVISED
OF THE POSSIBILITY OF SUCH DAMAGES OR NOT.

 

		12.2	DISCLAIMER OF WARRANTY. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY PROVIDES ANY WARRANTIES, WHETHER
WRITTEN OR ORAL, EXPRESS OR IMPLIED, AND EACH PARTY HEREBY DISCLAIMS ALL OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS AND
IMPLIED, INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND FREEDOM FROM
INFRINGEMENT OF THIRD PARTY RIGHTS.

 

		13.	CONFIDENTIALITY.

 

		13.1	Confidential Information, Defined; Exclusions. 

 

		(a)	Definition of Confidential Information. The term “Confidential Information” means, with respect to
a Disclosing Party, information and material, regardless of the form in which that information or material is constituted, any
and all regulatory, technical, manufacturing, business, financial, operational, administrative, marketing or economic information,
data, documents, designs, patents, materials, product samples, and Know-How asserted by such Disclosing Party as being confidential
to it and disclosed by the Disclosing Party to the Receiving Party, whether orally, in writing, or in pictorial form in hard copy,
electronic form or in any other form, in connection with the performance of this Agreement by the Parties, marked in English, or
otherwise identified, as confidential or proprietary or secret.

 

    	 	56	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(b)	Exclusions. The term “Confidential Information” does not apply to any portion of information or materials
that a Receiving Party can demonstrate by contemporaneous written records was: (i) known to the general public at the time of its
disclosure to the Receiving Party, or thereafter became generally known to the general public, other than as a result of actions
or omissions of the Receiving Party or anyone to whom the receiving Party disclosed such information or materials; (ii) known by
the Receiving Party prior to the date of disclosure by the Disclosing Party; (iii) disclosed to the Receiving Party on an unrestricted
basis from a source unrelated to the Disclosing Party and not under a duty of confidentiality to the Disclosing Party; or (iv)
independently developed by the Receiving Party by personnel that did not have access to or use of Confidential Information of the
Disclosing Party. Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely
because individual features are published or known to the general public or in the rightful possession of the Receiving Party unless
the combination itself and principle of operation thereof are published or known to the general public or are in the rightful possession
of the Receiving Party.

 

		13.2	Degree of Care. Each Party shall take Commercially Reasonable Efforts to maintain the confidentiality of the Confidential
Information of the other Party, which steps shall be no less protective than those steps that such Party takes to protect its own
information and materials of a similar confidential nature, but in no event less than a reasonable degree of care. Neither Party
shall use or permit the use of any Confidential Information of the other Party except for the purposes of carrying out its obligations
or exercising its rights under this Agreement, and neither Party shall copy any Confidential Information of the other Party except
as may be reasonably useful or necessary for such purposes. All Confidential Information of a Party, including without limitation
all copies and derivations thereof, is and shall remain the sole and exclusive property of such Party and subject to the restrictions
provided for herein. Neither Party shall disclose any Confidential Information of the other Party other than as permitted under
this Agreement.

 

		13.3	Required Disclosures. The obligations of Sections 13.2 and 13.7 shall not apply to the extent that the Receiving Party:

 

		(a)	is required to disclose Confidential Information it receives pursuant to (i) an order of a court of competent jurisdiction,
(ii) Applicable Laws, (iii) regulations or rules of a securities exchange, including without limitation as required in connection
with a public offering of the Receiving Party’s stock or to comply with regulations imposed by the United States Securities
and Exchange Commission, NASDAQ, or stock exchange disclosure requirements, or (iv) requirement of a governmental agency for purposes
of obtaining approval to test or market the Product; provided that, in the case of clauses (i) through (iv) of this subsection
(a), the Receiving Party shall provide prior written notice thereof to the Disclosing Party and, where practicable, reasonable
opportunity for the Disclosing Party to review and comment on such required disclosure and request confidential treatment thereof
or a protective order therefore in a reasonably timely manner, or

 

		(b)	discloses such Confidential Information to Affiliates, potential or actual acquirers, merger partners, external advisors, licensees,
sublicensees, assignees, subcontractors, investment bankers, investors, lenders, venture capital firms, investment bankers, or
other potential financial partners, and their and each of the Parties’ respective directors, employees, contractors, and
agents; provided that such any such person or entity listed in the first part of this subsection (b) agrees to confidentiality
and nonuse obligations with respect thereto at least as stringent as those specified in Section 13.2.

 

    	 	57	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		13.4	Permitted Disclosures. At each Receiving Party’s request, the Disclosing Party shall review and approve in good
faith the use by the Receiving Party any packet of Confidential Information of the Disclosing Party that the Receiving Party proposes
to disclose, under commercially reasonable confidentiality obligations that are less stringent than those specified in Section
13.2 to actual or potential investment bankers, investors, lenders, venture capital firms, investment bankers, or other potential
financial partners, and their and the Receiving Party’s respective directors, employees, contractors, and agents for purposes
of raising capital.

 

		13.5	Irreparable Injury. The Parties acknowledge that either Party’s breach of this Article 13 would cause the other
Party irreparable injury for which it would not have an adequate remedy at law. In the event of a breach of this Article 13, the
nonbreaching Party may seek injunctive relief, whether preliminary or permanent, in addition to any other remedies it may have
at law or in equity, without necessity of posting a bond.

 

		13.6	Return of Confidential Information. Each Receiving Party shall return or destroy, at the Disclosing Party’s instruction,
all Confidential Information of the Disclosing Party in the Receiving Party’s possession upon termination or expiration of
this Agreement, except any Confidential Information that is necessary to allow the Receiving Party to perform or enjoy any of its
rights or obligations that expressly survive the termination or expiration of this Agreement.

 

		13.7	Public Disclosure. 

 

		(a)	The Parties agree that the initial public announcement of the execution of this Agreement shall be in the form set forth on
Exhibit 13.7 (the “Press Release”).

 

		(b)	During the term of this Agreement, in all cases other than the announcement set forth in the Press Release, Licensor and Licensee
shall submit to each other in a reasonably timely manner for review and approval all proposed press releases involving medical
or scientific information, academic, scientific, and medical Publications and public presentations, including without limitation
any and all abstracts, public presentations at congresses or scientific meetings or other public meetings, and any Publication
manuscripts, relating to the Product, the Nocturia Indication, the PNE Indication and any Additional Indication that have not been
previously publicly disclosed and that are not otherwise permitted to be disclosed under this Article 13. Such review and approval
shall be conducted in a timely manner for the purposes of preserving intellectual property protection and determining whether any
portion of the proposed publication or presentation containing the Confidential Information of either Party should be modified
or deleted. Notwithstanding the foregoing and for clarity sake, this provision shall not apply for any disclosures or releases
required by the SEC or any other Regulatory Authority, which such disclosures and releases will be subject to Section 13.3.

 

		(c)	Effect on Existing Confidentiality Agreement. The provisions of this Article 13 do not supersede that certain letter
agreement, dated April 3, 2017, between Licensor and Licensee.

 

		14.	TERM AND TERMINATION.

 

		14.1	Term. The term of this Agreement shall commence as of the Effective Date and shall continue in effect until it is terminated
as specifically provided in this Agreement.

 

    	 	58	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		14.2	Termination for Material Breach. 

 

		(a)	If either Party (the “non-breaching Party”) believes the other Party (the “alleged breaching party”)
is in material breach of any of such alleged breaching Party’s obligations under this Agreement, the non-breaching Party
may give notice of such breach to the alleged breaching Party, and the alleged breaching Party shall have sixty (60) days in which
to remedy such material breach or establish that it is not in material breach hereunder. Subject to Section 14.2(b), if such alleged
material breach is not remedied in the time period set forth above, the non-breaching Party shall be entitled, without prejudice
to any of its other rights conferred on it by this Agreement, and in addition to any other remedies available to it by law or in
equity, to terminate this Agreement upon written notice to the alleged breaching Party.

 

		(b)	If the alleged breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided
by the non-breaching Party pursuant to Section 14.2(a), and the alleged breaching Party provides notice to the non-breaching Party
of such dispute within fifteen (15) days after receipt of such notice, the non-breaching Party shall not have the right to terminate
this Agreement unless and until the existence of such material breach by the alleged breaching Party has been determined in accordance
with the dispute resolution procedures set forth in Section 15.8 (each such termination delay, a “Toll Period”)
and the breaching Party fails to cure such default within sixty (60) days following such determination; provided that, if it is
determined that such material breach occurred and such breach is not cured within such sixty (60) day period, then, for purposes
of Section 14.4(c)(iii), this Agreement shall be deemed to have been terminated as of the date of delivery of notice of such breach
under Section 14.2(a). During the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in
effect and the Parties shall continue to perform all of their respective obligations hereunder.

 

		14.3	Termination upon Insolvency. To the extent permitted under Applicable Laws, either Party may terminate this Agreement
with respect to the other Party if, at any time, such other Party shall file in any court or agency pursuant to any statute or
regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the
appointment of a receiver or trustee of such other Party or of its assets, or if such other Party proposes a written agreement
of composition or extension of its debts, or if such other Party shall be served with an involuntary petition against it, filed
in any insolvency proceeding, and such petition shall not be dismissed within forty-five (45) days after the filing thereof, or
if such other Party shall propose or be a party to any dissolution or liquidation, or if such other Party shall make an assignment
for the benefit of its creditors.

 

		14.4	Termination upon Force Majeure. Either Party may terminate this agreement due to a Force Majeure event pursuant to Section
15.13.

 

		14.5	Consequences of Expiration or Termination. 

 

		(a)	Upon termination of this Agreement by either Party pursuant to Sections 14.2, 14.3, or 14.4,

 

		(i)	all of the licenses granted by Licensor to Licensee shall therewith immediately terminate and any sublicenses granted by Licensee
thereunder will be subject to the provisions set forth in Section 2.4(f);

 

		(ii)	Licensee must assign and transfer to Licensor, and shall cause its Affiliates and Sublicensees to assign and transfer to Licensor,
without additional compensation, all of their right, title, and interest in to, and under, subject to any licenses or sublicenses
granted by Licensee that expressly survive any such termination pursuant to Section 2.4(f), all clinical and related study data
based on use of Products, all Regulatory Filings and Regulatory Approvals for Products in respect of each country in the Territory;
and the Renaissance Supply Agreements.

 

    	 	59	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(b)	If at the time of any such termination of this Agreement by Licensor pursuant to Sections 14.2 or 14.3 Licensee has in its
possession or under its control any inventory of the Product approved and allocated for sale in the Territory, Licensee shall for
a period not to exceed six (6) months following the effective date of such termination be permitted to sell any such inventory
of the Product in the Field in the Territory, and the licenses hereunder shall continue on a nonexclusive basis until all such
units of the Product have been sold, provided that (A) the Product shall not be sold at a discount to a purchaser that is greater
than the average discount provided to such purchaser for the Product during the twelve (12) month period preceding such termination
and, in addition, such sales shall not result in the applicable wholesaler inventory levels for the Product exceeding the average
levels for the twelve (12) month period preceding such termination, and (B) Licensee continues to pay, during the applicable Royalty
Term, the applicable royalty and, if applicable, sales milestones, on resulting applicable Net Sales of Product in the Territory
by it Licensee, its Sublicensees or any Third Party Distributors.

 

		(c)	In the event of a material breach of this Agreement by Licensor that is not successfully disputed or cured by Licensor in accordance
with Section 14.2(b), Licensee may elect to terminate this Agreement or continue the Agreement; provided, that in the event Licensee
elects to continue the Agreement in lieu of terminating the Agreement in accordance with Section 14.2, Licensee will have the right
in its discretion to fully reduce the royalty payments or milestone payments required under Article 8 by the amount of damages
suffered by Licensee due to such material breach by Licensor, which such amount will be determined by an independent third party
with requisite expertise and agreed upon by the Parties, with any dispute as to the determination being subject to the dispute
resolution process set forth in Section 15.8(b).

 

		(d)	In the event of the insolvency or bankruptcy of Licensor that gives rise to Licensee’s right to terminate this Agreement
in accordance with Section 14.3, Licensee may elect to terminate this Agreement or continue the Agreement (subject, to the extent
applicable, Section 14.7).

 

		14.6	General Surviving Obligations. The rights and obligations set forth in this Agreement shall extend beyond the expiration
or termination of the Agreement only to the extent expressly provided for herein, or to the extent that the survival of such rights
or obligations are necessary to permit their complete fulfillment or discharge. Expiration or termination of this Agreement for
any reason shall not (a) release either Party from any obligation that has accrued prior to the effective date of such expiration
or termination (including without limitation the obligation to pay amounts accrued and due under this Agreement prior to the effective
date of such termination but that are unpaid or become payable thereafter), (b) preclude either Party from claiming any other damages,
compensation, or relief that it may be entitled to upon such expiration or termination, or (c) terminate any right to obtain performance
of any obligation provided for in this Agreement that shall survive expiration or termination. Without limiting the foregoing,
the Parties have identified various rights and obligations which are understood to survive, as follows. In the event of expiration
or termination of this Agreement for any reason, the following provisions shall survive in addition to others specified in this
Agreement to survive in such event: Sections 7.7, 7.8, 9.1(a), 9.2(b), 9.5(a), and Articles 1 (to the extent that any term defined
therein is used in any of the sections or articles specified in this list as surviving termination of this Agreement), 8, 11, 12,
13, 14, and 15.

 

    	 	60	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		14.7	Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by either Party are, and shall
otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, licenses of right to “intellectual
property” as defined under Section 61 of the United States Bankruptcy Code. The Parties agree that the Parties, as licensees
of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the United States
Bankruptcy Code. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either
Party under the United States Bankruptcy Code, the other Party will be entitled to a complete duplicate of (or complete access
to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in
the non-subject Party’s possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding
upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects to continue to
perform all of its obligations under this Agreement, or (b) if not delivered under clause (a) above, following the rejection of
this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party.

 

		15.	MISCELLANEOUS.

 

		15.1	Agency. Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer, or legal representative of the
other Party for any purpose, except as expressly set forth herein. No Party shall be entitled to enter into any contracts in the
name of, or on behalf of the other Parties, nor shall either Party be entitled to pledge the credit of the other Parties in any
way or hold itself out as having the authority to do so.

 

		15.2	Assignment. Except as expressly provided in this Agreement, neither Party may assign any rights or delegate any duties
under this Agreement to any Third Party without the prior written consent of the other Party; provided, however, that (a) Licensor
may freely assign its right to receive any payments hereunder without such consent of Licensee, (b) in the case where either Party
seeks to assign this Agreement as a whole to an Affiliate or to a Successor in connection with a Change of Control of such Party
or of that part of such Party’s business to which this Agreement relates, such consent shall not be unreasonably withheld,
delayed, or conditioned, provided that such Party provides written notice to the other Party of such Change of Control and such
Successor agrees in writing to be bound as such Party hereunder. This Agreement shall be binding upon and inure to the successors
and permitted assignees of the Parties and the name of a Party appearing herein shall be deemed to include the names of such Party’s
Successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment or transfer
not in accordance with this Section 15.2 shall be null and void.

 

		15.3	Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such
other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

		15.4	Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been given:
(a) when personally delivered or sent by confirmed facsimile or email (with hard copy to follow); (b) one (1) Business Day after
sent by reputable overnight express courier (charges prepaid); or (c) five (5) Business Days following mailing by certified or
registered mail, postage prepaid and return receipt requested. Unless another address is specified in writing, such notices to
Licensor or Licensee shall be sent to the addresses indicated below:

 

If to Licensor, addressed to:

 

Serenity Pharmaceuticals, LLC

105 Hawk Court

Milford, PA 18327

Attention: Chief Executive Officer

With a copy to:

email: docsam122@gmail.com>

 

With a further copy to:

Mr. Alain Kodsi

email: alainkodsi@gmail.com

 

    	 	61	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

If to Licensee, addressed to:

 

Avadel Specialty Pharmaceuticals, LLC

16640 Chesterfield Grove Road, Suite 200

Chesterfield, MO 63005

Attention: Chief Executive Officer

With a copy to: General Counsel

 

		15.5	Amendment. No amendment, modification, or supplement of any provision of this Agreement shall be valid or effective
unless made in writing and signed by a duly authorized officer of each Party.

 

		15.6	Waiver. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or
employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving
Party.

 

		15.7	Counterparts; Electronic Delivery. This Agreement may be executed simultaneously in two counterparts, either of which
need not contain the signature of more than one Party but both such counterparts taken together shall constitute one and the same
agreement. Signatures to this Agreement transmitted by facsimile, by email in “portable document format” (“.pdf”),
or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Agreement shall have
the same effect as physical delivery of the paper document bearing original signature.

 

		15.8	Governing Law; Dispute Resolution. 

 

		(a)	This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of New York, U.S.A.
without regard to its or any other jurisdiction’s choice of law rules that would result in the application of the laws of
any jurisdiction other than the State of New York, U.S.A.

 

		(b)	Except as otherwise provided in this Agreement, in the event of any dispute, controversy, or claim (“Dispute”)
between the Parties in connection with this Agreement, the construction hereof, or the rights, duties or liabilities of either
Party under this Agreement, the Parties shall first attempt in good faith to resolve such Dispute by negotiation and consultation
between themselves. In the event that such Dispute is not resolved on an informal basis within ten (10) Business Days after one
Party provides notice to the other Party of such Dispute, either Party providing such notice may, by written notice to the other
Party refer such Dispute to the other Party for attempted resolution by good faith negotiation by the Chief Executive Officers
or President of Licensor and the Chief Executive Officer, President or an Executive Vice President within thirty (30) days after
such notice is received. In the event that any such Dispute is not resolved under the foregoing provisions, each Party may, at
its sole discretion, seek resolution of such Dispute in accordance with Section 15.8(c). Any Disputes of the type described in
Section 3.2(i) shall first be subject to the dispute resolution mechanism set forth in Section 3.2(i) before being subject to this
Section 15.8.

 

    	 	62	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		(c)	In the event such officers of the Parties are not able to resolve any such Dispute, either Party may at any time after such
thirty (30) day period submit such Dispute to be finally settled by arbitration administered in accordance with the Commercial
Arbitration Rules of the American Arbitration Association (“AAA”) in effect at the time of submission. The arbitration
shall be heard and determined by three (3) arbitrators. Each such Party shall each appoint one arbitrator and the third arbitrator
shall be selected by the two Party-appointed arbitrators, or, failing agreement within thirty (30) days following the date of receipt
by the respondent of the claim, by the AAA. Such arbitration shall take place in New York, NY. The arbitration award so given shall
be a final and binding determination of the dispute, shall be fully enforceable in any court of competent jurisdiction, and shall
not include any damages expressly prohibited by Section 12.1. The Parties agree that all applicable statutes of limitation and
time-based defenses (such as estoppel and laches) shall be tolled while the dispute resolution procedures set forth in this Section
15.8(c) are pending.

 

		(d)	Notwithstanding anything herein to the contrary, nothing in this Section 15.8 shall preclude either Party from seeking interim
or provisional relief, including a temporary restraining order, preliminary injunction or other interim equitable relief concerning
a Dispute, including in a court of law, if necessary to protect the interests of such Party. This Section 15.8 shall be specifically
enforceable.

 

		(e)	Notwithstanding the foregoing, any disputes regarding the validity, scope or enforceability of Patent Rights or trademarks
shall be submitted to a court of competent jurisdiction in the territory in which such rights apply.

 

		15.9	Hart-Scott-Rodino. Licensee, at its expense, with the reasonable cooperation of Licensor, will be responsible for making
any filing with the U.S. Federal Trade Commission (“FTC”) in respect of this Agreement and the transaction contemplated
hereby under Hart-Scott-Rodino Antitrust Improvements Act of 1976. This Agreement shall not become effective until the expiration
of any applicable waiting period under such Act.

 

		15.10	Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective
and valid under Applicable Laws, but if any provision of this Agreement is held to be prohibited by or invalid under Applicable
Laws, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder
of this Agreement. In the event of such invalidity, the Parties shall seek to agree on an alternative enforceable provision that
preserves the original purpose of this Agreement.

 

		15.11	Compliance with Applicable Laws. Each Party will comply with all Applicable Laws in performing its obligations and exercising
its rights hereunder.

 

		15.12	Remedies. The exercise of any remedies hereunder shall be cumulative and in addition to and not in limitation of any
other remedies available to such Party at law or in equity.

 

		15.13	Force Majeure. Neither Party shall be liable for delay or failure in the performance of any of its obligations hereunder
if such delay or failure is due to causes beyond its reasonable control, including, without limitation, acts of nature, fires,
earthquakes, strikes and labor disputes, acts of war, terrorism, or civil unrest (“Force Majeure”); provided
that the affected Party promptly notifies the other Party and further provided that the affected Party shall use its commercially
reasonable efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and shall continue
performance with the utmost dispatch whenever such causes are removed. In the event any such Force Majeure event continues for
three (3) months or more, the unaffected Party shall have the right to terminate this Agreement, effective as of the date of delivery
of notice, which notice shall not be delivered prior to the end of such three (3) month period.

 

		15.14	Interpretation. Each Party represents that it has been represented by legal counsel in connection with this Agreement
and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this
Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions.

 

    	 	63	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

		15.15	Construction. In construing this Agreement, unless expressly specified otherwise: (a) unless otherwise specifically
provided, any references to Articles, Sections, Exhibits, Schedules, and Appendices are to articles in, sections of, and exhibits,
schedules and appendices to, this Agreement; (b) except where the context otherwise requires, use of either gender includes the
other gender and use of the singular includes the plural and vice versa; (c) headings and titles are for convenience only and do
not affect the construction or interpretation of this Agreement; (d) any list or examples following the word “including”
shall be interpreted without limitation to the generality of the preceding words; (e) the words “herein”, “hereof”
and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not
to any particular provision hereof; (f) except where the context otherwise requires, the word “or” is used in the inclusive
sense; (g) all references to “dollars” or “$” herein shall mean US Dollars; (h) any definition of or reference
to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document
as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or
modifications set forth herein or therein), (i) any reference to any Applicable Laws herein shall be construed as referring to
such Applicable Laws as from time to time enacted, repealed or amended, and (j) any reference herein to any person or entity shall
be construed to include the person’s or entity’s successors and assigns.

 

		15.16	Entire Agreement of the Parties. This Agreement and the exhibits attached hereto constitute and contain the complete,
final, and exclusive understanding and agreement of the Parties, and cancel and supersede any and all prior and contemporaneous
negotiations, correspondence, understandings, and agreements, whether oral or written, between the Parties respecting the subject
matter hereof, including without limitation the Confidentiality Agreement, and neither Party shall be liable or bound to any other
Party in any manner by any representations, warranties, covenants, or agreements except as specifically set forth herein or therein.
Nothing in this Agreement, express or implied, is intended to confer upon either Party, other than the Parties and their respective
successors and assigns, any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided herein. To the extent that anything set forth in an exhibit attached hereto conflicts with the terms of this Agreement,
the terms of this Agreement shall control.

 

[Signature Page Follows]

 

    	 	64	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to
be executed as of the date set forth in the first paragraph hereof by their duly authorized representatives as set forth below:

 

	LICENSOR:	LICENSEE:
	SERENITY PHARMACEUTICALS, LLC	AVADEL SPECIALTY PHARMACEUTICALS, LLC

 

	By:	/s/ Samuel Herschkowitz, M.D.	 	By:	/s/ Michael S. Anderson

	Name: Samuel Herschkowitz, M.D.	 	Name: Michael S. Anderson
	Title: Chief Executive Officer	 	Title: Chief Executive Officer

 

	By:	/s/ Alain Kodsi	 	 
	Name: Alain Kodsi	 	 
	Title: President	 	 

 

    	 	65	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

Exhibit 4.4

Commercialization Plan

 

[to be prepared in accordance with
Article 4]

 

Exhibit 5.5

Manufacturing and Supply Plan

 

[to be prepared in accordance with Article
5]

 

    	 	66	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]	 

     

    

 

Exhibit __

Development Plan

 

    	 	67	 
	 	[CONFIDENTIAL TREATMENT REQUESTED BY AVADEL PHARMACEUTICALS PLC]Exhibit

THIRD SUPPLEMENTAL INDENTURE
DATED AS OF NOVEMBER 17, 2017
BETWEEN
TORCHMARK CORPORATION,
AS ISSUER
AND
REGIONS BANK, 
AS TRUSTEE

s

TABLE OF CONTENTS

PAGE
	
				
	ARTICLE 1 DEFINITIONS
	4
	

	Section 1.01.
	Definitions.
	4
	

	ARTICLE 2 GENERAL TERMS AND CONDITIONS OF THE DEBENTURES
	9
	

	Section 2.01.
	Designation, Principal Amount and Authorized Denominations; Legends.
	9
	

	Section 2.02.
	Repayment.
	10
	

	Section 2.03.
	Form.
	11
	

	Section 2.04.
	Interest.
	11
	

	Section 2.05.
	Interest Deferral.
	12
	

	Section 2.06.
	Events of Default.
	13
	

	Section 2.07.
	Security Registrar; Paying Agent.
	15
	

	Section 2.08.
	Subordination.
	15
	

	Section 2.09.
	Restrictions on Transfer and Exchange.
	15
	

	Section 2.10.
	Temporary Offshore Global Securities.
	17
	

	Section 2.11.
	Satisfaction, Discharge and Defeasance.
	17
	

	ARTICLE 3 COVENANTS
	18
	

	Section 3.01.
	Dividend and Other Payment Stoppages.
	18
	

	ARTICLE 4 REDEMPTION OF THE DEBENTURES
	19
	

	Section 4.01.
	Redemption.
	19
	

	Section 4.02.
	Redemption Price.
	19
	

	ARTICLE 5 ORIGINAL ISSUE OF DEBENTURES
	20
	

	Section 5.01.
	Original Issue of Debentures.
	20
	

	Section 5.02.
	Calculation of Original Issue Discount.
	20
	

	ARTICLE 6 MISCELLANEOUS
	20
	

	Section 6.01.
	Effectiveness.
	20
	

	Section 6.02.
	Effect of Recitals.
	21
	

	Section 6.03.
	Ratification of Base Indenture; Conflicts.
	21
	

	Section 6.04.
	Debentures Unaffected by Officer’s Certificates.
	21
	

	Section 6.05.
	Tax Treatment.
	21
	

	Section 6.06.
	Governing Law.
	21
	

	Section 6.07.
	Severability.
	21
	

	Section 6.08.
	Counterparts.
	22
	

	Section 6.09.
	Waiver of Jury Trial.
	22
	

	Section 6.10.
	Force Majeure.
	22
	

	Section 6.11.
	Trustee Liability.
	22
	

	Section 6.12.
	Submission to Jurisdiction.
	22
	

	Section 6.13.
	Electronic Communications.
	22
	

	Section 6.14.
	FATCA.
	23
	

	EXHIBIT A
	 
	A-1
	

	EXHIBIT B
	 
	B-1
	

i
    
    

	
				
	EXHIBIT C
	 
	C-1
	

	EXHIBIT D
	 
	D-1
	

	EXHIBIT E
	 
	E-1
	

	EXHIBIT F
	 
	F-1
	

ii
    

THIRD SUPPLEMENTAL INDENTURE, dated as of November 17, 2017 (this “Third Supplemental Indenture”), between Torchmark Corporation, a Delaware corporation, as issuer (the “Company”) and Regions Bank (as successor in interest to The Bank of New York and The Bank of New York Mellon Trust Company, N.A. ), as trustee (the “Trustee”), supplementing the Junior Subordinated Indenture between the Company and the Trustee, dated as of November 2, 2001 (the “Base Indenture,” and together with this Third Supplemental Indenture, the “Indenture”), and the Second Supplemental Indenture, dated as of April 5, 2016 (the “Second Supplemental Indenture”), the First Supplemental Indenture, dated as of September 24, 2012 (the “First Supplemental Indenture”), each between the Company and the Trustee.
RECITALS
WHEREAS, the Company executed and delivered the Base Indenture to the Trustee to provide for the future issuance of the Company’s unsecured junior subordinated debentures, notes or other evidence of indebtedness (the “Securities”), to be issued from time to time in one or more series as might be determined by the Company under the Base Indenture;
WHEREAS, the Company and the Trustee entered into that certain First Supplemental Indenture dated as of September 24, 2012 creating and authorizing a series of securities under the Base Indenture entitled 5.875% Junior Subordinated Debentures due 2052;
WHEREAS, the Company and the Trustee entered into that certain Second Supplemental Indenture dated as of April 5, 2016 creating and authorizing a series of securities under the Base Indenture entitled 6.125% Junior Subordinated Debentures due 2056;
WHEREAS, Section 8.1 of the Base Indenture provides that the Company and the Trustee may, without the consent of any Holders, enter into a supplemental indenture to establish the forms or terms of the Securities of any series as provided in Sections 2.1 and 2.3 thereof;
WHEREAS, pursuant to Sections 2.1 and 2.3 of the Base Indenture and this Third Supplemental Indenture, the Company desires to provide for the establishment of a new series of its Securities to be known as its 5.275% Junior Subordinated Debentures due 2057 (the “Debentures”), with the form and terms thereof as hereinafter set forth; and
WHEREAS, the Company has requested that the Trustee execute and deliver this Third Supplemental Indenture, and all requirements necessary to make this Third Supplemental Indenture a valid instrument in accordance with its terms, and to make the Debentures, when executed by the Company and authenticated and delivered by the Trustee, the valid obligations of the Company, have been done and performed, and the execution and delivery of this Third Supplemental Indenture have been duly authorized in all respects.
NOW, THEREFORE, in consideration of the premises and the purchase and acceptance of the Debentures by the Holders thereof, and for the purpose of setting forth, as provided in the Indenture, the form and substance of the Debentures and the terms, provisions and conditions thereof, the Company covenants and agrees with the Trustee as follows:

iii
    

Article 1 
DEFINITIONS

Section 1.01.    Definitions.
For all purposes of this Third Supplemental Indenture, except as otherwise expressly provided or unless the context otherwise requires:
(a)    a term not defined herein that is defined in the Base Indenture has the same meaning when used in this Third Supplemental Indenture;
(b)    the definition of any term in this Third Supplemental Indenture that is also defined in the Base Indenture shall supersede the definition of such term in the Base Indenture;
(c)    a term defined anywhere in this Third Supplemental Indenture has the same meaning throughout;
(d)    the singular includes the plural and vice versa;
(e)    the words “herein,” “hereof” and “hereunder” and other words of similar import refer to this Third Supplemental Indenture as a whole and not to any particular Article, Section or other subdivision, and any reference to an Article, Section or other subdivision refers to an Article, Section or other subdivision of this Third Supplemental Indenture;
(f)    headings are for convenience of reference only and do not affect interpretation; and
(g)    the following terms have the meanings given to them in this Section 1.1(g):
“Bankruptcy Law” means Title 11, U.S. Code, or any similar federal or state bankruptcy, insolvency, reorganization or other law for the relief of debtors.
“Base Indenture” has the meaning specified in the introduction to this Third Supplemental Indenture.
“Business Day” means any day which is not a Saturday, a Sunday, a legal holiday or a day on which banking institutions or trust companies located in New York City are authorized or obligated by law to close.
“Certificate of Beneficial Ownership” means a certificate substantially in the form of Exhibit E.
“Certificated Security” means a Debenture in registered individual form as described in Section 2.03 hereof.

iv
    

“Common Stock” means shares of common stock of the Company, including treasury shares and shares sold pursuant to the Company’s dividend reinvestment plans and employee benefit plans.
“Company” has the meaning specified in the introduction to this Third Supplemental Indenture.
“Comparable Treasury Issue” means the United States Treasury security or securities selected by an Independent Investment Banker as having an actual or interpolated maturity that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing a new issue of corporate debt securities maturing on November 17, 2022.
“Comparable Treasury Price” means with respect to any date of redemption for the Debentures (1) the average of the Reference Treasury Dealer Quotations for such date of redemption, after excluding the highest and lowest of such Reference Treasury Dealer Quotations, or (2) if the Company obtains fewer than four such Reference Treasury Dealer Quotations, the average of all such quotations.
“Compounded Interest” means accrued and unpaid interest on the Debentures, together with interest thereon, to the extent permitted by applicable law, compounded quarterly at the Coupon Rate.
“Coupon Rate” has the meaning specified in Section 2.04(a) hereof.
“Corporate Trust Office” means the corporate trust office of the Trustee at Regions Bank Attn: Corporate Trust. 3773 Richmond Avenue, Suite 1100 Houston, Texas 77046.
“Custodian” means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.
“Debentures” has the meaning specified in the Recitals of this Third Supplemental Indenture.
“Deferral Period” means the period commencing on an Interest Payment Date with respect to which the Company elects or is deemed to elect to defer interest pursuant to Section 2.05 and ending on the earlier of (i) the fifth anniversary of that Interest Payment Date and (ii) the next Interest Payment Date on which the Company has paid all deferred and unpaid amounts (including Compounded Interest) and all other accrued interest on the Debentures.
“Depositary”, with respect to the Debentures, means The Depository Trust Company or any successor clearing agency.
“Euroclear” means Euroclear Bank S.A./N.V., and its successors or assigns, as operator of the Euroclear System.
“Event of Default” has the meaning specified in Section 2.06 hereof.

v
    

“Exchange Act” means the Securities Exchange Act of 1934, as amended, including the rules and regulations of the Securities and Exchange Commission promulgated thereunder.
“First Supplemental Indenture” has the meaning specified in the introduction to this Supplemental Indenture.
“Global Security” means a Security in the form prescribed in Section 2.03 hereof and Exhibit A hereto evidencing all or part of the Debentures registered in the name of the Depositary or its nominee for such series.
“Indenture” has the meaning specified in the Recitals of this Third Supplemental Indenture.
“Independent Investment Banker” means Morgan Stanley & Co. International plc and its successors, appointed by us or, if such firm is unwilling or unable to select the Comparable Treasury Issue, an independent investment banking institution of national standing appointed by the Company.
“Initial Purchaser” means the initial purchaser party to the Purchase Agreement.
“Interest Payment Date” means each June 15 and December 15, commencing June 15, 2018; provided that, if any such day is not a Business Day, then the Interest Payment Date shall be the immediately succeeding Business Day.
“Interest Payment Period” means the semi-annual period from and including an Interest Payment Date to but not including the next succeeding Interest Payment Date, except for the first Interest Payment Period which shall be the period from and including the date of initial issuance of the Debentures (subject to Section 2.01(b) hereof) to but excluding June 15, 2018.
“Maturity Date” has the meaning specified in Section 2.02 hereof.
 “Non-U.S. Person” means a Person that is not a U.S. person, as defined in Regulation S.
“NRSRO” means a nationally recognized statistical rating organization within the meaning of Section 3(a)(62) of the Exchange Act.
“Parity Securities” shall have the meaning specified in Section 3.01(b) hereof.
“Paying Agent” means any Person authorized by the Company to pay the principal of or interest and any other payments on the Debentures on behalf of the Company.
“Permanent Offshore Global Security” means an Offshore Global Security that does not bear the Temporary Offshore Global Security Legend.
“Predecessor Security” of any particular Security means every previous Security evidencing all or a portion of the same debt as that evidenced by such particular Security; and, for the purposes of this definition, any Security authenticated and delivered under Section 2.9 of 

vi
    

the Base Indenture in exchange for or in lieu of a mutilated, defaced, destroyed, lost or stolen Security shall be deemed to evidence the same debt as the mutilated, defaced, destroyed, lost or stolen Security.
“Purchase Agreement” means that certain Purchase Agreement, dated November 13, 2017, between the Company and Morgan Stanley & Co. International plc, as initial purchaser.
“Rating Agency Event” means that any nationally recognized statistical rating organization within the meaning of Section 3(a)(62) under the Exchange Act, that then publishes a rating for the Company (a “rating agency”) amends, clarifies or changes the criteria it uses to assign equity credit to securities such as the Debentures, which amendment, clarification or change results in (a) the shortening of the length of time the Debentures are assigned a particular level of equity credit by that rating agency as compared to the length of time they would have been assigned that level of equity credit by that rating agency or its predecessor on the initial issuance of the Debentures; or (b) the lowering of the equity credit (including up to a lesser amount) assigned to the Debentures by that rating agency compared to the equity credit assigned by that rating agency or its predecessor on the initial issuance of the Debentures.
“Redemption Date,” when used with respect to any Security to be redeemed, means the date fixed for such redemption by or pursuant to this Third Supplemental Indenture.
“Reference Treasury Dealer” means each of (i) Morgan Stanley & Co. International plc (or its affiliate that is a Primary Treasury Dealer (as defined below)) and its successors; and (ii) one other primary U.S. government securities dealer (each, a “Primary Treasury Dealer”) specified by the Company; provided that if any of the foregoing shall cease to be a Primary Treasury Dealer, the Company will substitute therefor another Primary Treasury Dealer.
“Reference Treasury Dealer Quotations” means, with respect to the Reference Treasury Dealer and any Redemption Date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed, in each case, as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third business day preceding such Redemption Date.
“Regular Record Date” means, with respect to an Interest Payment Date, the June 1 and December 1, as the case may be, next preceding such Interest Payment Date, in each case whether or not a Business Day, and with respect to the accrued and unpaid interest due on the Maturity Date, the November 1 immediately preceding the Maturity Date.
“Regulation S” means Regulation S under the Securities Act.
 “Regulation S Certificate” means a certificate substantially in the form of Exhibit C hereto.
“Restricted Legend” means the legend set forth in Exhibit B.

vii
    

“Restricted Period” means the relevant 40-day distribution compliance period as defined in Regulation S.
“Rule 144A” means Rule 144A under the Securities Act.
“Rule 144A Certificate” means (i) a certificate substantially in the form of Exhibit D hereto or (ii) a written certification addressed to the Company and the Trustee to the effect that the Person making such certification (x) is acquiring such Debenture (or beneficial interest) for its own account or one or more accounts with respect to which it exercises sole investment discretion and that it and each such account is a qualified institutional buyer within the meaning of Rule 144A, (y) is aware that the transfer to it or exchange, as applicable, is being made in reliance upon the exemption from the provisions of Section 5 of the Securities Act provided by Rule 144A, and (z) acknowledges that it has received such information regarding the Company as it has requested pursuant to Rule 144A(d)(4) or has determined not to request such information.
“Securities Act” means the Securities Act of 1933, as amended.
“Third Supplemental Indenture” has the meaning specified in the introduction to this Third Supplemental Indenture.
“Securities” has the meaning specified in the Recitals of this Third Supplemental Indenture.
“Security Registrar” means, with respect to the Debentures, Regions Bank., or any other firm appointed by the Company, acting as security registrar for the Debentures.
“Security Registrar Office” means the office of the applicable Security Registrar at which at any particular time its corporate agency business shall principally be administered, which office at the date hereof in the case of Regions Bank, in its capacity as Security Registrar under the Indenture, is located at 3773 Richmond Avenue, Suite 1100 Houston, TX 77046, ATTN: Corporate Trust.
“Subsidiary” means, at any time, any Person the shares of stock or other ownership interests of which ordinarily have voting power to elect a majority of the board of directors or other managers of such Person, are at the time owned or the management and policies of which are otherwise at the time controlled, directly or indirectly through one or more intermediaries (including other Subsidiaries) or both, by another Person.
“Tax Event” means the receipt by the Company of an opinion of counsel, rendered by a law firm of nationally recognized standing that is experienced in such tax matters, stating that, as a result of any: (i) amendment to, or change in, (including any promulgation, enactment, execution or modification of) the laws (or any regulations under those laws) of the United States or any political subdivision thereof or therein affecting taxation, (ii) official administrative pronouncement (including a revenue ruling, private letter ruling, technical advice memorandum or similar pronouncement) or judicial decision or administrative action or other official 

viii
    

pronouncement interpreting or applying the laws or regulations enumerated in clause (i) above, by any court, government agency or regulatory authority, or (iii) threatened challenge asserted in connection with an audit of the Company or any of its Subsidiaries, or a threatened challenge asserted in writing against any taxpayer that has raised capital through the issuance of securities that are substantially similar to the Debentures (collectively, a “Tax Change”), which Tax Change is enacted or effective or which pronouncement or decision is announced or which challenge is asserted against the Company or becomes publicly known on or after the date hereof, there is more than an insubstantial increase in the risk that interest accruable or payable by the Company on the Debentures is not, or will not be, deductible by the Company, in whole or in part, for United States federal income tax purposes.
“Temporary Offshore Global Security” means an Offshore Global Security that bears the Temporary Offshore Global Security Legend.
“Temporary Offshore Global Security Legend” means the legend set forth in Exhibit F.
“Total Assets” means, at any date, the total assets appearing on the most recently prepared consolidated balance sheet of the Company and its consolidated Subsidiaries as at the end of a fiscal quarter of the Company, prepared in accordance with generally accepted accounting principles.
“Treasury Rate” means, with respect to any date of redemption, the rate per annum equal to the semiannual equivalent yield to maturity or interpolated maturity (on a day count basis) of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such date of redemption.
“U.S. Global Security” means a Global Security that bears the Restricted Legend representing Debentures issued and sold pursuant to Rule 144A.

ARTICLE 2     
GENERAL TERMS AND CONDITIONS OF THE DEBENTURES

Section 2.01.    Designation, Principal Amount and Authorized Denominations; Legends.
(a)    Designation.  Pursuant to Sections 2.1 and 2.3 of the Base Indenture, there is hereby established a series of Securities of the Company designated as the 5.275% Junior Subordinated Debentures due 2057, the principal amount of which to be issued shall be in accordance with Section 2.01(b) hereof and as set forth in any Issuer Order for the authentication and delivery of Debentures pursuant to Section 2.4 of the Base Indenture, and the form and terms of which shall be as set forth hereinafter.
(b)    Principal Amount.  Debentures in an initial aggregate principal amount of $125,000,000 shall, upon execution of this Third Supplemental Indenture, be executed by the Company and delivered to the Trustee or an Authenticating Agent for authentication, and the 

ix
    

Trustee or an Authenticating Agent shall thereupon authenticate and deliver said Debentures in accordance with Section 2.4 of the Base Indenture.  Additional Debentures may be issued from time to time pursuant to this Third Supplemental Indenture on the same terms and conditions as the Debentures issued under this Third Supplemental Indenture in all respects, except for any difference in the issue date, issue price and, if applicable, the first payment of interest thereon and the initial interest accrual date. Additional Debentures issued pursuant to this Third Supplemental Indenture will be consolidated with, and will form a single series with, the previously outstanding Debentures issued pursuant to this Third Supplemental Indenture so long as any such additional Debentures have the same tenor and terms (including, without limitation, rights to receive accrued and unpaid interest as the previously outstanding Debentures); provided that if such additional Debentures are not fungible with the outstanding Debentures for U.S. federal income tax purposes, then they will be issued under a separate CUSIP number.  Any additional Debentures issued under this Third Supplemental Indenture will rank equally and ratably in right of payment with the Debentures originally issued under this Third Supplemental Indenture.
(c)    Authorized Denominations.  The denominations in which Debentures shall be issuable is a minimum of $200,000 principal amount and integral multiples of $200,000 thereafter.
(d)    Legend. 
(i)    Except as otherwise provided in paragraph (c) or Section 2.09(b)(iii) or (c), each Debenture will bear the Restricted Legend.
(ii)    Each Temporary Offshore Global Security will bear the Temporary Offshore Global Security Legend.
(iii)    Debentures offered and sold in reliance Regulation S will be issued as provided in Section 2.10(a).
(iv)    If the Company determines (upon the advice of counsel and such other certifications and evidence as the Company may reasonably require) that a Debenture is eligible for resale pursuant to Rule 144 under the Securities Act (or a successor rule) and that the Restricted Legend is no longer necessary or appropriate in order to ensure that subsequent transfers of the Debenture (or a beneficial interest therein) are effected in compliance with the Securities Act, the Company may instruct the Trustee to cancel the Debenture and issue to the Holder thereof (or to its transferee) a new Debenture of like tenor and amount, registered in the name of the Holder thereof (or its transferee), that does not bear the Restricted Legend, and the Trustee will comply with such instruction.
(v)    By its acceptance of any Debenture bearing the Restricted Legend (or any beneficial interest in such a Debenture), each Holder thereof and each owner of a beneficial interest therein acknowledges the restrictions on transfer of such Debenture (and any such beneficial interest) set forth in this Indenture and in the Restricted Legend 

x
    

and agrees that it will transfer such Debenture (and any such beneficial interest) only in accordance with the Indenture and such legend.

Section 2.02.    Repayment.
The principal of, and all accrued and unpaid interest on, all Outstanding Debentures shall be due and payable on November 17, 2057 or, if such date is not a Business Day, the following Business Day (the “Maturity Date”).

Section 2.03.    Form.
The Debentures shall be substantially in the form of Exhibit A attached hereto and shall be issued in fully registered definitive form without interest coupons.  Principal of and interest on the Debentures issued in definitive form will be payable, the transfer of such Debentures will be registrable and such Debentures will be exchangeable for Debentures bearing identical terms and provisions and notices and demands to or upon the Company in respect of the Debentures and the Indenture may be served at the Corporate Trust Office of the Trustee, and the Company appoints the Trustee as its agent for the foregoing purposes, provided that payment of interest may be made at the option of the Company by check mailed to the Holders at such address as shall appear in the Security Register or by wire transfer in immediately available funds to the bank account number of the Holders specified in writing by the Holders not less than 10 days before the relevant Interest Payment Date and entered in the Security Register by the Security Registrar.  The Debentures may be presented for registration of transfer or exchange at the Security Registrar Office.  The Debentures are initially solely issuable as Global Securities. The Depository Trust Company is hereby designated as Depositary.  Certificated Securities shall be physically transferred to all beneficial owners in definitive form in exchange for their beneficial interests in a Global Security if the Depositary with respect to such Global Securities notifies the Company that it is unwilling or unable to continue as Depositary for such Global Security or the Depositary ceases to be a clearing agency registered under the Exchange Act, as the case may be, and a successor Depositary is not appointed by the Company within 90 days of such notice.
In addition, beneficial interests in the Global Securities may be exchanged for Certificated Securities upon request by or on behalf of the Depositary in accordance with customary procedures following the request of a beneficial owner seeking to exercise or enforce its rights under such Debentures in connection with an Event of Default. If the Company determines at any time that the Debentures shall no longer be represented by a Global Security, the Company shall inform the Depositary of such determination which will, in turn, notify participants of their right to withdraw their beneficial interest from the Global Security. If such participants then elect to withdraw their beneficial interests, the Company shall issue Certificated Securities in exchange for such beneficial interests in the Global Security. Any Global Security, or portion thereof, that is exchangeable pursuant to this Section 2.03 shall be exchangeable for Certificated Securities registered in the names directed by the Depositary.

Section 2.04.    Interest.

xi
    

(a)    From and including the original issue date up to but excluding the Maturity Date or earlier Redemption Date, as applicable, the Debentures will bear interest, accruing from the date of initial issuance (except as further described in the following sentence), at the per annum rate of 5.275% (the “Coupon Rate”), payable quarterly in arrears on each Interest Payment Date, commencing on June 15, 2018.
(b)    Interest payments will include accrued interest from and including the last date in respect of which interest has been paid or duly provided for to, but excluding, the next succeeding Interest Payment Date, the Maturity Date or the Redemption Date, as the case may be.  The amount of interest payable for any full Interest Payment Period will be computed on the basis of a 360-day year of twelve thirty-day months, and the amount of interest payable for any period shorter than a full Interest Payment Period for which interest is computed will be computed on the basis of thirty-day months and, for periods of less than a thirty-day month, the actual number of days elapsed per thirty-day month.
(c)    Otherwise than in connection with the maturity or early redemption of the Debentures or the payment in whole or in part of deferred or overdue interest on the Debentures, interest on the Debentures may be paid only on an Interest Payment Date.  Notwithstanding the preceding sentence, in the event that any Interest Payment Date is not a Business Day, then payment of interest payable on such Interest Payment Date will be made on the next succeeding day which is a Business Day (and without any interest or other payment in respect of such delay).
(d)    To the extent permitted by applicable law, interest not paid when due hereunder, including, without limitation, all deferred interest, will accrue and compound quarterly at the Coupon Rate on each Interest Payment Date until paid. References to the term “interest” in this Indenture shall include such Compounded Interest.
(e)    For so long as the Debentures are represented by one or more Global Securities, the interest installment so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in the Base Indenture, be paid to the Person in whose name the Debentures (or one or more Predecessor Securities) are registered at the close of business on the Regular Record Date next preceding the Interest Payment Date, which shall be the record date for such Interest Payment Date; provided that, in the event the Debentures at any time are not represented solely by one or more Global Securities, the Company may select a different record date for such Interest Payment Date, which shall be at least one Business Day before an Interest Payment Date.  Any such interest installment not punctually paid or duly provided for shall forthwith cease to be payable to the registered Holders of Debentures on such record date, and may be paid to the Person in whose name the Debentures (or one or more Predecessor Securities) is registered at the close of business on a special record date to be fixed by the Trustee for the payment of such defaulted interest after the Company has deposited with the Trustee an amount of money equal to the aggregate amount proposed to be paid in respect of such defaulted interest, notice whereof shall be given to the registered Holders of Debentures not less than 10 days prior to such special record date, or may be paid at any time in any other lawful manner not 

xii
    

inconsistent with the requirements of any securities exchange on which the Debentures may be listed, and upon such notice as may be required by such exchange.

Section 2.05.    Interest Deferral.
(a)    Option to Defer Interest Payments.
(i)    So long as no Event of Default with respect to the Debentures has occurred and is continuing, the Company shall have the right on one or more occasions, to defer the payment of interest on the Debentures for one or more Interest Payment Periods up to five consecutive years, provided that no Deferral Period shall extend beyond the Maturity Date, the earlier accelerated maturity date of the Debentures or other redemption in full of the Debentures.  If the Company shall fail to pay interest on the Debentures on any Interest Payment Date, the Company shall be deemed to elect to defer payment of such interest on such Interest Payment Date, unless the Company shall pay such interest in full within five Business Days after any such Interest Payment Date.  If the Company shall have paid all deferred interest on the Debentures, the Company shall have the right to elect to begin a new Deferral Period pursuant to this Section 2.05.
(ii)    During a Deferral Period, interest will continue to accrue on the Debentures at the Coupon Rate, compounded quarterly, as of each Interest Payment Date to the extent permitted by applicable law.
(iii)    The Company shall pay all deferred interest in accordance with the provisions of Section 2.7 of the Base Indenture applicable to Defaulted Interest.
(b)    Payment of Deferred Interest.  On the Maturity Date or if the principal amount of the Debentures shall have been accelerated and such acceleration has not been rescinded, the Company shall pay all accrued and unpaid interest, including deferred interest, from any available funds.  On any Interest Payment Date the Company may pay any accrued and unpaid interest from any available funds.
(c)    Notice of Deferral.  The Company shall provide written notice to the Trustee and the Holders of the Debentures of its election to commence or continue any Deferral Period at least one Business Day and not more than sixty Business Days prior to the applicable Interest Payment Date.  Notice of the Company’s election of a Deferral Period shall be given to the Trustee and each Holder of Debentures at such Holder’s address appearing in the Security Register by first-class mail, postage prepaid.  Notwithstanding the foregoing, the failure of the Company to provide notice in accordance with this Section 2.05(c) of its election to commence or continue any Deferral Period, including any deemed election as provided in Section 2.05(a)(i), shall not affect the validity of such deferral hereunder.

Section 2.06.    Events of Default.

xiii
    

Solely for purposes of the Debentures, the first paragraph of Section 5.1, Section 5.1(a)-(i) and the following three paragraphs of the Base Indenture shall be deleted and replaced by the following:
“Event of Default”, wherever used herein with respect to the Debentures, means any one of the following events (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment, decree or order of any court or any order, rule or regulation of any administrative or governmental body):
(a)    default in the payment of interest in full, including Compounded Interest, on any Debenture for a period of 30 days, other than during a Deferral Period, or on the Maturity Date;
(b)    default in the payment of principal of or premium, if any, on any Debenture on the Maturity Date or upon redemption;
(c)    failure by the Company to comply in any material respect with any of its agreements or covenants in, or any of the provisions of, the Indenture with respect to the Debentures (other than an agreement, covenant or provision for which non-compliance is elsewhere in this Section specifically dealt with), and such non-compliance continues for a period of 60 days after there has been given, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in aggregate principal amount of the Outstanding Debentures, a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder;
(d)    a default under any mortgage, agreement, indenture or instrument under which there may be issued, or by which there may be secured, guaranteed or evidenced any Debt of the Company (including this Indenture) whether such Debt now exists or shall hereafter be created, in an aggregate principal amount then outstanding of $10,000,000 or more, which default (i) shall constitute a failure to pay any portion of the principal of such Debt when due and payable after the expiration of any applicable grace period with respect thereto or (ii) shall result in such Debt becoming or being declared due and payable prior to the date on which it would otherwise become due and payable, and such acceleration shall not be rescinded or annulled, or such Debt shall not be paid in full within a period of 30 days after there has been given, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in aggregate principal amount of the Debentures a written notice specifying such event of default and requiring the Company to cause such acceleration to be rescinded or annulled or to pay in full such Debt and stating that such notice is a “Notice of Default” hereunder; (it being understood however, that the Trustee shall not be deemed to have knowledge of such default under such agreement or instrument unless either (i) a Responsible Officer of the Trustee shall have actual knowledge of such default or (ii) a Responsible Officer of the Trustee shall have received written notice thereof from the Company or from any Holder); provided, however, that if such default under such agreement or instrument is remedied or cured by the Company or waived by the holders of such indebtedness, then the Event of Default hereunder by reason thereof shall be deemed likewise to have been thereupon remedied, cured or waived without further action upon the part of either the Trustee or any of such Holders; provided, further, that the foregoing shall 

xiv
    

not apply to any secured Debt under which the obligee has recourse (exclusive of recourse for ancillary matters such as environmental indemnities, misapplication of funds, costs of enforcement and the like) only to the collateral pledged for repayment so long as the fair market value of such collateral does not exceed 2% of Total Assets at the time of the default;
(e)    the Company, pursuant to or within the meaning of any Bankruptcy Law, (i) commences a voluntary case or proceeding, (ii) consents to the entry of an order for relief against it in an involuntary case or proceeding, (iii) consents to the appointment of a Custodian of it or for all or substantially all of its property, (iv) makes a general assignment for the benefit of its creditors (v) makes an admission in writing of its inability to pay its debts generally as they become due or (vi) takes corporate action in furtherance of any such action; or
(f)    a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (i) is for relief against the Company, in an involuntary case, (ii) adjudges the Company as bankrupt or insolvent, or approves as properly filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Company, or appoints a Custodian of the Company, or for all or substantially all of its property, or (iii) orders the liquidation of the Company, and the order or decree remains unstayed and in effect for 60 days.
The Trustee shall have no right or obligation under the Indenture or otherwise to exercise any remedies on behalf of the Holders of the Debentures in connection with any failure by the Company to comply with any covenant or warranty of the Company contained in the Base Indenture (other than any covenant referred to in Section 5.1(a) or (b)), unless the Trustee is directed to exercise such remedies pursuant to and subject to the provisions of Section 5.9 of the Base Indenture. 
If an Event of Default has occurred under Section 5.1(a), 5.1(b), 5.1(c) or 5.1(d), then, and in each and every such case, unless the Principal of all of the Securities shall have already become due and payable, either the Trustee or the Holders of not less than 25% in aggregate principal amount of all of the Debentures then Outstanding hereunder (treated as one class) by notice in writing to the Company (and to the Trustee if given by Holders), may declare the entire principal of all of the Debentures then Outstanding, and the interest accrued thereon, if any, to be due and payable immediately, and upon such declaration, the same shall become immediately due and payable. 
If an Event of Default has occurred under Section 5.1(e) or Section 5.1(f), the principal of and accrued but unpaid interest on the Debentures shall automatically, and without any declaration or other action on the part of the Trustee or any Holder of the Debentures, become immediately due and payable.  In connection with any such exercise of remedies, the Trustee shall be entitled to the same immunities and protections and remedial rights (other than acceleration) as if such failure to comply were an Event of Default.  The Trustee shall not be charged with knowledge or notice of any such failure to comply unless and until it shall have received the foregoing direction under Section 5.9 of the Base Indenture.

Section 2.07.    Security Registrar; Paying Agent.

xv
    

The Company appoints Regions Bank, N.A. as Security Registrar and Paying Agent with respect to the Debentures.

Section 2.08.    Subordination.
The subordination provisions of Article XIII of the Base Indenture shall apply to the Debentures, provided that, for purposes of such Article XIII, Senior Indebtedness will not include (i) (A) any indebtedness which by its terms ranks equally with the Debentures in right of payment, including guarantees of such indebtedness and including the Company’s 6.125% Junior Subordinated Debentures Due 2056 and 4.620% Floating Rate Junior Subordinated Debentures Due 2036, (B) any indebtedness which by its terms is subordinated to the Debentures in right of payment, which shall rank junior in right of payment to the Debentures, (C) any indebtedness incurred for the purchase of goods or material or for services obtained in the ordinary course of business, which shall rank equally in right of payment to the Debentures, (D) indebtedness owed by the Company to its subsidiaries, or (E) indebtedness owed by the Company to its employees, which shall rank equally in right of payment to the Debentures.

Section 2.09.    Restrictions on Transfer and Exchange.  
(a)    The transfer or exchange of any Debenture (or a beneficial interest therein) may only be made in accordance with this Section and Section 2.03 and, in the case of a Global Security (or a beneficial interest therein), the applicable rules and procedures of the Depositary.  The Trustee shall refuse to register any requested transfer or exchange that does not comply with the preceding sentence.
(b)    Subject to paragraph (c), the transfer or exchange of any Debenture (or a beneficial interest therein) of the type set forth in column A below for a Debenture (or a beneficial interest therein) of the type set forth opposite in column B below may only be made in compliance with the certification requirements (if any) described in the clause of this paragraph set forth opposite in column C below.

	
					
	A
	 
	B
	 
	C

	U.S. Global Security
	 
	U.S. Global Security
	 
	(i)

	U.S. Global Security
	 
	Offshore Global Security
	 
	(ii)

	Certificated Security
	 
	Certificated Security
	 
	(iii)

	Offshore Global Security
	 
	U.S. Global Security
	 
	(iv)

	Offshore Global Security
	 
	Offshore Global Security
	 
	(i)

(i)    No certification is required.
(ii)    The Person requesting the transfer or exchange must deliver or cause to be delivered to the Trustee a duly completed Regulation S Certificate.

xvi
    

(iii)    The Person requesting the transfer or exchange must deliver or cause to be delivered to the Trustee (x) a duly completed Rule 144A Certificate or (y) a duly completed Regulation S Certificate, and/or an opinion of counsel and such other certifications and evidence as the Company may reasonably require in order to determine that the proposed transfer or exchange is being made in compliance with the Securities Act and any applicable securities laws of any state of the United States; provided that if the requested transfer or exchange is made by the Holder of a Certificated Security that does not bear the Restricted Legend, then no certification is required.  In the event that (1) the requested transfer or exchange takes place after the Restricted Period and a duly completed Regulation S Certificate is delivered to the Trustee or (2) a Certificated Security that does not bear the Restricted Legend is surrendered for transfer or exchange, upon transfer or exchange the Trustee will deliver a Certificated Security that does not bear the Restricted Legend.
(iv)    The Person requesting the transfer or exchange must deliver or cause to be delivered to the Trustee a duly completed Rule 144A Certificate.
(c)    No certification is required in connection with any transfer or exchange of any Debenture (or a beneficial interest therein) after such Debenture (i) is eligible for resale pursuant to Rule 144 under the Securities Act (or a successor provision); provided that the Company has provided the Trustee with an officer’s certificate to that effect, and the Company may require from any Person requesting a transfer or exchange in reliance upon this clause an opinion of counsel and any other reasonable certifications and evidence in order to support such certificate; or (ii) sold pursuant to an effective registration statement.
Any Certificated Security delivered in reliance upon this paragraph will not bear the Restricted Legend.
(d)    The Trustee will retain copies of all certificates, opinions and other documents received in connection with the transfer or exchange of a Debenture (or a beneficial interest therein), and the Company will have the right to inspect and make copies thereof at any reasonable time upon reasonable prior written notice to the Trustee.

Section 2.10.    Temporary Offshore Global Securities.
(a)    Each Debenture originally sold by the Initial Purchaser in reliance upon Regulation S will be evidenced by one or more Offshore Global Securities that bear the Temporary Offshore Global Security Legend.
(b)    An owner of a beneficial interest in a Temporary Offshore Global Security (or a Person acting on behalf of such an owner) may provide to the Trustee (and the Trustee will accept) a duly completed Certificate of Beneficial Ownership at any time after the Restricted Period (it being understood that the Trustee will not accept any such certificate during the Restricted Period).  Promptly after acceptance of a Certificate of Beneficial Ownership with respect to such a beneficial interest, the Trustee will cause such beneficial interest to be exchanged for an equivalent beneficial interest in a Permanent Offshore Global Security, and will 

xvii
    

(x) permanently reduce the principal amount of such Temporary Offshore Global Security by the amount of such beneficial interest and (y) increase the principal amount of such Permanent Offshore Global Security by the amount of such beneficial interest.
(c)    Notwithstanding anything to the contrary contained herein, beneficial interests in a Temporary Offshore Global Security may be held through the Depositary only through Euroclear and Clearstream and their respective direct and indirect participants.
(d)    Notwithstanding paragraph (b), if after the Restricted Period the Initial Purchaser owns a beneficial interest in a Temporary Offshore Global Security, the Initial Purchaser may, upon written request to the Trustee accompanied by a certification as to its status as an Initial Purchaser, exchange such beneficial interest for an equivalent beneficial interest in a Permanent Offshore Global Security, and the Trustee will comply with such request and will (x) permanently reduce the principal amount of such Temporary Offshore Global Security by the amount of such beneficial interest and (y) increase the principal amount of such Permanent Offshore Global Security by the amount of such beneficial interest.

Section 2.11.    Satisfaction, Discharge and Defeasance.
The provisions of Article X of the Base Indenture shall apply to the Debentures except that Section 10.1(b)(iii) shall read: 
(iii)    the Company has delivered to the Trustee an opinion of counsel from a law firm experienced in such matters based on the fact that (x) the Company has received from, or there has been published by, the IRS a ruling or (y) since the date hereof, there has been a change in the applicable United States federal income tax law, in either case to the effect that, and such opinion shall confirm that, the beneficial owner of the Securities of such series and Coupons appertaining thereto will not recognize income, gain or loss for United States federal income tax purposes as a result of such deposit, defeasance and discharge and will be subject to United States federal income tax on the same amount and in the same manner and at the same times, as would have been the case if such deposit, defeasance and discharge had not occurred;

ARTICLE 3     
COVENANTS

Section 3.01.    Dividend and Other Payment Stoppages.
So long as any Debentures remain Outstanding, if the Company shall have given notice of its election to defer interest payments on the Debentures but the related Deferral Period has not yet commenced or a Deferral Period is continuing, the Company shall not, and shall not permit any Subsidiary of the Company to:
(a)    declare or pay any dividends or distributions on, or redeem, purchase, acquire or make a liquidation payment with respect to, any shares of capital stock of the Company other than:

xviii
    

(i)    purchases or acquisitions of shares of the Company’s capital stock in connection with the satisfaction by the Company of its obligations under any employment contract, benefit plan or other similar arrangement with or for the benefit of employees, officers, directors, consultants or agents of the Company or its subsidiaries, or in connection with the satisfaction by the Company of its obligations under any dividend reinvestment plan;
(ii)    purchases or acquisitions of shares of the Company’s capital stock in satisfaction of the Company’s obligations under any contract or security requiring it to purchase shares of its capital stock entered into prior to the commencement of the deferral period;
(iii)    as a result of a reclassification of any series or class of the Company’s capital stock, or the exchange or conversion of one class or series of the Company’s capital stock for or into another class or series of its capital stock;
(iv)    the purchase of fractional interests in shares of the Company’s capital stock pursuant to an acquisition or the conversion or exchange provisions of that capital stock or the security being converted or exchanged;
(v)    dividends or distributions of the Company’s capital stock, or rights to acquire capital stock, or repurchases or redemptions of capital stock, in each case solely from the issuance or exchange of capital stock;
(vi)    any declaration of a dividend in connection with the implementation of a shareholder rights plan, or issuances of capital stock under any such plan in the future, or redemptions or repurchases of any rights outstanding under a shareholder rights plan; or
(vii)    acquisitions of the Company’s capital stock in connection with acquisitions of businesses made by the Company (which acquisitions are made by the Company in connection with the satisfaction of indemnification obligations of the sellers of such businesses); or
(b)    make any payment of principal, premium, if any, or interest on, or repay, repurchase or redeem, any of the Company’s debt securities or guaranties that rank equally with the Debentures (the “Parity Securities”) or junior to the Debentures, other than (i) any payment of current or deferred interest on Parity Securities and the Debentures made pro rata to the amounts due on such Parity Securities and the Debentures; (ii) any payments of deferred interest on Parity Securities that, if not made, would cause the Company to breach the terms of the instrument governing such Parity Securities; or (iii) any payment of principal on Parity Securities necessary to avoid a breach of the instrument governing such Parity Securities.

ARTICLE 4     
REDEMPTION OF THE DEBENTURES

xix
    

Section 4.01.    Redemption.
(a)    The Debentures shall be redeemable in accordance with Article XII of the Base Indenture, except to the extent otherwise provided in this Third Supplemental Indenture:
(i)    in whole at any time or in part from time to time on or after November 17, 2022; 
(ii)    in whole, but not in part, at any time prior to November 17, 2022, within 90 days after the occurrence of a Tax Event; or
(iii)    in whole, but not in part, at any time prior to November 17, 2022, within 90 days after the occurrence of a Rating Agency Event;
provided that no partial redemption pursuant to Section 4.01(a)(i) shall be effected (x) unless at least $25 million aggregate principal amount of the Debentures shall remain Outstanding after giving effect to such redemption and (y) if the principal amount of the Debentures shall have been accelerated and such acceleration has not been rescinded or unless all accrued and unpaid interest, including deferred interest, shall have been paid in full on all Outstanding Debentures for all Interest Payment Periods terminating on or before the Redemption Date.
(b)    Notwithstanding any provision of Article XII of the Base Indenture to the contrary, the Debentures shall be subject to partial redemption only in the amount of $200,000 and integral multiples of $200,000 in excess thereof.

Section 4.02.    Redemption Price.
The Redemption Price for any redemption pursuant to Section 4.01 will be equal to (1) in the case of any redemption pursuant to Section 4.01(a)(i) or Section 4.01(a)(ii), 100% of the principal amount of the Debentures being redeemed, plus accrued and unpaid interest to but excluding the Redemption Date, and (2) in the case of any redemption pursuant to Section 4.01(a)(iii), the greater of (a) 100% of the principal amount of the Debentures being redeemed or (b) the present value of a payment on November 17, 2022 in an amount equal to the outstanding principal amount and scheduled payments of interest that would have accrued from the Redemption Date to November 17, 2022 on the Debentures being redeemed, discounted to the Redemption Date on a quarterly basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 50 basis points, in each case, plus accrued and unpaid interest (including compounded interest, if any) to, but excluding, the Redemption Date.
If less than all of the Debentures are to be redeemed, the particular Debentures to be redeemed will be selected not more than 45 days prior to the Redemption Date, in the case that the Debentures are issued as Global Securities, in accordance with the policies and procedures of the Depositary, and in the case that the Debentures are not issued as Global Securities by the Trustee from the outstanding Debentures not previously called for redemption, by such method as the Trustee in its sole discretion deems fair and appropriate and which may provide for the selection for redemption of a portion of the principal amount of any Debentures, provided that 

xx
    

the unredeemed portion of the principal amount of any debenture shall be in an authorized denomination (which shall not be less than the minimum authorized denomination) for such Debenture.

ARTICLE 5     
ORIGINAL ISSUE OF DEBENTURES

Section 5.01.    Original Issue of Debentures.
Debentures in the aggregate principal amount not to exceed $125,000,000, except as provided in Section 2.01(b) hereof, may, upon execution of this Third Supplemental Indenture, be executed by the Company and delivered to the Trustee for authentication, and the Trustee shall thereupon authenticate and deliver said Debentures to or upon the written order of the Company, signed by its Chief Executive Officer, its President, or any Vice President (or more senior officer) and its Treasurer or an Assistant Treasurer, without any further action by the Company.

Section 5.02.    Calculation of Original Issue Discount.
If during any calendar year any original issue discount shall have accrued on the Debentures, the Company shall file with each Paying Agent (including the Trustee if it is a Paying Agent) by January 31 of the following calendar year (a) a written notice specifying the amount of original issue discount (including daily rates and accrual periods) accrued on Outstanding Debentures as of the end of such year and (b) such other specific information relating to such original issue discount as may then be relevant under the Internal Revenue Code of 1986, as amended from time to time.

ARTICLE 6     
MISCELLANEOUS

Section 6.01.    Effectiveness.
This Third Supplemental Indenture will become effective upon its execution and delivery.

Section 6.02.    Effect of Recitals.
The recitals contained herein and in the Debentures, except the Trustee’s certificates of authentication, shall be taken as the statements of the Company, and neither the Trustee nor any Authenticating Agent assumes any responsibility for their correctness. The Trustee makes no representations as to the validity or sufficiency of this Third Supplemental Indenture or of the Debentures.  Neither the Trustee nor any Authenticating Agent shall be accountable for the use or application by the Company of the Debentures or the proceeds thereof.

xxi
    

Section 6.03.    Ratification of Base Indenture; Conflicts.
The Base Indenture, as supplemented by this Third Supplemental Indenture, is in all respects ratified and confirmed, and this Third Supplemental Indenture shall be deemed part of the Indenture in the manner and to the extent herein and therein provided.  In the event of any conflict between this Third Supplemental Indenture and the Base Indenture or the provisions set forth in the certificates of Debentures, as the case may be, this Third Supplemental Indenture shall control.

Section 6.04.    Debentures Unaffected by Officer’s Certificates.
None of the Company’s officer’s certificates pursuant to the Base Indenture entered into prior to the date hereof applies to the Debentures.  To the extent the terms of the Base Indenture are amended by any of such officer’s certificates, no such amendment shall relate or apply to the Debentures.  To the extent the terms of the Base Indenture are amended as provided herein, no such amendment shall in any way affect the terms of any such officer’s certificate or any other series of Securities.  This Third Supplemental Indenture shall relate and apply solely to the Debentures.

Section 6.05.    Tax Treatment.
The Company agrees, and by acceptance of a Debenture or a beneficial interest in a Debenture each Holder of a Debenture and any Person acquiring a beneficial interest in a Debenture agrees, to treat the Debentures as indebtedness for United States federal income tax purposes.

Section 6.06.    Governing Law.
This Third Supplemental Indenture, the Indenture as supplemented hereby and the Debentures shall be governed by and construed in accordance with the laws of the State of New York without regard to the principles of conflict of laws.

Section 6.07.    Severability.
In case any provision in this Third Supplemental Indenture, the Indenture as supplemented hereby or in the Debentures shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

Section 6.08.    Counterparts.
This Third Supplemental Indenture may be executed in any number of counterparts each of which shall be an original; but such counterparts shall together constitute but one and the same instrument.

xxii
    

Section 6.09.    Waiver of Jury Trial.
EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE SECURITIES OR THE TRANSACTION CONTEMPLATED HEREBY.

Section 6.10.    Force Majeure.
In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.

Section 6.11.    Trustee Liability.
In no event shall the Trustee be responsible or liable for special, indirect, or consequential loss or damage of any kind whatsoever (including, but not limited to, loss of profit) unless it shall be proved that the Trustee acted in bad faith or was grossly negligent in acting or failing to act.

Section 6.12.    Submission to Jurisdiction.
The parties irrevocably submit to the non-exclusive jurisdiction of any New York State or federal court sitting in the Borough of Manhattan, City of New York, over any suit, action or proceeding arising out of or relating to this Indenture.  To the fullest extent permitted by applicable law, the parties irrevocably waive and agree not to assert, by way of motion, as a defense or otherwise, any claim that it is not subject to the jurisdiction of any such court, any objection that it may now or hereafter have to the laying of the venue of any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.

Section 6.13.    Electronic Communications.
The Trustee agrees to accept and act upon instructions or directions pursuant to this Indenture sent by unsecured e-mail, pdf, facsimile transmission or other similar unsecured electronic methods, provided, however, that the Trustee shall have received an incumbency certificate listing persons designated to give such instructions or directions and containing specimen signatures of such designated persons, which such incumbency certificate shall be amended and replaced whenever a person is to be added or deleted from the listing.  If the Company elects to give the Trustee e-mail or facsimile instructions (or instructions by a similar 

xxiii
    

electronic method) and the Trustee in its discretion elects to act upon such instructions, the Trustee’s understanding of such instructions shall be deemed controlling. The Trustee shall not be liable for any losses, costs or expenses arising directly or indirectly from the Trustee’s reliance upon and compliance with such instructions notwithstanding such instructions conflict or are inconsistent with a subsequent written instruction. The Company agrees to assume all risks arising out of the use of such electronic methods to submit instructions and directions to the Trustee, including without limitation the risk of the Trustee acting on unauthorized instructions, and the risk of interception and misuse by third parties.

Section 6.14.    FATCA.
The Company agrees (i) to provide the Trustee with such reasonable information as it has in its possession to enable the Trustee to determine whether any payments pursuant to the Indenture are subject to the withholding requirements described in Section 1471(b) of the US Internal Revenue Code of 1986 (the “Code”) or otherwise imposed pursuant to Sections 1471 through 1474 of the Code and any regulations, or agreements thereunder or official interpretations thereof (“Applicable Law”), and (ii) that the Trustee shall be entitled to make any withholding or deduction from payments under the Indenture to the extent necessary to comply with Applicable Law, for which the Trustee shall not have any liability.

IN WITNESS WHEREOF,  the Company has caused this Third Supplemental Indenture to be signed and delivered, and the Trustee has caused this Third Supplemental Indenture to be signed and delivered, all as of the day and year first written above. 

	
		
	TORCHMARK CORPORATION

	By:
	/s/ W. Michael Pressley

	 
	Name:   W. Michael Pressley

	 
	Title:   Executive Vice President and Chief Investment Office

	
		
	REGIONS BANK

	By:
	/s/ Alejandro Hoyos

	 
	Name:   Alejandro Hoyos

	 
	Title:   Vice President, CCTS

xxiv
    

EXHIBIT A
[FORM OF FACE OF DEBENTURE]
[UNLESS THIS SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY SECURITY ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.
THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF DTC OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN DTC OR SUCH NOMINEE, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE.]

A-1
    

No. 001    Principal Amount: $125,000,000
Issue Date:  November 17, 2017                        CUSIP No.:  144A: 891027 AR5 / US891027AR59
      Reg S: U8910P AA1 / USU8910PAA13        
TORCHMARK CORPORATION
5.275% Junior Subordinated Debentures due 2057
TORCHMARK CORPORATION, a corporation organized and existing under the laws of Delaware (hereinafter called the “Company”, which term includes any successor corporation under the Indenture hereinafter referred to), for value received, hereby promises to pay to [Cede & Co.], or registered assigns, the principal sum of One Hundred and Twenty Five Million Dollars ($125,000,000), and all accrued and unpaid interest thereon on November 17, 2057 or, if such date is not a Business Day, the following Business Day (the “Maturity Date”).
The Company further promises to pay interest on said principal sum from November 17, 2017 or from the most recent interest payment date to which interest has been paid or duly provided for.  Until the Maturity Date or earlier Redemption Date, each Debenture will bear interest at the per annum rate of  5.275% (the “Coupon Rate”) payable (subject to the interest deferral provisions of Section 2.05 of the Third Supplemental Indenture) semi-annually in arrears on June 15 and December 15 of each year (each such date, an “Interest Payment Date”), commencing on June 15, 2018, and (to the extent that payment of such interest is enforceable under applicable law) on any overdue installment of interest at such interest rate, compounded quarterly.  Interest payments will include accrued interest from and including the last date in respect of which interest has been duly paid or provided for to, but not including, the next succeeding Interest Payment Date, the Maturity Date or the Redemption Date, as the case may be.  The amount of interest payable for any full Interest Payment Period will be computed on the basis of a 360-day year of twelve thirty-day months, and the amount of interest payable for any period shorter than a full Interest Payment Period for which interest is computed will be computed on the basis of thirty-day months and, for periods of less than a thirty-day month, the actual number of days elapsed per thirty-day month.
In the event that any date on which interest is payable on this Debenture is not a Business Day, then payment of interest payable on such date will be made on the next succeeding day which is a Business Day (and without any interest or other payment in respect of such delay).  For so long as the Debentures are represented by one or more Global Securities, the interest installment so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in the Base Indenture, be paid to the Person in whose name this Debenture (or one or more Predecessor Securities) is registered at the close of business on the Regular Record Date next preceding the Interest Payment Date, which shall be the record date for such Interest Payment Date; provided that in the event the Debentures at any time are not represented solely by one or more Global Securities, the Company may select a different record date for such Interest Payment Date, which shall be at least one Business Day before an Interest Payment Date.  Any such interest installment not punctually paid or duly provided for shall forthwith cease to be payable to the registered Holders on such record date, and may be paid to the Person in whose name the Debentures (or one or more Predecessor Securities) is registered at the close of business on a special record date to be fixed by the Trustee for the payment of such defaulted interest after the 

2
    

Company has deposited with the Trustee an amount of money equal to the aggregate amount proposed to be paid in respect of such defaulted interest, notice whereof shall be given to the registered Holders of this series of Debenture not less than ten days prior to such special record date, or may be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Debentures may be listed, and upon such notice as may be required by such exchange, all as more fully provided in the Indenture.
The principal of (and premium, if any) and the interest (including Compounded Interest) on this Debenture shall be payable at the office or agency of the Trustee maintained for that purpose in the United States, in any coin or currency of the United States of America which at the time of payment is legal tender for payment of public and private debts; provided, however, that payment of interest may be made at the option of the Company by check mailed to the registered Holder at such address as shall appear in the Security Register; provided further that, notwithstanding the foregoing provisions of this sentence, for so long as the Depositary (as defined in the Indenture referred to on the reverse hereof) is the Holder of all of the Debentures Outstanding, and provided that the Depositary has provided wire transfer instructions to the Company or the Paying Agent in a timely manner prior to each Interest Payment Date (which it may do by standing instructions) designating an account of the Depositary or its nominee at a commercial bank in the United States to which it wishes payments of interest on the Debentures to be made, the Company shall pay interest on the Debentures by wire transfer of federal (same day) funds to the account of the Depositary or its nominee in accordance with such wire transfer instructions.
The indebtedness evidenced by this Debenture is, to the extent provided in the Indenture, subordinate and subject in right of payment to the prior payment in full of all Senior Indebtedness, and this Debenture is issued subject to the provisions of the Indenture with respect thereto.  Each Holder of this Debenture by accepting the same, (a) agrees to and shall be bound by such provisions, (b) authorizes and directs the Trustee on its behalf to take such actions as may be necessary or appropriate to effectuate the subordination so provided and (c) appoints the Trustee its attorney-in-fact for any and all such purposes.  Each Holder hereof, by its acceptance hereof, waives all notice of the acceptance of the subordination provisions contained herein and in the Indenture by each holder of Senior Indebtedness, whether now Outstanding or hereafter incurred, and waives reliance by each such holder upon said provisions.
As provided in the Indenture, so long as no Event of Default has occurred and is continuing, the Company shall have the right on one or more occasions, to defer the payment of interest for one or more Interest Payment Periods up to five consecutive years, provided that no Deferral Period shall extend beyond the Maturity Date, the earlier accelerated maturity date hereof or other redemption in full hereof.  If the Company shall fail to pay interest hereon on any Interest Payment Date, the Company shall be deemed to elect to defer payment of such interest on such Interest Payment Date, unless the Company shall pay such interest in full within five Business Days after any such Interest Payment Date.  If the Company shall have paid all deferred interest hereon, the Company shall have the right to elect to begin a new Deferral Period as provided in the Indenture.
Reference is hereby made to the further provisions of this Debenture set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place.

3
    

Unless the certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Debenture shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose.
Any additional Debentures issued under the same CUSIP as this Debenture shall be fungible with this Debenture for U.S. federal income tax purposes.

4
    

IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed.
Dated: November 17, 2017
(Corporate Seal)    TORCHMARK CORPORATION, as Issuer

By:        
Name:    W. Michael Pressley
Title:    Executive Vice President and Chief Investment Officer

Certificate of Authentication
This is one of the Securities referred to in the within-mentioned Indenture.
Regions Bank

By:        
Authorized Signatory

Dated:        

5
    

REVERSE OF SECURITY
This Debenture is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to be issued in one or more series under a Subordinated Indenture, dated as of November 2, 2001 (herein called the “Base Indenture”), between the Company and Regions Bank. (as successor in interest to The Bank of New York and The Bank of New York Mellon Trust Company, N.A. ), as Trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), as supplemented and amended by the First Supplemental Indenture, dated as of September 24, 2012 and the Second Supplemental Indenture, dated as of April 5, 2016, each between the Company and the Trustee (the “Supplemental Indenture”, and together with the Base Indenture, the “Indenture”), to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Trustee, the Company and the Holders of the Debentures, and of the terms upon which the Debentures are, and are to be, authenticated and delivered.  The terms of the Debentures include those stated in the Indenture, and the Debentures are subject to all such terms.  This Debenture is one of the series designated on the face hereof, initially limited in aggregate principal amount to $125,000,000.
All terms used in this Debenture that are defined in the Indenture shall have the meanings assigned to them in the Indenture.
This Debenture shall be redeemable at the option of the Company in accordance with the terms of the Indenture.  In particular, this Security is redeemable:
(a)    in whole at any time or in part from time to time on or after November 17, 2022; or
(b)    in whole, but not in part, at any time prior to November 17, 2022 within 90 days after the occurrence of a Tax Event or a Rating Agency Event;
provided that no such partial redemption shall be effected (x) in the case of redemption pursuant to subsection (a), unless at least $25 million aggregate principal amount of Securities of this series shall remain Outstanding after giving effect to such redemption and (y) if the principal amount of the Debentures of this series shall have been accelerated and such acceleration has not been rescinded or unless all accrued and unpaid interest, including deferred interest, shall have been paid in full on all Outstanding Debentures for all Interest Payment Periods terminating on or before the Redemption Date.
Notice of redemption shall be given at least 30 but not more than 60 days before the Redemption Date to each Holder of Securities of this series to be redeemed at its registered address.  The notice of redemption for such Debentures shall state, among other things, the amount of Debentures to be redeemed, the Redemption Date, if not then ascertainable, the manner in which the Redemption Price shall be calculated and the place or places that payment shall be made upon presentation and surrender of such Debenture to be redeemed.  Unless the Company defaults in the payment of the Redemption Price together with accrued interest, interest will cease to accrue on any Debentures that have been called for redemption on the Redemption Date.

6
    

In the event of redemption of this Debenture in part only, a new Debenture or Debentures for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof.
Installments of accrued and unpaid interest whose Stated Maturity is on or prior to the Redemption Date will be payable to the Holders of the Debentures, or one or more Predecessor Securities, registered as such at the close of business on the relevant Regular Record Dates according to their terms.
The Indenture contains provisions for satisfaction, discharge and defeasance of the entire indebtedness on this Debenture, upon compliance by the Company with certain conditions set forth therein.
The Debentures are not entitled to the benefit of any sinking fund.
If an Event of Default with respect to the Debentures shall occur and be continuing, the principal of the Debentures may be declared due and payable in the manner and with the effect provided in the Indenture.
The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time Outstanding of each series to be affected.  The Indenture also contains provisions permitting Holders of specified percentages in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences.  Any such consent or waiver by the Holder of this Debenture shall be conclusive and binding upon such Holder and upon all future Holders of this Debenture and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Debenture.
No reference herein to the Indenture and no provision of this Debenture or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of (and premium, if any) and interest on this Debenture at the times, place and rate, and in the coin or currency, herein prescribed.
As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Debenture is registrable in the Security Register, upon surrender of this Debenture for registration of transfer at the office or agency of the Company in any place where the principal of (and premium, if any) and interest on this Debenture are payable duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new Debentures, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees.

7
    

The Debenture are issuable only in registered form without coupons in denominations of $200,000 and any integral multiples of $200,000 in excess thereof.  As provided in the Indenture and subject to certain limitations therein set forth, Debentures are exchangeable for a like aggregate principal amount of Debentures of a different authorized denomination, as requested by the Holder surrendering the same.
No service charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith.
The Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Debenture is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary.
No recourse shall be had for the payment of the principal of or the interest on this Debenture, or for any claim based hereon, or otherwise in respect hereof, or based on or in respect of the Indenture, against any incorporator, shareholder, officer or director, past, present or future, as such, of the Company or of any predecessor or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise, all such liability being, by the acceptance hereof and as part of the consideration for the issuance hereof, expressly waived and released.
THIS DEBENTURE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICT OF LAWS.

8
    

ASSIGNMENT
FOR VALUE RECEIVED, the undersigned assigns and transfers this Debenture to:
    
    
    

(Insert assignee’s social security or tax identification number)
    
    

(Insert address and zip code of assignee)
agent to transfer this Debenture on the books of the Security Registrar.  The agent may substitute another to act for him or her.

9
    

[THE FOLLOWING PROVISION TO BE INCLUDED ON ALL 
CERTIFICATES BEARING A RESTRICTED LEGEND]
In connection with any transfer of this Debenture occurring prior to November 17, 2018 the undersigned confirms that such transfer is made without utilizing any general solicitation or general advertising and further as follows:
Check One
☐    (1) This Debenture is being transferred to a “qualified institutional buyer” in compliance with Rule 144A under the Securities Act of 1933, as amended and certification in the form of Exhibit D to the Indenture is being furnished herewith.
☐    (2) This Debenture is being transferred to a Non-U.S. Person in compliance with the exemption from registration under the Securities Act of 1933, as amended, provided by Regulation S thereunder, and certification in the form of Exhibit C to the Indenture is being furnished herewith.
or
☐    (3) This Debenture is being transferred other than in accordance with (1) or (2) above and documents are being furnished which comply with the conditions of transfer set forth in this Debenture and the Indenture.  If none of the foregoing boxes is checked, the Trustee is not obligated to register this Debenture in the name of any Person other than the Holder hereof unless and until the conditions to any such transfer of registration set forth herein and in the Indenture have been satisfied.

Date:       

SELLER

By:         

NOTICE: The signature to this assignment must correspond with the name as written upon the face of the within-mentioned instrument in every particular, without alteration or any change whatsoever.

10
    

SIGNATURE
Guarantee:1

11
    

(Sign exactly as your name appears on the other side of this Security)
1 Signatures must be guaranteed by an “eligible guarantor institution” meeting the requirements of the Security Registrar, which requirements include membership or participation in the Security Transfer Agent Medallion Program (“STAMP”) or such other “signature guarantee program” as may be determined by the Security Registrar in addition to, or in substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as amended.

By:        

To be executed by an executive officer

12
    

EXHIBIT B

RESTRICTED 
LEGEND
NEITHER THIS DEBENTURE NOR ANY BENEFICIAL INTEREST HEREIN HAS BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”).  EACH HOLDER HEREOF, AND EACH OWNER OF A BENEFICIAL INTEREST HEREIN, BY PURCHASING THIS DEBENTURE, AGREES FOR THE BENEFIT OF TORCHMARK CORPORATION (THE “COMPANY”) THAT THIS DEBENTURE MAY NOT BE RESOLD, PLEDGED OR OTHERWISE TRANSFERRED PRIOR TO THE DATE WHICH IS SIX MONTHS (IF ALL APPLICABLE CONDITIONS TO SUCH RESALE UNDER RULE 144 UNDER THE 1933 ACT (OR ANY SUCCESSOR PROVISION THEREOF) ARE SATISFIED) AFTER THE LATER OF THE ORIGINAL ISSUANCE DATE THEREOF, THE ISSUANCE DATE OF ANY SUBSEQUENT ISSUANCE OF ADDITIONAL DEBENTURES OF THE SAME SERIES AND THE LAST DATE ON WHICH THE COMPANY OR ANY AFFILIATE THEREOF WAS THE OWNER OF THIS DEBENTURE OR THE EXPIRATION OF SUCH SHORTER PERIOD AS MAY BE PRESCRIBED BY SUCH RULE 144 (OR SUCH SUCCESSOR PROVISION) PERMITTING RESALES OF THIS DEBENTURE WITHOUT ANY CONDITIONS (THE “RESALE RESTRICTION TERMINATION DATE”) OTHER THAN (A)(1) TO THE COMPANY, (2) IN A TRANSACTION ENTITLED TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE 1933 ACT (IF AVAILABLE), (3) SO LONG AS THIS DEBENTURE IS ELIGIBLE FOR RESALE PURSUANT TO RULE 144A UNDER THE 1933 ACT (“RULE 144A”), TO A PERSON WHOM THE SELLER REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER TO WHOM NOTICE IS GIVEN THAT THE RESALE, PLEDGE OR OTHER TRANSFER IS BEING MADE IN RELIANCE ON RULE 144A UNDER THE 1933 ACT (AS INDICATED BY THE BOX CHECKED BY THE TRANSFEROR ON THE CERTIFICATE OF TRANSFER ATTACHED TO THIS DEBENTURE), (4) IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH RULE 903 OR 904 OF REGULATION S UNDER THE 1933 ACT (AS INDICATED BY THE BOX CHECKED BY THE TRANSFEROR ON THE CERTIFICATE OF TRANSFER ATTACHED TO THIS DEBENTURE), (5) IN ACCORDANCE WITH ANOTHER APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE 1933 ACT (AND BASED UPON AN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY), OR (6) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT AND (B) IN EACH CASE IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE FOREGOING RESTRICTIONS ON RESALE WILL NOT APPLY SUBSEQUENT TO THE RESALE RESTRICTION TERMINATION DATE.  THE HOLDER HEREOF, BY PURCHASING THIS DEBENTURE, REPRESENTS AND AGREES FOR THE BENEFIT OF THE COMPANY THAT IT IS (i) A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE 1933 ACT OR (ii) A NON-U.S. PERSON OUTSIDE THE UNITED STATES WITHIN THE MEANING OF, OR AN ACCOUNT SATISFYING THE REQUIREMENTS OF, PARAGRAPH (k)(2) OF RULE 902 UNDER REGULATION S UNDER THE 1933 ACT. THE HOLDER OF THIS DEBENTURE ACKNOWLEDGES THAT THE 

B-1
    

COMPANY OR THE TRUSTEE RESERVES THE RIGHT PRIOR TO ANY OFFER, SALE OR OTHER TRANSFER (I) PURSUANT TO CLAUSE (A)(2) PRIOR TO THE RESALE RESTRICTION TERMINATION DATE TO REQUIRE THE DELIVERY OF AN OPINION OF COUNSEL, CERTIFICATIONS OR OTHER INFORMATION SATISFACTORY TO THE COMPANY AND THE TRUSTEE AND (2) IN EACH OF THE FOREGOING CASES, TO REQUIRE THAT A CERTIFICATE AS TO COMPLIANCE WITH CERTAIN CONDITIONS TO TRANSFER IS COMPLETED AND DELIVERED BY THE TRANSFEROR TO THE COMPANY AND THE TRUSTEE.

B-2
    

EXHIBIT C

Regulation S Certificate
     ,      
Regions Bank
3773 Richmond Avenue, Suite 1100 
Houston, TX 77046

Attn: Corporate Trust
Re:    Torchmark Corporation 
5.275% Junior Subordinated Debentures due 2057 (the 
“Debentures”) Issued under the Indenture (the “Indenture”) 
dated as of November 17, 2017, relating to the Debentures
Dear Sirs:
Terms are used in this Certificate as used in Regulation S (“Regulation S”) under the Securities Act of 1933, as amended (the “Securities Act”), except as otherwise stated herein.
[CHECK A OR B AS APPLICABLE.]
☐    A.  This Certificate relates to our proposed transfer of $     principal amount of Debentures issued under the Indenture.  We hereby certify as follows:
1.    The offer and sale of the Debentures was not and will not be made to a person in the United States (unless such person is excluded from the definition of “U.S. person” pursuant to Rule 902(k)(2)(vi) or the account held by it for which it is acting is excluded from the definition of “U.S. person” pursuant to Rule 902(k)(2)(i) under the circumstances described in Rule 902(g)(3)) and such offer and sale was not and will not be specifically targeted at an identifiable group of U.S. citizens abroad.
2.    Unless the circumstances described in the parenthetical in paragraph 1 above are applicable, either (a) at the time the buy order was originated, the buyer was outside the United States or we and any person acting on our behalf reasonably believed that the buyer was outside the United States or (b) the transaction was executed in, on or through the facilities of a designated offshore securities market, and neither we nor any person acting on our behalf knows that the transaction was pre-arranged with a buyer in the United States.
3.    Neither we, any of our affiliates, nor any person acting on our or their behalf has made any directed selling efforts in the United States with respect to the Debentures.

C-1
    

4.    The proposed transfer of Debentures is not part of a plan or scheme to evade the registration requirements of the Securities Act.

5.    If we are a dealer or a person receiving a selling concession, fee or other remuneration in respect of the Debentures, and the proposed transfer takes place during the Restricted Period (as defined in the Indenture), or we are an officer or director of the Company or an Initial Purchaser (as defined in the Indenture), we certify that the proposed transfer is being made in accordance with the provisions of Rule 904(b) of Regulation S.
☐    B.  This Certificate relates to our proposed exchange of $        principal amount of Debentures issued under the Indenture for an equal principal amount of Debentures to be held by us.  We hereby certify as follows:
1.    At the time the offer and sale of the Debentures was made to us, either (i) we were not in the United States or (ii) we were excluded from the definition of “U.S. person” pursuant to Rule 902(k)(2)(vi) or the account held by us for which we were acting was excluded from the definition of “U.S. person” pursuant to Rule 902(k)(2)(i) under the circumstances described in Rule 902(g)(3); and we were not a member of an identifiable group of U.S. citizens abroad.
2.    Unless the circumstances described in paragraph 1(ii) above are applicable, either (a) at the time our buy order was originated, we were outside the United States or (b) the transaction was executed in, on or through the facilities of a designated offshore securities market and we did not prearrange the transaction in the United States.
3.    The proposed exchange of Debentures is not part of a plan or scheme to evade the registration requirements of the Securities Act.
You and the Company are entitled to rely upon this Certificate and are irrevocably authorized to produce this Certificate or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby.
Very truly yours,

C-1
    

	
		
	[NAME OF SELLER (FOR  
TRANSFERS) OR OWNER (FOR EXCHANGES)]

	By:
	 

	 
	Name:   

	 
	Title:   

	 
	Address:   

Date:      

C-2
    

EXHIBIT D
Rule 144A Certificate
,      
Regions Bank
3773 Richmond Avenue, Suite 1100 Houston, TX 77046 
Attn: Corporate Trust
Re:    Torchmark Corporation 
5.275% Junior Subordinated Debentures due 2057 (the 
“Debentures”) Issued under the Indenture (the “Indenture”) 
dated as of November 17, 2017, relating to the Debentures
Ladies and Gentlemen:
TO BE COMPLETED BY PURCHASER IF (1) ABOVE IS CHECKED.
This Certificate relates to:
[CHECK A OR B AS APPLICABLE.]
☐    A.  Our proposed purchase of $    principal amount of Debentures issued under the Indenture.
☐    B.  Our proposed exchange of $    principal amount of Debentures issued under the Indenture for an equal principal amount of Debentures to be held by us.
We and, if applicable, each account for which we are acting in the aggregate owned and invested more than $100,000,000 in securities of issuers that are not affiliated with us (or such accounts, if applicable), as of    , 20   , which is a date on or since close of our most recent fiscal year.  We and, if applicable, each account for which we are acting, are a qualified institutional buyer within the meaning of Rule 144A (“Rule 144A”) under the Securities Act of 1933, as amended (the “Securities Act”).  If we are acting on behalf of an account, we exercise sole investment discretion with respect to such account.  We are aware that the transfer of Debentures to us, or such exchange, as applicable, is being made in reliance upon the exemption from the provisions of Section 5 of the Securities Act provided by Rule 144A. Prior to the date of this Certificate we have received such information regarding the Company as we have requested pursuant to Rule 144A(d)(4) or have determined not to request such information.
You and the Company are entitled to rely upon this Certificate and are irrevocably authorized to produce this Certificate or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby.

D-1
    

Very truly yours,

	
		
	[NAME OF SELLER (FOR 
TRANSFERS) OR OWNER (FOR EXCHANGES)]

	By:
	 

	 
	Name:   

	 
	Title:   

	 
	Address:   

Date:      

D-2
    

EXHIBIT E

[COMPLETE FORM I OR FORM II AS APPLICABLE.]
[FORM I]
Certificate of Beneficial Ownership
		
	To:
	Regions Bank

3773 Richmond Avenue, Suite 1100 
Houston, TX 77046

Attn: Corporate Trust OR
[Euroclear Bank S.A./N.V., as operator of the Euroclear System] OR
[Clearstream Banking S.A.]
Re:    Torchmark Corporation 
5.275% Junior Subordinated Debentures due 2057 (the 
“Debentures”) Issued under the Indenture (the “Indenture”) 
dated as of November 17, 2017, relating to the Debentures
Ladies and Gentlemen:
We are the beneficial owner of $    principal amount of Debentures issued under the Indenture and represented by a Temporary Offshore Global Security (as defined in the Indenture).
We hereby certify as follows:
[CHECK A OR B AS APPLICABLE.]
☐    A. We are a non-U.S. person (within the meaning of Regulation S under the Securities Act of 1933, as amended).
☐     B.  We are a U.S. person (within the meaning of Regulation S under the Securities Act of 1933, as amended) that purchased the Debentures in a transaction that did not require registration under the Securities Act of 1933, as amended.
You and the Company are entitled to rely upon this Certificate and are irrevocably authorized to produce this Certificate or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby.

E-1
    

Very truly yours,

	
		
	[NAME OF BENEFICIAL OWNER]

	By:
	 

	 
	Name:   

	 
	Title:   

	 
	Address:   

Date:      

E-2
    

[FORM II]
Certificate of Beneficial Ownership
		
	To:
	Regions Bank

3773 Richmond Avenue, Suite 1100 
Houston, TX 770464

Attn: Global Corporate Trust Services 
Attention:  Corporate Trust Administration
		
	Re:
	Torchmark Corporation  

5.275% Junior Subordinated Debentures due 2057 (the “Debentures”) 
Issued under the Indenture (the “Indenture”) dated as 
of November 17, 2017, relating to the Debentures
Ladies and Gentlemen:
This is to certify that based solely on certifications we have received in writing, by tested telex or by electronic transmission from member organizations (“Member Organizations”) appearing in our records as persons being entitled to a portion of the principal amount of Debentures represented by a Temporary Offshore Global Security issued under the above- referenced Indenture, that as of the date hereof, $     principal amount of Debentures represented by the Temporary Offshore Global Security being submitted herewith for exchange is beneficially owned by persons that are either (i) non-U.S. persons (within the meaning of Regulation S under the Securities Act of 1933, as amended) or (ii) U.S. persons that purchased the Debentures in a transaction that did not require registration under the Securities Act of 1933, as amended.
We further certify that (i) we are not submitting herewith for exchange any portion of such Temporary Offshore Global Security excepted in such Member Organization certifications and (ii) as of the date hereof we have not received any notification from any Member Organization to the effect that the statements made by such Member Organization with respect to any portion of such Temporary Offshore Global Security submitted herewith for exchange are no longer true and cannot be relied upon as of the date hereof.
You and the Company are entitled to rely upon this Certificate and are irrevocably authorized to produce this Certificate or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby.

E-3
    

Yours faithfully,
	
		
	[EUROCLEAR BANK S.A./N.V., as  
operator of the Euroclear System]
OR
[CLEARSTREAM BANKING S.A.]

	By:
	 

	 
	Name:   

	 
	Title:   

	 
	Address:   

Date:      

E-4
    

EXHIBIT F
THIS DEBENTURE IS A TEMPORARY GLOBAL SECURITY. PRIOR TO THE EXPIRATION OF THE RESTRICTED PERIOD APPLICABLE HERETO, BENEFICIAL INTERESTS HEREIN MAY NOT BE HELD BY ANY PERSON OTHER THAN (1) A NON-U.S. PERSON OR (2) A U.S. PERSON THAT PURCHASED SUCH INTEREST IN A TRANSACTION EXEMPT FROM REGISTRATION UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”).  BENEFICIAL INTERESTS HEREIN ARE NOT EXCHANGEABLE FOR PHYSICAL DEBENTURES OTHER THAN A PERMANENT GLOBAL SECURITY IN ACCORDANCE WITH THE TERMS OF THE INDENTURE. TERMS IN THIS LEGEND ARE USED AS USED IN REGULATION S UNDER THE SECURITIES ACT.

F-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]